Agents modulating beta-catenin functions and methods thereof

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 16, 2020, is named 2012675-0124_SL.txt and is 170,360 bytes in size.

BACKGROUND

Beta-catenin is a multifunctional protein and is involved in many biological pathways and processes.

SUMMARY

Beta-catenin has many functions and regulates and coordinates many processes, e.g., gene transcription, cell-cell adhesion, embryogenesis, cell growth, regeneration, etc. Among other things, beta-catenin plays important roles in the Wnt/beta-catenin pathway. Many conditions, disorders, and diseases, including a number of cancers (e.g., hepatocellular carcinoma, colorectal carcinoma, lung cancer, malignant breast tumors, ovarian and endometrial cancer, etc.), various forms of heart diseases, etc., are associated with beta-catenin (e.g., its abnormal levels, activities, localization, etc.).

Among other things, the present disclosure provides technologies (e.g., compounds, compositions, methods, etc.) for modulating beta-catenin function. In some embodiments, such technologies are useful for, e.g., preventing or treating beta-catenin associated conditions, disorders, or diseases.

In some embodiments, the present disclosure encompasses the recognition that it can be beneficial to selectively or specifically modulate one or more certain functions of beta-catenin, for example, functions that involve an Axin binding site of beta-catenin. In some embodiments, such functions involve interactions of Axin with beta-catenin. In some embodiments, the present disclosure provides technologies for selectively or specifically modulating beta-catenin functions. In some embodiments, provided technologies selectively or specifically modulate beta-catenin functions involving one or more beta-catenin sites that interact with Axin. In some embodiments, provided technologies selectively or specifically modulate beta catenin functions that involve interactions between beta-catenin and Axin.

Among other things, the present disclosure provides agents, e.g., stapled peptides, that physically interact with beta-catenin. In some embodiments, provided agents binds to beta-catenin at a site that Axin binds to beta-catenin (e.g., at a site that overlaps with or is identical to that at which Axin binds; alternatively or additionally, in some embodiments at a site with sufficient proximity to such Axin binding site that the provided agent competes with Axin for binding to beta-catenin). In some embodiments, provided agents interacts with some or all amino acid residues of beta-catenin that interact with Axin when Axin binds to beta-catenin. In some embodiments, provided agents compete with Axin for binding to beta-catenin.

In some embodiments, provided agents are stapled peptides. In some embodiments, provided stapled peptides comprise a number of natural or non-natural amino acid residues (e.g., 7-50, 10-25, 10-20, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, etc.), and one or more staples, each of which is independently a linker that can link one amino acid residue to another amino acid residue and, as is understood by those skilled in the art, is not part of the peptide backbone.

In some embodiments, the present disclosure provides the insights that structural elements of staples (e.g., chemistry [e.g., hydrocarbon, non-hydrocarbon (e.g., comprising one or more heteroatoms or heteroatom-containing moieties such as amino, carbamate, etc.)], stereochemistry [e.g., stereochemistry of backbone atoms that staples are connected to (e.g., if staples are connected to alpha-carbon atoms of amino acid residues, such carbon atoms being chiral (R S) or achiral)], positioning (to what amino acid residues/backbone atoms staples are connected), sizes (length of staples), etc.), peptide sequences, lengths, and/or other modifications (e.g., incorporation of unnatural amino acids, labels, targeting moieties [carbohydrate, protein ligand, etc.], etc.) can significantly impact properties and/or activities, and can be employed to design stapled peptides having significantly improved properties and/or activities (e.g., increased solubility, increased cell permeability, increased stability, increased selectivity, lowered toxicity, increased activity, etc.).

Among other things, the present disclosure provides staples with various structural elements, and peptides that contain them. In some embodiments, a staple is a hydrocarbon staple. In some embodiments, a staple is a non-hydrocarbon staple in that it comprises one or more heteroatoms. In some embodiments, a staple comprises an amino moiety (e.g., —N(R′)—, wherein R′ is as described in the present disclosure). In some embodiments, a staple comprises a carbamate moiety (e.g., —N(R)—C(O)—O—, wherein R is as described in the present disclosure). In some embodiments, a staple is a Pro-staple in that an end of the staple is connected to a proline residue. In some embodiments, a staple is -L^s- as described in the present disclosure.

In some embodiments, provided stapled peptides comprising a staple comprising an amino moiety or a carbamate moiety have improved solubility compared to an appropriate reference peptide (e.g., in some embodiments, peptides which are otherwise identical but do not contain any staples or contain hydrocarbon staples instead of staples comprising an amino or carbamate moiety). In some embodiments, provided peptides comprising a staple comprising an amino moiety or a carbamate moiety have increased cell permeability compared to an appropriate reference peptide. In some embodiments, provided peptides comprising a staple comprising an amino moiety or a carbamate moiety have increased activities, e.g., increased inhibition of gene expression, cell growth, etc.

In some embodiments, a staple connects amino acid residue i and i+m (wherein each of i and m is independently as described in the present disclosure), and the connecting atoms at amino acid residue i (C) and at amino acid residue i+m (C^i+m) are independently chiral and achiral, and if chiral, are independently racemic, R or S. In some embodiments, both Cⁱand C^i+mare carbon atoms. In some embodiments, Cⁱis achiral and C^i+mchiral. In some embodiments, Cⁱis a chiral and C^i+mis R. In some embodiments, Cⁱis a chiral and C^i+mis S. In some embodiments, Cⁱis chiral and C^i+machiral. In some embodiments, Cⁱis R and C^i+machiral. In some embodiments, Cⁱis S and C^i+machiral. In some embodiments, Cⁱis R and C^i+mis R. In some embodiments, Cⁱis R and C^i+mis S. In some embodiments, Cⁱis S and C^i+mis R. In some embodiments, Cⁱis S and C^i+mis S. In some embodiments, controlling chemistry and/or stereochemistry significantly improves yields and/or purity of prepared stapled peptides, and/or properties and activities of provided stapled peptides.

In some embodiments, the present disclosure provides a peptide comprising:

[X¹]_p1[X²]_p2—X³X⁴X⁵X⁶X⁷X⁸X⁹X¹⁰—[X¹¹]_p11[X¹²]_p12[X¹³]_p13,

wherein:

each of p1, p2, p11, p12 and p13 is independently 0 or 1;

each of X, X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹⁰, X¹¹, X¹², and X¹³is independently an amino acid residue;

at least two of X, X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹⁰, X¹¹, X¹², and X¹³comprise side chains that are optionally linked together to form a staple.

In some embodiments, p1 is 0. In some embodiments, p1 is 1. In some embodiments, p2 is 0. In some embodiments, p2 is 1.

In some embodiments, p11 is 0. In some embodiments, p11 is 1. In some embodiments, p12 is 0. In some embodiments, p12 is 1. In some embodiments, p13 is 0. In some embodiments, p13 is 1.

In some embodiments, the present disclosure provides a peptide comprising a staple L^s, wherein L^sis an optionally substituted, bivalent C_1-50aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—; each -Cy- is independently an optionally substituted bivalent group selected from a C_3-20cycloaliphatic ring, a C_6-20aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon;

each R′ is independently —R, —C(O)R, —CO₂R, or —SO₂R;

each R is independently —H, or an optionally substituted group selected from C1-30 aliphatic, C_1-30heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C_6-30aryl, C_6-30arylaliphatic, C_6-30arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

In some embodiments, the present disclosure provides a peptide having the structure:

embedded image

or a salt thereof, wherein

each of R^a, R¹, R², R³, and R⁴is independently R′;

R^bis R′, —OR′ or —N(R′)₂;

each of X is independently an amino acid residue;

each of a, b, c, s, and d is independently 1-20;

each of C¹and C²is independently a carbon atom;

each L^sis independently -L^s1-L^s2-L^s3-, wherein L^s1is bonded to C¹and L^s3is bonded to C²;

each of L^s1, L^s2, and L^s3is independently L;

each L is independently a covalent bond, or an optionally substituted, bivalent C₁-C₂₀aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—;

each -Cy- is independently an optionally substituted bivalent group selected from a C_3-20cycloaliphatic ring, a C_6-20aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon;

each R′ is independently —R, —C(O)R, —CO₂R, or —SO₂R;

each R is independently —H, or an optionally substituted group selected from C_1-30aliphatic, C_1-30heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C_6-30aryl, C_6-30arylaliphatic, C_6-30arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or

two R groups are optionally and independently taken together to form a covalent bond, or:

In some embodiments, R^ais R′, wherein R′ is as described in the present disclosure. In some embodiments, R^ais —H. In some embodiments, R^ais R—C(O)—.

In some embodiments, X is a residue of an amino acid of formula A-I. In some embodiments, X is a residue of an amino acid of formula A-II. In some embodiments, X is a residue of an amino acid of formula A-III.

In some embodiments, a is 1. In some embodiments, a is 2. In some embodiments, a is 3. In some embodiments, a is 4. In some embodiments, a is 5. In some embodiments, a is 6. In some embodiments, a is 7. In some embodiments, a is 8. In some embodiments, a is 9. In some embodiments, a is 10. In some embodiments, a is 11. In some embodiments, a is 12. In some embodiments, a is 13. In some embodiments, a is 14. In some embodiments, a is 15. In some embodiments, a is 16. In some embodiments, a is 17. In some embodiments, a is 18. In some embodiments, a is 19. In some embodiments, a is 20.

In some embodiments, R¹is R′ as described in the present disclosure. In some embodiments, R¹is R as described in the present disclosure. In some embodiments, R¹is —H. In some embodiments, R¹is not H. In some embodiments, R¹and R′ of a —N(R′)— or —N(R′)—C(O)O— moiety of L^sor L^s1are R and are taken together with their intervening atoms to form an optionally substituted ring as described in the present disclosure.

In some embodiments, R²is R′ as described in the present disclosure. In some embodiments, R²is R as described in the present disclosure. In some embodiments, R²is —H. In some embodiments, R²is not H. In some embodiments, R¹and R′ of a —N(R′)— or —N(R′)—C(O)O— moiety of L^sor L^s3are R and are taken together with their intervening atoms to form an optionally substituted ring as described in the present disclosure.

In some embodiments, R³is R′ as described in the present disclosure. In some embodiments, R³is R as described in the present disclosure. In some embodiments, R³is —H. In some embodiments, R³is not H.

In some embodiments, R⁴is R′ as described in the present disclosure. In some embodiments, R⁴is R as described in the present disclosure. In some embodiments, R⁴is —H. In some embodiments, R⁴is not H.

In some embodiments, C¹is achiral. In some embodiments, C¹is chiral. In some embodiments, C¹is R. In some embodiments, C¹is S.

In some embodiments, C²is achiral. In some embodiments, C²is chiral. In some embodiments, C²is R. In some embodiments, C²is S.

In some embodiments, b is 2-11. In some embodiments, b is 2. In some embodiments, b is 3. In some embodiments, b is 4. In some embodiments, b is 5. In some embodiments, b is 6. In some embodiments, b is 7. In some embodiments, b is 8. In some embodiments, b is 9. In some embodiments, b is 10. In some embodiments, b is 11.

In some embodiments, c is 1. In some embodiments, c is 2. In some embodiments, c is 3. In some embodiments, c is 4. In some embodiments, c is 5. In some embodiments, c is 6. In some embodiments, c is 7. In some embodiments, c is 8. In some embodiments, c is 9. In some embodiments, c is 10. In some embodiments, c is 11. In some embodiments, c is 12. In some embodiments, c is 13. In some embodiments, c is 14. In some embodiments, c is 15. In some embodiments, c is 16. In some embodiments, c is 17. In some embodiments, c is 18. In some embodiments, c is 19. In some embodiments, c is 20.

In some embodiments, s is 1-5. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3. In some embodiments, s is 4. In some embodiments, s is 5.

In some embodiments, d is 1. In some embodiments, d is 2. In some embodiments, d is 3. In some embodiments, d is 4. In some embodiments, d is 5. In some embodiments, d is 6. In some embodiments, d is 7. In some embodiments, d is 8. In some embodiments, d is 9. In some embodiments, d is 10. In some embodiments, d is 11. In some embodiments, d is 12. In some embodiments, d is 13. In some embodiments, d is 14. In some embodiments, d is 15. In some embodiments, d is 16. In some embodiments, d is 17. In some embodiments, d is 18. In some embodiments, d is 19. In some embodiments, d is 20.

In some embodiments, R^bis R′ as described in the present disclosure. In some embodiments, R^bis R as described in the present disclosure. In some embodiments, R^bis —H. In some embodiments, R^bis —OR′ wherein R′ is as described in the present disclosure. In some embodiments, R^bis —OH. In some embodiments, R^bis —N(R′)₂, wherein each R′ is independently as described in the present disclosure. In some embodiments, R^bis —NH(R′) wherein R′ is independently as described in the present disclosure.

In some embodiments, the present disclosure provides a stapled peptide comprising a staple having the structure of L^s. In some embodiments, the present disclosure provides a stapled peptide comprising a staple having the structure of L^s, wherein:

L^sis -L^s1-L^s2-L^s3-;

one end of L^sis connected to an atom Aⁿ¹of the peptide backbone, wherein Aⁿ¹is bonded to R¹;

one end of L^sis connected to an atom Aⁿ²of the peptide backbone, wherein A²is bonded to R²;

each of R¹and R²is independently R′;

there are m amino acid residues between the amino acid residue comprising Aⁿ¹and the amino acid residue comprising Aⁿ², not including the amino acid residue comprising Aⁿ¹and the amino acid residue comprising Aⁿ²;

m is an integer of 1-12; and

wherein each other variable is independently as described in the present disclosure.

In some embodiments, Aⁿ¹is a carbon atom. In some embodiments, R¹bonded to Aⁿ¹and R′ of a —N(R′)— or —N(R′)—C(O)O— moiety of L^sare R and are taken together with their intervening atoms to form an optionally substituted ring as described in the present disclosure. In some embodiments, Aⁿ¹is achiral. In some embodiments, Aⁿ¹is chiral. In some embodiments, Aⁿ¹is R. In some embodiments, Aⁿ¹is S.

In some embodiments, A²is a carbon atom. In some embodiments, R²bonded to Aⁿ¹and R′ of a —N(R′)— or —N(R′)—C(O)O— moiety of L^sare R and are taken together with their intervening atoms to form an optionally substituted ring as described in the present disclosure. In some embodiments, Aⁿ²is achiral. In some embodiments, Aⁿ²is chiral. In some embodiments, A²is R. In some embodiments, A²is S.

In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9. In some embodiments, m is 10. In some embodiments, m is 11. In some embodiments, m is 12.

In some embodiments, provided agents, e.g., stapled peptides, are optionally conjugated with a second entity, e.g., a targeting moiety (e.g., a carbohydrate, a receptor ligand, etc.), a second peptide, etc. In some embodiments, provided peptides are conjugated to one or more ligands for targeted delivery to cells expressing receptors to which the ligands bind to. In some embodiments, provided agents are conjugated to one or more second entities that have an enzymatic activity, or ligands for proteins that have an enzymatic activity (e.g., E3 ubiquitin ligase).

In some embodiments, provided agents, e.g., stapled peptides, have lower toxicity compared to an appropriate reference peptide (e.g., a peptide having the same sequence but lacking a staple or having a staple that differs in one or more features (e.g., chemistry [e.g., presence or absence, and/or number and/or type of heteroatoms, degree of saturation, etc.], stereochemistry, length, etc.). Among other things, as demonstrated in the present disclosure, in some embodiments provided peptides have low cytotoxicity, and in particular low non-specific cytotoxicity, as compared to an appropriate reference peptide (e.g., in certain particular embodiments, an otherwise identical stapled peptide having a hydrocarbon staple).

In some embodiments, provided agents, e.g., stapled peptides, have unexpected selectivity and/or specificity for modulating beta-catenin functions and/or Wnt pathway compared to other one or more comparable reference agents.

In some embodiments, provided agents, e.g., stapled peptides, selectively interact with Axin-interacting sites of beta-catenin and modulate beta-catenin interactions with other entities (e.g., proteins, small molecules, etc.) at such Axin-interacting sites. As demonstrated in the present disclosure, in some embodiments, provided agents, e.g., stapled peptides, can selectively disrupt beta-catenin interactions at Axin sites without significantly impacting interactions at BCL9-interacting sites of beta-catenin. Technologies for assessing selectivity are widely known in the art and can be utilized in accordance with the present disclosure, e.g., certain fluorescence assays described in the present disclosure.

In some embodiments, the present disclosure provides pharmaceutical compositions comprising a provided agent, e.g., a stapled peptide, and a pharmaceutically acceptable carrier.

In some embodiments, the present disclosure provides technologies for modulating one or more beta-catenin functions. In some embodiments, the present disclosure provides agents, e.g., stapled peptides, and compositions thereof for modulating beta-catenin functions. In some embodiments, the present disclosure provides technologies for inhibiting aberrant beta-catenin activities. As appreciated by those skilled in the art, beta-catenin plays important roles in Wnt signaling pathways and other biological pathways. In some embodiments, the present disclosure provides technologies for modulating Wnt signaling pathway. In some embodiments, the present disclosure provides technologies for inhibiting aberrant Wnt signaling. In some embodiments, the present disclosure provides technologies for modulating expression of a nucleic acid sequence in a system, comprising contacting a system comprising beta-catenin a provided stapled peptide, wherein expression of the nucleic acid sequence is associated with beta-catenin. In some embodiments, the present disclosure provides technologies for modulating level of a product encoded by a nucleic acid sequence in a system, comprising contacting a system comprising beta-catenin a provided peptide, wherein level of a product encoded by a nucleic acid sequence is associated with beta-catenin.

In some embodiments, the present disclosure provides methods for preventing and/or treating a condition, disorder, or diseases associated with beta-catenin. In some embodiments, the present disclosure provides methods for preventing and/or treating a condition, disorder, or diseases associated with Wnt signaling. In some embodiments, provided methods comprise administering to a subject susceptible to or suffering from a condition, disorder or disease associated with beta-catenin and/or Wnt signaling. In some embodiments, a condition, disorder, or disease is cancer.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1. Provided agents can bind to beta-catenin. FIG. 1 depicts exemplary beta-catenin binding data from a competition fluorescence polarization assay. Peptide solutions were prepared in buffer (50 mM Tris pH 8.0, 250 mM NaCl, 2% glycerol, 0.5 mM EDTA, 0.02% w/v sodium azide) using a 3-fold serial dilution from 5 μM. Probe solution (15 nM full-length 13-Catenin, 20 nM FITC labeled peptide (FITC-PEG1-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 1) (hydrocarbon staple formed by two S5 via olefin metathesis)) in buffer) was prepared and incubated for 5 minutes, then 40 μL per well plated in a black polystyrene 384-well plate (Corning). Equal volume of the titrated peptide was added to the plate and incubated protected from light for 15 minutes prior to read. Reads were performed on a Spectramax M5 (Molecular Devices) in duplicate.

FIG. 2. Provided agents are active in cells. FIG. 2 depicts exemplary data from TCF/LEF reporter assays. Y-axes illustrate luminescence, and X-axes illustrate concentrations of peptides. Inhibition of TCF/LEF Reporter Activity by FP0025c and FPO217c Isomer 2. TCF/LEF Luciferase reporter HEK293 cell lines (BPS Bioscience) were treated with dilution series of FP0025c and FP00217c Isomer 2 for 18 hours. 300 ng/mL of Wnt3a (Peprotech) was added to the cells for the final 6 hours of incubation. Luciferase activity was measured using Bright-Glo Luciferase Assay (Promega) according to manufacturer's protocol.

FIG. 3. Provided agents modulate gene expression in cells. FIG. 3 illustrates modulation of gene expression by an exemplary stapled peptide. DLD-1 cells were treated with a dilution series of FPO217c isomer 2 for 18 hours. Total RNA was extracted using the RNeasy Plus kit (Qiagen) according to manufacturer's protocols, and reverse transcribed to cDNA using SuperScript Vilo IV master mix (ThermoFisher Scientific). Gene expression levels were determined by qPCR using Taqman probes (Applied Biosciences) and Taqman Advanced Fast Master Mix (Applied Biosciences) on a QuantStudio 3 (Applied Biosciences). Relative expression was quantified using delta Ct method. For each group, from left to right, Axin 2, LEF1, Cyclin D, LRP6 and c-myc.

FIG. 4. Provided agents modulate gene expression in cells. FIG. 4 illustrates modulation of gene expression by an exemplary stapled peptide. HCT-116 cells were treated with a dilution series of FPO217c isomer 2 for 18 hours. Total RNA was extracted using the RNeasy Plus kit (Qiagen) according to manufacturer's protocols, and reverse transcribed to cDNA using SuperScript Vilo IV master mix (ThermoFisher Scientific). Gene expression levels were determined by qPCR using Taqman probes (Applied Biosciences) and Taqman Advanced Fast Master Mix (Applied Biosciences) on a QuantStudio 3 (Applied Biosciences). Relative expression was quantified using delta Ct method. For each group, from left to right, Axin 2, VEGF, Cyclin D, LRP6 and c-myc.

FIG. 5. Provided agents can selectively modulate gene expression. DLD-1 cells were treated with either 3 uM or 10 uM of each compound for 18 hours. Total RNA was extracted using the RNeasy Plus kit (Qiagen) according to manufacturer's protocols, and reverse transcribed to cDNA using SuperScript Vilo IV master mix (ThermoFisher Scientific). Gene expression levels were determined by qPCR using Taqman probes (Applied Biosciences) and Taqman Advanced Fast Master Mix (Applied Biosciences) on a QuantStudio 3 (Applied Biosciences). Relative expression was quantified using delta Ct method. For each group, from left to right: Axin2, LEF1 and Cyclin D.

FIG. 6. Exemplary pharmacokinetic properties. Peptides were formulated in 10% DMSO:90% saline and dosed by IV at 0.5 mg/kg per compound in three male Sprague-Dawley rats. Serial bleed time-points were taken at 2 min, 6 min, 10 min, 15 min, 30 min, 1, 2, 4, 6, 8, 12 and 24 h and analyzed by quantitative LC/MS using a Thermo Q-Exactive Focus LC/MS/MS. Samples were prepared by protein precipitation with MeOH. Data were fit to a two-compartment model.

FIG. 7. Provided agents selectively disrupts interactions with Axin. In some embodiments, provided agents, e.g., stapled peptides, selectively disrupts interactions at one or more beta-catenin sites that interact with Axin over interactions at one or more beta-catenin sites that interact with BCL9. As illustrated in Panel A, FPO217c isomer 2 and FP0597c displaced a labeled Axin site probe. They, as shown in Panel B, did not displace the labeled BCL9 site probe but FP0650c (stapled peptides designed to interact with one or more beta-catenin sites that interact with BCL9) did. BCL9 Competition FP assay: Peptide solutions were prepared in buffer (50 mM Tris pH 8.0, 250 mM NaCl, 2% glycerol, 0.5 mM EDTA, 0.02% w/v sodium azide) using a 3-fold serial dilution from 10 μM. Probe solution (250 nM full-length beta-catenin, 20 nM 5FAM labeled peptide in buffer) was prepared and 40 μL per well plated in a black polystyrene 384-well plate (Corning). Equal volume of the titrated peptide was added to the plate and incubated protected from light for 15 minutes prior to read. Reads were performed on a Spectramax M5 (Molecular Devices) in duplicate. Probe: Ac-Leu-Ser-Gln-Glu-Gln-Leu-Glu-His-Arg-Glu-Arg-Ser-Leu-Gln-Thr-Leu-Arg-Asp-Ile-Gln-Arg-nLeu-Leu-2NapA-bala-bala-Lys5FAM-NH2 (SEQ ID NO: 2) (from Biochemistry, 2009, 48 (40), pp 9534-9541). Axin Competition FP assay: Peptide solutions were prepared in buffer (50 mM Tris pH 8.0, 250 mM NaCl, 2% glycerol, 0.5 mM EDTA, 0.02% w/v sodium azide) using a 3-fold serial dilution from 5 μM. Probe solution (15 nM full-length beta-catenin, 20 nM FITC labeled peptide in buffer) was prepared and incubated for 5 minutes, then 40 μL per well plated in a black polystyrene 384-well plate (Corning). Equal volume of the titrated peptide was added to the plate and incubated protected from light for 15 minutes prior to read. Reads were performed on a Spectramax M5 (Molecular Devices) in duplicate. Probe: FITC-StAx-33 from Grossmann et al. PNAS 109 17942-17947.

FIG. 8. Exemplary results of various olefin metathesis methods. (A) Grubbs I, one treatment in DCE, at 40° C., 2 hrs. (B) Grubbs II, one treatment in DCE, at 40° C., 2 hrs. (C) Hoveyda-Grubbs I, one treatment in DCE, at 40° C., 2 hrs. (D) Hoveyda-Grubbs II, one treatment in DCE, at 60° C., 2 hrs.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
1. Definitions

As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this disclosure, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75^thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5^thEd., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001.

Administration: As used herein, the term “administration” typically refers to the administration of a composition to a subject or system. Those of ordinary skill in the art will be aware of a variety of routes that may, in appropriate circumstances, be utilized for administration to a subject, for example a human. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some particular embodiments, administration may be bronchial (e.g., by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e. g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc. In some embodiments, administration may involve dosing that is intermittent (e.g., a plurality of doses separated in time) and/or periodic (e.g., individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (e.g., perfusion) for at least a selected period of time.

Agent: In general, the term “agent”, as used herein, may be used to refer to a compound or entity of any chemical class including, for example, a polypeptide, nucleic acid, saccharide, lipid, small molecule, metal, or combination or complex thereof. In appropriate circumstances, as will be clear from context to those skilled in the art, the term may be utilized to refer to an entity that is or comprises a cell or organism, or a fraction, extract, or component thereof. Alternatively or additionally, as context will make clear, the term may be used to refer to a natural product in that it is found in and/or is obtained from nature. In some instances, again as will be clear from context, the term may be used to refer to one or more entities that is man-made in that it is designed, engineered, and/or produced through action of the hand of man and/or is not found in nature. In some embodiments, an agent may be utilized in isolated or pure form; in some embodiments, an agent may be utilized in crude form. In some embodiments, potential agents may be provided as collections or libraries, for example that may be screened to identify or characterize active agents within them. In some cases, the term “agent” may refer to a compound or entity that is or comprises a polymer; in some cases, the term may refer to a compound or entity that comprises one or more polymeric moieties. In some embodiments, the term “agent” may refer to a compound or entity that is not a polymer and/or is substantially free of any polymer and/or of one or more particular polymeric moieties. In some embodiments, the term may refer to a compound or entity that lacks or is substantially free of any polymeric moiety. In some embodiments, an agent is a compound. In some embodiments, an agent is a stapled peptide.

Aliphatic: As used herein, “aliphatic” means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a substituted or unsubstituted monocyclic, bicyclic, or polycyclic hydrocarbon ring that is completely saturated or that contains one or more units of unsaturation, or combinations thereof. Unless otherwise specified, aliphatic groups contain 1-100 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-20 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-9 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-7 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1, 2, 3, or 4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof.

Alkenyl: As used herein, the term “alkenyl” refers to an aliphatic group, as defined herein, having one or more double bonds.

Alkenylene: The term “alkenylene” refers to a bivalent alkenyl group.

Alkyl: As used herein, the term “alkyl” is given its ordinary meaning in the art and may include saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In some embodiments, alkyl has 1-100 carbon atoms. In certain embodiments, a straight chain or branched chain alkyl has about 1-20 carbon atoms in its backbone (e.g., C₁-C₂₀for straight chain, C₂-C₂₀for branched chain), and alternatively, about 1-10. In some embodiments, cycloalkyl rings have from about 3-10 carbon atoms in their ring structure where such rings are monocyclic, bicyclic, or polycyclic, and alternatively about 5, 6 or 7 carbons in the ring structure. In some embodiments, an alkyl group may be a lower alkyl group, wherein a lower alkyl group comprises 1-4 carbon atoms (e.g., C₁-C₄for straight chain lower alkyls).

Alkylene: The term “alkylene” refers to a bivalent alkyl group.

Amino acid: In its broadest sense, as used herein, refers to any compound and/or substance that can be incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds. In some embodiments, an amino acid comprising an amino group and an a carboxylic acid group. In some embodiments, an amino acid has the structure of NH(R^a1)-L^a1-C(R^a2)(R^a3)-L^a2-COOH, wherein each variable is independently as described in the present disclosure. In some embodiments, an amino acid has the general structure NH(R′)—C(R′)₂—COOH, wherein each R′ is independently as described in the present disclosure. In some embodiments, an amino acid has the general structure H₂N—C(R′)₂—COOH, wherein R′ is as described in the present disclosure. In some embodiments, an amino acid has the general structure H₂N—C(H)(R′)—COOH, wherein R′ is as described in the present disclosure. In some embodiments, an amino acid is a naturally-occurring amino acid. In some embodiments, an amino acid is a non-natural amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid. “Standard amino acid” refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. “Nonstandard amino acid” refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. In some embodiments, an amino acid, including a carboxy- and/or amino-terminal amino acid in a polypeptide, can contain a structural modification as compared with the general structure above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and/or substitution (e.g., of the amino group, the carboxylic acid group, one or more protons, one or more hydrogens, and/or the hydroxyl group) as compared with the general structure. In some embodiments, such modification may, for example, alter the circulating half-life of a polypeptide containing the modified amino acid as compared with one containing an otherwise identical unmodified amino acid. In some embodiments, such modification does not significantly alter a relevant activity of a polypeptide containing the modified amino acid, as compared with one containing an otherwise identical unmodified amino acid. As will be clear from context, in some embodiments, the term “amino acid” may be used to refer to a free amino acid; in some embodiments it may be used to refer to an amino acid residue of a polypeptide.

Analog: As used herein, the term “analog” refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an “analog” shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways. In some embodiments, an analog is a substance that can be generated from the reference substance, e.g., by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance. In some embodiments, an analog is or can be generated through performance of a synthetic process different from that used to generate the reference substance.

Animal: As used herein refers to any member of the animal kingdom. In some embodiments, “animal” refers to humans, of either sex and at any stage of development. In some embodiments, “animal” refers to non-human animals, at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and/or worms. In some embodiments, an animal may be a transgenic animal, genetically engineered animal, and/or a clone.

Approximately: As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%%, 15%, 14%, 13%, %12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

Aryl: The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” “aryloxyalkyl,” etc. refers to monocyclic, bicyclic or polycyclic ring systems having a total of five to thirty ring members, wherein at least one ring in the system is aromatic. In some embodiments, an aryl group is a monocyclic, bicyclic or polycyclic ring system having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 3 to 7 ring members. In some embodiments, an aryl group is a biaryl group. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present disclosure, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, binaphthyl, anthracyl and the like, which may bear one or more substituents. In some embodiments, also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like, where a radical or point of attachment is on an aryl ring.

Associated with: Two events or entities are “associated” with one another, as that term is used herein, if the presence, level and/or form of one is correlated with that of the other. For example, a particular entity (e.g., nucleic acid (e.g., genomic DNA, transcripts, mRNA, etc.), polypeptide, genetic signature, metabolite, microbe, etc.) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and/or form correlates with incidence of and/or susceptibility to the disease, disorder, or condition (e.g., across a relevant population).

Carrier: as used herein, refers to a diluent, adjuvant, excipient, or vehicle with which a composition is administered. In some exemplary embodiments, carriers can include sterile liquids, such as, for example, water and oils, including oils of petroleum, animal, vegetable or synthetic origin, such as, for example, peanut oil, soybean oil, mineral oil, sesame oil and the like. In some embodiments, carriers are or include one or more solid components.

Comparable: As used herein, the term “comparable” refers to two or more agents, entities, situations, sets of conditions, etc., that may not be identical to one another but that are sufficiently similar to permit comparison there between so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc. to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied.

Composition: Those skilled in the art will appreciate that the term “composition” may be used to refer to a discrete physical entity that comprises one or more specified components. In general, unless otherwise specified, a composition may be of any form—e.g., gas, gel, liquid, solid, etc.

Comprising: A composition or method described herein as “comprising” one or more named elements or steps is open-ended, meaning that the named elements or steps are essential, but other elements or steps may be added within the scope of the composition or method. To avoid prolixity, it is also understood that any composition or method described as “comprising” (or which “comprises”) one or more named elements or steps also describes the corresponding, more limited composition or method “consisting essentially of” (or which “consists essentially of”) the same named elements or steps, meaning that the composition or method includes the named essential elements or steps and may also include additional elements or steps that do not materially affect the basic and novel characteristic(s) of the composition or method. It is also understood that any composition or method described herein as “comprising” or “consisting essentially of” one or more named elements or steps also describes the corresponding, more limited, and closed-ended composition or method “consisting of” (or “consists of”) the named elements or steps to the exclusion of any other unnamed element or step. In any composition or method disclosed herein, known or disclosed equivalents of any named essential element or step may be substituted for that element or step.

Cycloaliphatic: The term “cycloaliphatic,” as used herein, refers to saturated or partially unsaturated aliphatic monocyclic, bicyclic, or polycyclic ring systems having, e.g., from 3 to 30, members, wherein the aliphatic ring system is optionally substituted. Cycloaliphatic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, norbornyl, adamantyl, and cyclooctadienyl. In some embodiments, the cycloalkyl has 3-6 carbons. The terms “cycloaliphatic” may also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as decahydronaphthyl or tetrahydronaphthyl, where a radical or point of attachment is on an aliphatic ring. In some embodiments, a carbocyclic group is bicyclic. In some embodiments, a carbocyclic group is tricyclic. In some embodiments, a carbocyclic group is polycyclic. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C₃-C₆hydrocarbon, or a C₅-C₁₀bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, or a C₉-C₁₆tricyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic.

Derivative: As used herein, the term “derivative” refers to a structural analogue of a reference substance. That is, a “derivative” is a substance that shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways. In some embodiments, a derivative is a substance that can be generated from the reference substance by chemical manipulation. In some embodiments, a derivative is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance.

Dosage form or unit dosage form: Those skilled in the art will appreciate that the term “dosage form” may be used to refer to a physically discrete unit of an active agent (e.g., a therapeutic or diagnostic agent) for administration to a subject. Typically, each such unit contains a predetermined quantity of active agent. In some embodiments, such quantity is a unit dosage amount (or a whole fraction thereof) appropriate for administration in accordance with a dosing regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., with a therapeutic dosing regimen). Those of ordinary skill in the art appreciate that the total amount of a therapeutic composition or agent administered to a particular subject is determined by one or more attending physicians and may involve administration of multiple dosage forms.

Dosing regimen: Those skilled in the art will appreciate that the term “dosing regimen” may be used to refer to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which is separated in time from other doses. In some embodiments, individual doses are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (i.e., is a therapeutic dosing regimen).

Halogen: The term “halogen” means F, Cl, Br, or I.

Heteroaliphatic: The term “heteroaliphatic” is given its ordinary meaning in the art and refers to aliphatic groups as described herein in which one or more carbon atoms are replaced with one or more heteroatoms (e.g., oxygen, nitrogen, sulfur, silicon, phosphorus, and the like).

Heteroalkyl: The term “heteroalkyl” is given its ordinary meaning in the art and refers to alkyl groups as described herein in which one or more carbon atoms is replaced with a heteroatom (e.g., oxygen, nitrogen, sulfur, silicon, phosphorus, and the like). Examples of heteroalkyl groups include, but are not limited to, alkoxy, poly(ethylene glycol)-, alkyl-substituted amino, tetrahydrofuranyl, piperidinyl, morpholinyl, etc.

Heteroaryl: The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to monocyclic, bicyclic or polycyclic ring systems having, for example, a total of five to thirty, e.g., 5, 6, 9, 10, 14, etc., ring members, wherein at least one ring in the system is aromatic and at least one aromatic ring atom is a heteroatom. In some embodiments, a heteroatom is nitrogen, oxygen or sulfur. In some embodiments, a heteroaryl group is a group having 5 to 10 ring atoms (i.e., monocyclic, bicyclic or polycyclic), in some embodiments 5, 6, 9, or 10 ring atoms. In some embodiments, a heteroaryl group has 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. In some embodiments, a heteroaryl is a heterobiaryl group, such as bipyridyl and the like. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where a radical or point of attachment is on a heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. A heteroaryl group may be monocyclic, bicyclic or polycyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl group, wherein the alkyl and heteroaryl portions independently are optionally substituted.

Heteroatom: The term “heteroatom” means an atom that is not carbon and is not hydrogen. In some embodiments, a heteroatom is oxygen, sulfur, nitrogen, phosphorus, boron or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or a substitutable nitrogen of a heterocyclic ring (for example, N as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as in N-substituted pyrrolidinyl); etc.). In some embodiments, a heteroatom is boron, nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen or sulfur.

Heterocyclyl: As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a monocyclic, bicyclic or polycyclic ring moiety (e.g., 3-30 membered) that is saturated or partially unsaturated and has one or more heteroatom ring atoms. In some embodiments, a heteroatom is boron, nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen or sulfur. In some embodiments, a heterocyclyl group is a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or ⁺NR (as in N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where a radical or point of attachment is on a heteroaliphatic ring. A heterocyclyl group may be monocyclic, bicyclic or polycyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.

Homology: As used herein, the term “homology” refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% similar (e.g., containing residues with related chemical properties at corresponding positions). For example, as is well known by those of ordinary skill in the art, certain amino acids are typically classified as similar to one another as “hydrophobic” or “hydrophilic” amino acids, and/or as having “polar” or “non-polar” side chains. Substitution of one amino acid for another of the same type may often be considered a “homologous” substitution. Typical amino acid categorizations are summarized below:

Alanine
Ala
A
nonpolar
neutral
1.8

Arginine
Arg
R
polar
positive
−4.5

Asparagine
Asn
N
polar
neutral
−3.5

Aspartic acid
Asp
D
polar
negative
−3.5

Cysteine
Cys
C
nonpolar
neutral
2.5

Glutamic acid
Glu
E
polar
negative
−3.5

Glutamine
Gln
Q
polar
neutral
−3.5

Glycine
Gly
G
nonpolar
neutral
−0.4

Histidine
His
H
polar
positive
−3.2

Isoleucine
Ile
I
nonpolar
neutral
4.5

Leucine
Leu
L
nonpolar
neutral
3.8

Lysine
Lys
K
polar
positive
−3.9

Methionine
Met
M
nonpolar
neutral
1.9

Phenylalanine
Phe
F
nonpolar
neutral
2.8

Proline
Pro
P
nonpolar
neutral
−1.6

Serine
Ser
S
polar
neutral
−0.8

Threonine
Thr
T
polar
neutral
−0.7

Tryptophan
Trp
W
nonpolar
neutral
−0.9

Tyrosine
Tyr
Y
polar
neutral
−1.3

Valine
Val
V
nonpolar
neutral
4.2

Ambiguous Amino Acids
3-Letter
1-Letter

Asparagine or aspartic acid
Asx
B

Glutamine or glutamic acid
Glx
Z

Leucine or Isoleucine
Xle
J

Unspecified or unknown amino acid
Xaa
X

As will be understood by those skilled in the art, a variety of algorithms are available that permit comparison of sequences in order to determine their degree of homology, including by permitting gaps of designated length in one sequence relative to another when considering which residues “correspond” to one another in different sequences. Calculation of the percent homology between two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-corresponding sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position; when a position in the first sequence is occupied by a similar nucleotide as the corresponding position in the second sequence, then the molecules are similar at that position. The percent homology between the two sequences is a function of the number of identical and similar positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. Representative algorithms and computer programs useful in determining the percent homology between two nucleotide sequences include, for example, the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent homology between two nucleotide sequences can, alternatively, be determined for example using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.

“Improved,” “increased” or “reduced”: As used herein, these terms, or grammatically comparable comparative terms, indicate values that are relative to a comparable reference measurement. For example, in some embodiments, an assessed value achieved with an agent of interest may be “improved” relative to that obtained with a comparable reference agent. Alternatively or additionally, in some embodiments, an assessed value achieved in a subject or system of interest may be “improved” relative to that obtained in the same subject or system under different conditions (e.g., prior to or after an event such as administration of an agent of interest), or in a different, comparable subject (e.g., in a comparable subject or system that differs from the subject or system of interest in presence of one or more indicators of a particular disease, disorder or condition of interest, or in prior exposure to a condition or agent, etc). In some embodiments, comparative terms refer to statistically relevant differences (e.g., that are of a prevalence and/or magnitude sufficient to achieve statistical relevance). Those skilled in the art will be aware, or will readily be able to determine, in a given context, a degree and/or prevalence of difference that is required or sufficient to achieve such statistical significance.

Partially unsaturated: As used herein, the term “partially unsaturated” refers to a moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass groups having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties.

Peptide: The term “peptide” as used herein refers to a polypeptide that is typically relatively short, for example having a length of less than about 100 amino acids, less than about 50 amino acids, less than about 40 amino acids less than about 30 amino acids, less than about 25 amino acids, less than about 20 amino acids, less than about 15 amino acids, or less than 10 amino acids.

Pharmaceutical composition: As used herein, the term “pharmaceutical composition” refers to an active agent, formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginally or intrarectally, for example, as a pessary, cream, or foam; sublingually; ocularly; transdermally; or nasally, pulmonary, and to other mucosal surfaces.

Pharmaceutically acceptable: As used herein, the phrase “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

Pharmaceutically acceptable carrier: As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.

Pharmaceutically acceptable salt: The term “pharmaceutically acceptable salt”, as used herein, refers to salts of such compounds that are appropriate for use in pharmaceutical contexts, i.e., salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). In some embodiments, pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts, which are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other known methods such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, nontoxic base addition salts, such as those formed by acidic groups of provided compounds (e.g., phosphate linkage groups of oligonucleotides, phosphorothioate linkage groups of oligonucleotides, etc.) with bases. Representative alkali or alkaline earth metal salts include salts of sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, pharmaceutically acceptable salts are ammonium salts (e.g., —N(R)₃). In some embodiments, pharmaceutically acceptable salts are sodium salts. In some embodiments, pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.

Polypeptide: As used herein refers to any polymeric chain of amino acids. In some embodiments, a polypeptide has an amino acid sequence that occurs in nature. In some embodiments, a polypeptide has an amino acid sequence that does not occur in nature. In some embodiments, a polypeptide has an amino acid sequence that is engineered in that it is designed and/or produced through action of the hand of man. In some embodiments, a polypeptide may comprise or consist of natural amino acids, non-natural amino acids, or both. In some embodiments, a polypeptide may comprise or consist of only natural amino acids or only non-natural amino acids. In some embodiments, a polypeptide may comprise D-amino acids, L-amino acids, or both. In some embodiments, a polypeptide may comprise only D-amino acids. In some embodiments, a polypeptide may comprise only L-amino acids. In some embodiments, a polypeptide may include one or more pendant groups or other modifications, e.g., modifying or attached to one or more amino acid side chains, at the polypeptide's N-terminus, at the polypeptide's C-terminus, or any combination thereof. In some embodiments, such pendant groups or modifications may be selected from the group consisting of acetylation, amidation, lipidation, methylation, pegylation, etc., including combinations thereof. In some embodiments, a polypeptide may be cyclic, and/or may comprise a cyclic portion. In some embodiments, a polypeptide is not cyclic and/or does not comprise any cyclic portion. In some embodiments, a polypeptide is linear. In some embodiments, a polypeptide may be or comprise a stapled polypeptide. In some embodiments, the term “polypeptide” may be appended to a name of a reference polypeptide, activity, or structure; in such instances it is used herein to refer to polypeptides that share the relevant activity or structure and thus can be considered to be members of the same class or family of polypeptides. For each such class, the present specification provides and/or those skilled in the art will be aware of exemplary polypeptides within the class whose amino acid sequences and/or functions are known; in some embodiments, such exemplary polypeptides are reference polypeptides for the polypeptide class or family. In some embodiments, a member of a polypeptide class or family shows significant sequence homology or identity with, shares a common sequence motif (e.g., a characteristic sequence element) with, and/or shares a common activity (in some embodiments at a comparable level or within a designated range) with a reference polypeptide of the class; in some embodiments with all polypeptides within the class). For example, in some embodiments, a member polypeptide shows an overall degree of sequence homology or identity with a reference polypeptide that is at least about 30-40%, and is often greater than about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more and/or includes at least one region (e.g., a conserved region that may in some embodiments be or comprise a characteristic sequence element) that shows very high sequence identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99%. Such a conserved region usually encompasses at least 3-4 and often up to 20 or more amino acids; in some embodiments, a conserved region encompasses at least one stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids. In some embodiments, a relevant polypeptide may comprise or consist of a fragment of a parent polypeptide. In some embodiments, a useful polypeptide as may comprise or consist of a plurality of fragments, each of which is found in the same parent polypeptide in a different spatial arrangement relative to one another than is found in the polypeptide of interest (e.g., fragments that are directly linked in the parent may be spatially separated in the polypeptide of interest or vice versa, and/or fragments may be present in a different order in the polypeptide of interest than in the parent), so that the polypeptide of interest is a derivative of its parent polypeptide.

Prevent or prevention: as used herein when used in connection with the occurrence of a disease, disorder, and/or condition, refers to reducing the risk of developing the disease, disorder and/or condition and/or to delaying onset of one or more characteristics or symptoms of the disease, disorder or condition. Prevention may be considered complete when onset of a disease, disorder or condition has been delayed for a predefined period of time.

Protecting Group: The phrase “protecting group,” as used herein, refers to temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. A “Si protecting group” is a protecting group comprising a Si atom, such as Si-trialkyl (e.g., trimethylsilyl, tributylsilyl, t-butyldimethylsilyl), Si-triaryl, Si-alkyl-diphenyl (e.g., t-butyldiphenylsilyl), or Si-aryl-dialkyl (e.g., Si-phenyldialkyl). Generally, a Si protecting group is attached to an oxygen atom. The field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). Such protecting groups (and associated protected moieties) are described in detail below.

Protected hydroxyl groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3^rdedition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. Examples of suitably protected hydroxyl groups further include, but are not limited to, esters, carbonates, sulfonates, allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of suitable esters include formates, acetates, propionates, pentanoates, crotonates, and benzoates. Specific examples of suitable esters include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetate), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate. Examples of suitable carbonates include 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl carbonate. Examples of suitable silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl ether, and other trialkylsilyl ethers. Examples of suitable alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, and allyl ether, or derivatives thereof. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyran-2-yl ether. Examples of suitable arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl ethers.

Protected amines are well known in the art and include those described in detail in Greene (1999). Suitable mono-protected amines further include, but are not limited to, aralkylamines, carbamates, allyl amines, amides, and the like. Examples of suitable mono-protected amino moieties include t-butyloxycarbonylamino (—NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonylamino, allyloxycarbonylamino (—NHAlloc), benzyloxocarbonylamino (—NHCBZ), allylamino, benzylamino (—NHBn), fluorenylmethylcarbonyl (—NHFmoc), formamido, acetamido, chloroacetamido, dichloroacetamido, trichloroacetamido, phenylacetamido, trifluoroacetamido, benzamido, t-butyldiphenylsilyl, and the like. Suitable di-protected amines include amines that are substituted with two substituents independently selected from those described above as mono-protected amines, and further include cyclic imides, such as phthalimide, maleimide, succinimide, and the like. Suitable di-protected amines also include pyrroles and the like, 2,2,5,5-tetramethyl-[1,2,5]azadisilolidine and the like, and azide.

Protected aldehydes are well known in the art and include those described in detail in Greene (1999). Suitable protected aldehydes further include, but are not limited to, acyclic acetals, cyclic acetals, hydrazones, imines, and the like. Examples of such groups include dimethyl acetal, diethyl acetal, diisopropyl acetal, dibenzyl acetal, bis(2-nitrobenzyl) acetal, 1,3-dioxanes, 1,3-dioxolanes, semicarbazones, and derivatives thereof.

Protected carboxylic acids are well known in the art and include those described in detail in Greene (1999). Suitable protected carboxylic acids further include, but are not limited to, optionally substituted C_1-6aliphatic esters, optionally substituted aryl esters, silyl esters, activated esters, amides, hydrazides, and the like. Examples of such ester groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl ester, wherein each group is optionally substituted. Additional suitable protected carboxylic acids include oxazolines and ortho esters.

Protected thiols are well known in the art and include those described in detail in Greene (1999). Suitable protected thiols further include, but are not limited to, disulfides, thioethers, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates, and the like. Examples of such groups include, but are not limited to, alkyl thioethers, benzyl and substituted benzyl thioethers, triphenylmethyl thioethers, and trichloroethoxycarbonyl thioester, to name but a few.

Reference: As used herein describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and/or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and/or comparison to a particular possible reference or control.

Substitution: As described herein, compounds of the disclosure may contain optionally substituted and/or substituted moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, example substituents are described below.

Suitable monovalent substituents are halogen; —(CH₂)_0-4R^∘; —(CH₂)_0-4OR^∘; —O(CH₂)_0-4R^∘, —O—(CH₂)_0-4C(O)OR^∘; —(CH₂)_0-4CH(OR^∘)₂; —(CH₂)_0-4Ph, which may be substituted with R^∘; —(CH₂)_0-4O(CH₂)_0-1Ph which may be substituted with R^∘; —CH═CHPh, which may be substituted with R^∘; —(CH₂)_0-4O(CH₂)_0-1-pyridyl which may be substituted with R^∘; —NO₂; —CN; —N₃; —(CH₂)_0-4N(R^∘)₂; —(CH₂)_0-4N(R^∘)C(O)R^∘; —N(R^∘)C(S)R^∘; —(CH₂)_{0- 4}N(R^∘)C(O)N(R^∘)₂; —N(R^∘)C(S)N(R^∘)₂; —(CH₂)_0-4N(R^∘)C(O)OR^∘; —N(R^∘)N(R^∘)C(O)R^∘; —N(R^∘)N(R^∘)C(O)N(R^∘)₂; —N(R^∘)N(R^∘)C(O)OR^∘; —(CH₂)_0-4C(O)R^∘; —C(S)R^∘; —(CH₂)_0-4C(O)OR^∘; —(CH₂)_0-4C(O)SR^∘; —(CH₂)_0-4C(O)OSi(R^∘)₃; —(CH₂)_0-4OC(O)R^∘; —OC(O)(CH₂)_0-4SR^∘, —SC(S)SR^∘; —(CH₂)_0-4SC(O)R^∘; —(CH₂)_0-4C(O)N(R^∘)₂; —C(S)N(R^∘)₂; —C(S)SR^∘; —SC(S)SR^∘, —(CH₂)_0-4OC(O)N(R^∘)₂; —C(O)N(OR^∘)R^∘; —C(O)C(O)R^∘; —C(O)CH₂C(O)R^∘; —C(NOR^∘)R^∘; —(CH₂)_0-4SSR^∘; —(CH₂)_0-4S(O)₂R^∘; —(CH₂)_0-4S(O)₂₀R^∘; —(CH₂)_0-4OS(O)₂R^∘; —S(O)₂N(R^∘)₂; —(CH₂)_0-4S(O)R^∘; —N(R^∘)S(O)₂N(R^∘)₂; —N(R^∘)S(O)₂R^∘; —N(OR^∘)R^∘; —C(NH)N(R^∘)₂; —Si(R^∘)₃; —OSi(R^∘)₃; —P(R^∘)₂; —P(OR^∘)₂; —OP(R^∘)₂; —OP(OR^∘)₂; —N(R^∘)P(R^∘)₂; —B(R^∘)₂; —OB(R^∘)₂; —P(O)(R^∘)₂; —OP(O)(R^∘)₂; —N(R^∘)P(O)(R^∘)₂; —(C₁-4 straight or branched alkylene)O—N(R^∘)₂; or —(C_1-4straight or branched alkylene)C(O)O—N(R^∘)₂; wherein each R^∘ may be substituted as defined below and is independently hydrogen, C_1-20aliphatic, C_1-20heteroaliphatic having 1-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, —CH₂—(C_6-14aryl), —O(CH₂)_0-1(C_6-14aryl), —CH₂-(5-14 membered heteroaryl ring), a 5-20 membered, monocyclic, bicyclic, or polycyclic, saturated, partially unsaturated or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, or, notwithstanding the definition above, two independent occurrences of R^∘, taken together with their intervening atom(s), form a 5-20 membered, monocyclic, bicyclic, or polycyclic, saturated, partially unsaturated or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, which may be substituted as defined below.

Suitable monovalent substituents on R^∘(or the ring formed by taking two independent occurrences of R^∘together with their intervening atoms), are independently halogen, —(CH₂)_0-2R^●, -(haloR^●), —(CH₂)_0-2OH, —(CH₂)_0-2OR^●, —(CH₂)_0-2CH(OR^●)₂; —O(haloR^●), —CN, —N₃, —(CH₂)_0-2C(O)R^●, —(CH₂)_0-2C(O)OH, —(CH₂)_0-2C(O)OR^●, —(CH₂)_0-2SR^●, —(CH₂)_0-2SH, —(CH₂)_0-2NH₂, —(CH₂)_0-2NHR^●, —(CH₂)_0-2NR^●₂, —NO₂, —SiR^●₃, —OSiR^●₃, —C(O)SR^●, —(C_1-4straight or branched alkylene)C(O)OR^●, or —SSR^● wherein each R^● is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C_1-4aliphatic, —CH₂Ph, —O(CH₂)_0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents on a saturated carbon atom of R^∘ include ═O and ═S.

Suitable divalent substituents are the following: ═O, ═S, ═NNR*₂, ═NNHC(O)R*, ═NNHC(O)OR*, ═NNHS(O)₂R*, ═NR*, ═NOR*, —O(C(R*₂))_2-3O—, or —S(C(R*₂))_2-3S—, wherein each independent occurrence of R* is selected from hydrogen, C_1-6aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: —O(CR*₂)_2-3O—, wherein each independent occurrence of R* is selected from hydrogen, C₁-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

Suitable substituents on the aliphatic group of R* are halogen, —R^●, -(haloR^●), —OH, —OR^●, —O(haloR^●), —CN, —C(O)OH, —C(O)OR^●, —NH₂, —NHR^●, —NR′₂, or —NO₂, wherein each R^● is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C₁-4 aliphatic, —CH₂Ph, —O(CH₂)_0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In some embodiments, suitable substituents on a substitutable nitrogen are —R^†, —NR^†₂, —C(O)R^†, —C(O)OR^†, —C(O)C(O)R^†, —C(O)CH₂C(O)R^†, —S(O)₂R^†, —S(O)₂NR^†₂, —C(S)NR^†₂, —C(NH)NR^†₂, or —N(R^†)S(O)₂R; wherein each R is independently hydrogen, C_1-6aliphatic which may be substituted as defined below, unsubstituted —OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or, notwithstanding the definition above, two independent occurrences of R, taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

Suitable substituents on the aliphatic group of R^† are independently halogen, —R^●, -(haloR^●), —OH, —OR^●, —O(haloR^●), —CN, —C(O)OH, —C(O)OR^●, —NH₂, —NHR^●, —NR′₂, or —NO₂, wherein each R^● is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C_1-4aliphatic, —CH₂Ph, —O(CH₂)_0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

Subject: As used herein, the term “subject” or “test subject” refers to any organism to which a provided compound or composition is administered in accordance with the present disclosure e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans; insects; worms; etc.) and plants. In some embodiments, a subject may be suffering from, and/or susceptible to a disease, disorder, and/or condition. In some embodiments, a subject is a human.

Susceptible to: An individual who is “susceptible to” a disease, disorder, and/or condition is one who has a higher risk of developing the disease, disorder, and/or condition than does a member of the general public. In some embodiments, an individual who is susceptible to a disease, disorder and/or condition may not have been diagnosed with the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may not exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.

Therapeutic agent: As used herein, the phrase “therapeutic agent” refers to an agent that, when administered to a subject, has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and/or reduce incidence of one or more symptoms or features of a disease, disorder, and/or condition.

Therapeutic regimen: A “therapeutic regimen”, as that term is used herein, refers to a dosing regimen whose administration across a relevant population may be correlated with a desired or beneficial therapeutic outcome.

Therapeutically effective amount: As used herein, the term “therapeutically effective amount” means an amount of a substance (e.g., a therapeutic agent, composition, and/or formulation) that elicits a desired biological response when administered as part of a therapeutic regimen. In some embodiments, a therapeutically effective amount of a substance is an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the disease, disorder, and/or condition. As will be appreciated by those of ordinary skill in this art, the effective amount of a substance may vary depending on such factors as the desired biological endpoint, the substance to be delivered, the target cell or tissue, etc. For example, the effective amount of compound in a formulation to treat a disease, disorder, and/or condition is the amount that alleviates, ameliorates, relieves, inhibits, prevents, delays onset of, reduces severity of and/or reduces incidence of one or more symptoms or features of the disease, disorder, and/or condition. In some embodiments, a therapeutically effective amount is administered in a single dose; in some embodiments, multiple unit doses are required to deliver a therapeutically effective amount.

Treat: As used herein, the term “treat,” “treatment,” or “treating” refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and/or reduce incidence of one or more symptoms or features of a disease, disorder, and/or condition. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition. In some embodiments, treatment may be administered to a subject who exhibits only early signs of the disease, disorder, and/or condition, for example for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.

Unit dose: The expression “unit dose” as used herein refers to an amount administered as a single dose and/or in a physically discrete unit of a pharmaceutical composition. In many embodiments, a unit dose contains a predetermined quantity of an active agent. In some embodiments, a unit dose contains an entire single dose of the agent. In some embodiments, more than one unit dose is administered to achieve a total single dose. In some embodiments, administration of multiple unit doses is required, or expected to be required, in order to achieve an intended effect. A unit dose may be, for example, a volume of liquid (e.g., an acceptable carrier) containing a predetermined quantity of one or more therapeutic agents, a predetermined amount of one or more therapeutic agents in solid form, a sustained release formulation or drug delivery device containing a predetermined amount of one or more therapeutic agents, etc. It will be appreciated that a unit dose may be present in a formulation that includes any of a variety of components in addition to the therapeutic agent(s). For example, acceptable carriers (e.g., pharmaceutically acceptable carriers), diluents, stabilizers, buffers, preservatives, etc., may be included as described infra. It will be appreciated by those skilled in the art, in many embodiments, a total appropriate daily dosage of a particular therapeutic agent may comprise a portion, or a plurality, of unit doses, and may be decided, for example, by the attending physician within the scope of sound medical judgment. In some embodiments, the specific effective dose level for any particular subject or organism may depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of specific active compound employed; specific composition employed; age, body weight, general health, sex and diet of the subject; time of administration, and rate of excretion of the specific active compound employed; duration of the treatment; drugs and/or additional therapies used in combination or coincidental with specific compound(s) employed, and like factors well known in the medical arts.

Unsaturated: The term “unsaturated” as used herein, means that a moiety has one or more units of unsaturation.

Wild-type: As used herein, the term “wild-type” has its art-understood meaning that refers to an entity having a structure and/or activity as found in nature in a “normal” (as contrasted with mutant, diseased, altered, etc.) state or context. Those of ordinary skill in the art will appreciate that wild-type genes and polypeptides often exist in multiple different forms (e.g., alleles).

Unless otherwise specified, salts, such as pharmaceutically acceptable acid or base addition salts, stereoisomeric forms, and tautomeric forms, of provided compound are included.

Unless otherwise clear from context, in the present disclosure, (i) the term “a” may be understood to mean “at least one”; (ii) the term “or” may be understood to mean “and/or”; (iii) the terms “comprising” and “including” may be understood to encompass itemized components or steps whether presented by themselves or together with one or more additional components or steps; and (iv) the terms “about” and “approximately” may be understood to permit standard variation as would be understood by those of ordinary skill in the art; and (v) where ranges are provided, endpoints are included.

2. Beta-Catenin

Beta-catenin is a protein that is important to many biological processes, e.g., the development of tissue in animals. As part of the Wingless and INT-1 (Wnt) signaling pathway, beta-catenin helps to regulate expression of genes, which among other things, are involved in cell differentiation, proliferation, and survival. Aberrant Wnt signaling and/or maintenance of beta-catenin levels underlies a number of human diseases including but not limited to cancer, diabetes, and obesity [Cell. 2012; 149(6): 1192-1205]. It is reported that when Wnt signaling is inactive, beta-catenin resides in a multicomponent destruction complex that includes the proteins Axin, adenomatous polypois coli (APC), casein kinase 1α (CK1α), and glycogen synthase kinase 3β (GSK3β). In the destruction complex, beta-catenin may be phosphorylated by CK1α and GSK30. This consequently may tag beta-catenin for eventual ubiquitination and proteosomal degradation. It is also reported that when the Wnt signaling pathway is initiated at the cellular membrane by a ligand, a complex involving the proteins Frizzled and the low-density lipoprotein related receptor (LRP) is formed. This heterodimeric protein complex, reportedly, in turn recruits Axin to the membrane resulting in dissociation of the destruction complex and elevated levels of beta-catenin in the cytosol [Dev Cell. 2009; 18(1): 9-26].

It is reported that beta-catenin that has accumulated in the cytosol may subsequently translocate to the nucleus where it may influence the expression of genes through a transcription activation complex. In some reports, in this complex, beta-catenin associates with several proteins including different transcription factors, histone modifiers, and transcription co-activators including B-cell CLL/lymphoma 9 (BCL9) [Dev Cell. 2009; 18(1):9-26]. In some instances, BCL9 serves as a bridge between beta-catenin and another protein, pygopus; and studies have demonstrated that BCL9 mediated recruitment of pygopus is necessary for Wnt signaling [Nat Rev Mol Cell Biol. 2009; 10(4): 276-286, Cell. 2002; 109(1): 47-60].

In some embodiments, one strategy to address diseases related to Wnt signaling pathway is to affect the ability of β-catenin to interact with other components in the signaling pathway. Reported protein crystal structures reveal that β-catenin interacts with proteins such as Axin and BCL9 in the destruction complex and transcription complex, respectively. In some reported structures, Axin and BCL9 bind to β-catenin through interactions mediated by their α-helical Axin-CBD and HD2 domains, respectively. [Genes Dev. 2003; 17(22): 2753-2764, Mol Cell. 2006; 24(2): 293-300]. While some small molecules have been reported to modulate β-catenin protein-protein interactions [Curr Pharm Des. 2012; 19(40): 634-664], the present disclosure notes that it is generally challenging for small molecules to address interaction sites with extended surface areas as is the case between β-catenin and Axin or BCL9.

In some embodiments, one or more beta-catenin site interacting with Axin are those reported in, e.g., Xing et al., Genes & Development 2003, 17(22), 2753-2764. In some embodiments, interactions between beta-catenin and Axin comprise residues 469-481 of Xenopus Axin-CBD domain (which is highly homologous to human Axin) forming a continuous alpha helix that fits into a groove of beta-catenin formed by the armadillo repeats. It is reported that Axin-CBD specifically interacts with the third helices of beta-catenin armadillo repeats 3 and 4. As reported, the beta-catenin/Axin interface is rather hydrophobic. Reported interactions between beta-catenin and Xenopus Axin comprises hydrogen bonding (e.g. side chain of H476 in Xenopus Axin and H260 of beta-catenin), salt bridges (e.g. side chain or D474 in Xenopus Axin and K292 of beta-catenin), and/or hydrophobic interaction (e.g. I472, L473, V477, V480, M481 reside on helix surface complementary to a shallow beta-catenin groove; L473 in Xenopus Axin sits in a shallow hydrophobic pocket formed by F253, F293, and Y254 of beta-catenin; H476 and V477 of Xenopus Axin interact with T257 and I296 of beta-catenin respectively, P469 and M481 of Xenopus Axin interact with S250 and W338 of beta catenin, respectively). In some embodiments, residues 469-481 of Xenopus Axin are the human Axin residues corresponding to residues 469-481 in Xenopus Axin.

In some embodiments, one or more beta-catenin site interacting with BCL9 are those reported in, e.g., Sampietro et al., Molecular Cell, 24(2), 293-300, 2006; Kawamoto et al., Biochemistry 2009, 48, 9534-9541; etc. In some embodiments, interactions between beta-catenin and BCL9 comprise that residues 352-374 of human BCL9-HD2 form a continuous alpha helix that packs against a groove formed between helices 2 and 3 of armadillo repeat 1 of beta-catenin and forms a helix bundle with the three helices of the first armadillo repeat of beta-catenin. In some embodiments, interactions between beta-catenin and BCL9 comprises hydrogen bonding, salt bridge, (e.g., the N-terminal side of the BCL9 helix with conserved residues in beta-catenin that form an acidic knob (e.g., H358 and R359 of BCL9 forming hydrogen bond and salt bridge with D162 and D164 of beta-catenin, respectively; S362 of BCL9 potentially forming hydrogen bond with H358 of beta-catenin; etc.; see Sampietro 2006)), and/or hydrophobic interaction (e.g., the C-terminal side of BCL9 helix with a conserved beta-catenin surface, involving L366/L369/I373 in BCL9 and residues L156/L159/L178 of beta-catenin; M174 of beta-catenin protruding into hydrophobic interface; etc.; see Sampietro 2006)).

Among other things, the present disclosure provides stapled peptides that offer another therapeutic modality for targets such as β-catenin. In some embodiments, compared to small molecules, stapled peptides may better address the challenges of targeting protein-protein interactions. In some embodiments, stapled peptides present polypeptide side chain functional groups in a desired conformation for competing protein-protein interactions. Additionally or alternatively, stapled peptides in some embodiments may possess improved bioactivity, proteolytic stability, and cell permeability, than peptides without staples.

3. Peptide Agents

In some embodiments, provided agents are stapled peptides. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin and compete with Axin for interaction with beta-catenin. In some embodiments, the present disclosure provides stapled peptides that physically interact with one or more beta-catenin amino acid residues that physically interact with Axin.

Among other things, provided stapled peptides can modulate one or more functions of beta-catenin, including those involved in Wnt/beta-catenin pathway. In some embodiments, provided stapled peptides are useful for treating various conditions, disorders, and/or diseases that are associated with beta-catenin. Exemplary structural elements of provided stapled peptides are described herein.

a. Amino Acid Sequence

In some embodiments, the present disclosure provides amino acid sequences for stapled peptides. In some embodiments, stapled peptides comprising provided amino acid sequences interact with beta-catenin, e.g., as determined by one or more methods as described in the present disclosure. In some embodiments, stapled peptides comprising provided amino acid sequences interact with beta-catenin at one or more beta-catenin sites that interact with Axin, e.g., as determined by one or more methods as described in the present disclosure.

As appreciated by those skilled in the art reading the present disclosure, various amino acid sequences, including those specifically exemplified in the present disclosure and appropriate variants thereof, can be incorporated into provided stapled peptides. In some embodiments, a provided amino acid sequence is derived from a human Axin sequence. In some embodiments, a provided amino acid sequence is derived from the beta-catenin binding region of Axin (see Xing, et al.). In some embodiments, a provided amino acid sequence is derived from Axin sequence that interacts with beta-catenin. In some embodiments, a provided amino acid sequence comprises a sequence of Axin or a variant thereof. In some embodiments, a provided amino acid sequence comprises a sequence of the beta-catenin binding region of Axin or a variant thereof. In some embodiments, a provided amino acid sequence comprises an Axin sequence that interacts with beta-catenin or a variant thereof. In some embodiments, a provided amino acid sequence comprises a set of Axin residues, or a homolog thereof. In some embodiments, the set of Axin residues are those that interact with beta-catenin. In some embodiments, the set of Axin residues comprises H476, D474, 1472, L473, V477, V480, P469 and M481 of Xenopus Axin. In some embodiments, the set of Axin residues comprises or is L473, D474, and H476 of Xenopus Axin. In some embodiments, the set of Axin residues comprises H476 of Xenopus Axin. In some embodiments, the set of Axin residues comprises D474 of Xenopus Axin. In some embodiments, the set of Axin residues comprises I472 of Xenopus Axin. In some embodiments, the set of Axin residues comprises L473 of Xenopus Axin. In some embodiments, the set of Axin residues comprises V477 of Xenopus Axin. In some embodiments, the set of Axin residues comprises V480 of Xenopus Axin. In some embodiments, the set of Axin residues comprises P469 of Xenopus Axin. In some embodiments, the set of Axin residues comprises M481 of Xenopus Axin. In some embodiments, a homolog of a set of Axin residues is a set of Axin residues wherein one or more amino acid of the set are independently replaced with its or their homologs.

In some embodiments, a homolog of an amino acid is a naturally occurring or non-naturally occurring amino acid that has one or more similar properties to the amino acid, for example, that is typically classified as similar to one another as “hydrophobic”, “hydrophilic”, “basic”, or “acidic” amino acids, and/or as having “polar”, “non-polar”, “hydrophobic”, “hydrophilic”, “basic”, “acidic”, and/or “similar size” side chains. For example, in some embodiments, depending on context, a homolog of leucine can be an optionally substituted (substituted or unsubstituted) amino acid selected from isoleucine, alanine, homoleucine, 3-cyclobutylalanine, alpha-neopentylglycine, 3-cyclopropylalanine, alpha-methylleucine, and 3-cyclohexylalanine; a homolog of isoleucine can be an optionally substituted amino acid selected from alanine, leucine, homoleucine, 3-cyclobutylalanine, alpha-neopentylglycine, 3-cyclopropylalanine, L-alloisoleucine, and alpha-methylleucine; a homolog of phenylalanine can be an optionally substituted amino acid residue selected from tryptophan, tyrosine, 3-(1-naphthylalanine), 3-(2-naphthylalanine), 2-chlorophenyalanine, 3-chlorophenylalanine, 4-chlorophenylalanine, 4-tert-butylphenylalanine, O-methyl tyrosine, homophenylalanine, 4-fluorophenylalanine, 4-methylphenylalanine, 4-bromophenylalanine, 4-phenyl-L-phenylalanine, 5-chlorotryptophan, 5-hydroxytryptophan, 4-trifluoromethylphenylalanine, 4-guanidino-L-phenylalanine, 2-quinoyl-L-alanine, 3-cyclobutylalanine, alpha-neopentylglycine, and L-2-aminoadipic acid; etc.

In some embodiments, a homolog of a hydrophobic amino acid is another hydrophobic amino acid. In some embodiments, a homolog of an amino acid comprising a hydrophobic side chain is another hydrophobic amino acid comprising a hydrophobic side chain.

In some embodiments, a homolog of a hydrophilic amino acid is another hydrophilic amino acid. In some embodiments, a homolog of an amino acid comprising a hydrophilic side chain is another hydrophilic amino acid comprising a hydrophilic side chain.

In some embodiments, a homolog of a basic amino acid is another basic amino acid. In some embodiments, a homolog of an amino acid comprising a basic side chain is another basic amino acid comprising a basic side chain.

In some embodiments, a homolog of an acidic amino acid is another acidic amino acid. In some embodiments, a homolog of an amino acid comprising an acidic side chain is another acidic amino acid comprising an acidic side chain.

In some embodiments, a homolog of an aromatic amino acid is another aromatic amino acid. In some embodiments, a homolog of an amino acid comprising an aromatic side chain is another aromatic amino acid comprising an aromatic side chain.

In some embodiments, a homolog of a polar amino acid is another polar amino acid. In some embodiments, a homolog of an amino acid comprising a polar side chain is another polar amino acid comprising a polar side chain.

In some embodiments, a homolog of a non-polar amino acid is another non-polar amino acid. In some embodiments, a homolog of an amino acid comprising a non-polar side chain is another non-polar amino acid comprising a non-polar side chain.

In some embodiments, a homolog of an amino acid is sterically similar to the amino acid. In some embodiments, a homolog of an amino acid comprises a side chain that has a similar size to the side chain of the amino acid.

In some embodiments, when an amino acid in a provided agent, e.g., a provided stapled peptide, is replaced with its homolog, one or more properties or activities of the provided agent is not significantly decreased. For example, in some embodiments, when an amino acid in a provided stapled peptide is replaced with its homolog, interaction of the stapled peptide with beta-catenin is not significantly decreased. In some embodiments, an interaction is not significantly decreased in that FP EC50 (e.g., as illustrated in Table 2 measured by competition fluorescence polarization assay described in the present disclosure (competition with FITC-StAx-33 from Grossmann et al. PNAS 109 17942-17947 (FITC-PEG1-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 1), hydrocarbon staple formed by two S5 via olefin metathesis) or FITC-bA-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 3) (hydrocarbon staple formed by two S5 via olefin metathesis)) after replacement of an amino acid with its homolog does not increase more than 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 1000 fold. In some embodiments, an increase is no more than 10 fold. In some embodiments, an increase is no more than 20 fold. In some embodiments, an increase is no more than 30 fold. In some embodiments, an increase is no more than 40 fold. In some embodiments, an increase is no more than 50 fold. In some embodiments, an increase is no more than 60 fold. In some embodiments, an increase is no more than 70 fold. In some embodiments, an increase is no more than 80 fold. In some embodiments, an increase is no more than 90 fold. In some embodiments, an increase is no more than 100 fold. In some embodiments, an increase is no more than 200 fold. In some embodiments, an increase is no more than 500 fold. In some embodiments, as demonstrated in the present disclosure, replacement of an amino acid with a homolog improves one or more properties and/or activities of a provided stapled peptide. For example, in some embodiments, when an amino acid in a provided stapled peptide is replaced with its homolog, interaction of the stapled peptide with beta-catenin is enhanced. In some embodiments, an interaction is enhanced in that FP EC50 (e.g., as illustrated in Table 2 measured by competition fluorescence polarization assay described in the present disclosure (competition with FITC-StAx-33 from Grossmann et al. PNAS 109 17942-17947 (FITC-PEG1-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 1), hydrocarbon staple formed by two S5 via olefin metathesis) or FITC-bA-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 3) (hydrocarbon staple formed by two S5 via olefin metathesis)) after replacement of an amino acid with its homolog is decreased by at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 1000 fold. In some embodiments, a decrease is at least 2 fold (no more 12 of the original value). In some embodiments, a decrease is at least 3 fold. In some embodiments, a decrease is at least 4 fold. In some embodiments, a decrease is at least 5 fold. In some embodiments, a decrease is at least 6 fold. In some embodiments, a decrease is at least 7 fold. In some embodiments, a decrease is at least 8 fold. In some embodiments, a decrease is at least 9 fold. In some embodiments, a decrease is at least 10 fold. In some embodiments, a decrease is at least 15 fold. In some embodiments, a decrease is at least 20 fold. In some embodiments, a decrease is at least 30 fold. In some embodiments, a decrease is at least 40 fold. In some embodiments, a decrease is at least 50 fold. In some embodiments, a decrease is at least 60 fold. In some embodiments, a decrease is at least 70 fold. In some embodiments, a decrease is at least 80 fold. In some embodiments, a decrease is at least 90 fold. In some embodiments, a decrease is at least 100 fold.

Homologs of amino acids, both naturally occurring and non-naturally occurring, may be utilized in amino acid sequences in accordance with the present disclosure, including those known in the art.

In some embodiments, a homolog of leucine is an optionally substituted amino acid selected from isoleucine, alanine, homoleucine, 3-cyclobutylalanine, alpha-neopentylglycine, and 3-cyclopropylalanine. In some embodiments, a homolog of leucine is isoleucine, alanine, homoleucine, 3-cyclobutylalanine, alpha-neopentylglycine, or 3-cyclopropylalanine. In some embodiments, a homolog of leucine is an optionally substituted amino acid selected from isoleucine, alpha-neopentylglycine, homoleucine, 3-cyclobutylalanine, 3-cyclopropylalanine. In some embodiments, a homolog of leucine is an amino acid selected from isoleucine, alpha-neopentylglycine, homoleucine, 3-cyclobutylalanine, 3-cyclopropylalanine. In some embodiments, a homolog of leucine is an optionally substituted amino acid selected from isoleucine, alpha-neopentylglycine, homoleucine, and 3-cyclobutylalanine. In some embodiments, a homolog of leucine is an amino acid selected from isoleucine, alpha-neopentylglycine, homoleucine, and 3-cyclobutylalanine. In some embodiments, a homolog of leucine is an optionally substituted amino acid selected from homoleucine and cyclobutylalanine. In some embodiments, a homolog of leucine is an amino acid selected from homoleucine and cyclobutylalanine.

In some embodiments, a homolog of isoleucine is an optionally substituted amino acid selected from leucine, homoleucine, 3-cyclobutylalanine, alpha-neopentylglycine, 3-cyclopropylalanine, and L-alloisoleucine. In some embodiments, a homolog of isoleucine is an amino acid selected from leucine, homoleucine, 3-cyclobutylalanine, alpha-neopentylglycine, 3-cyclopropylalanine, and L-alloisoleucine. In some embodiments, a homolog of isoleucine is an optionally substituted amino acid selected from leucine and cyclobutylalanine. In some embodiments, a homolog of isoleucine is an amino acid selected from leucine and cyclobutylalanine.

In some embodiments, a homolog of phenylalanine is selected from an optionally substituted amino acid selected from tryptophan, 3-(1-naphthylalanine), 3-(2-naphthylalanine), 2-chlorophenyalanine, 3-chlorophenylalanine, 4-chlorophenylalanine, 4-tert-butylphenylalanine, O-methyl tyrosine, and homophenylalanine. In some embodiments, a homolog of phenylalanine is selected from an amino acid selected from tryptophan, 3-(1-naphthylalanine), 3-(2-naphthylalanine), 2-chlorophenyalanine, 3-chlorophenylalanine, 4-chlorophenylalanine, 4-tert-butylphenylalanine, O-methyl tyrosine, and homophenylalanine. In some embodiments, a homolog of phenylalanine is an optionally substituted amino acid selected from 3-(1-naphthylalanine), 3-(2-naphthylalanine), 3-chlorophenylalanine, 4-chlorophenylalanine and O-methyl tyrosine. In some embodiments, a homolog of phenylalanine is an amino acid selected from 3-(1-naphthylalanine), 3-(2-naphthylalanine), 3-chlorophenylalanine, 4-chlorophenylalanine and O-methyl tyrosine.

In some embodiments, a provided amino acid sequence is or comprises an amino acid sequence or a variant of a peptide selected from Table 1. In some embodiments, a provided amino acid sequence is or comprises an amino acid sequence or a variant of an amino acid sequence described in Sampietro et al., Molecular Cell, 24(2), 293-300, 2006; or Kawamoto et al., Biochemistry 2009, 48, 9534-9541; or WO2017062518; which amino acid sequences are incorporated herein by reference. In some embodiments, a provided amino acid sequence preferably comprises a set of Axin residues, or a homolog thereof, as described in the present disclosure. In some embodiments, a provided amino acid sequence comprises one or more elements reported in the art as required for affinity binding to beta-catenin, e.g., those reported in Xing, et al.

In some embodiments, a provided amino acid sequence comprises a set of Axin residues, or a homolog thereof, as described in the present disclosure. In some embodiments, a homolog of a set of Axin residues is a set of Axin residues wherein one or more amino acid of the set are independently replaced with its or their homologs. In some embodiments, a provided amino acid sequence comprises H476, D474, 1472, L473, V477, V480, P469 and M481 of Xenopus Axin, or one or more homologs thereof. In some embodiments, a provided amino acid sequence comprises L473, D474, and H476 of Xenopus Axin, or one or more homologs thereof. In some embodiments, a provided amino acid sequence comprises H476 of Xenopus Axin, or a homolog thereof. In some embodiments, a provided amino acid sequence comprises D474 of Xenopus Axin, or a homolog thereof. In some embodiments, a provided amino acid sequence comprises I472 of Xenopus Axin, or a homolog thereof. In some embodiments, a provided amino acid sequence comprises L473 of Xenopus Axin, or a homolog thereof. In some embodiments, a provided amino acid sequence comprises V477 of Xenopus Axin, or a homolog thereof. In some embodiments, a provided amino acid sequence comprises V480 of Xenopus Axin, or a homolog thereof. In some embodiments, a provided amino acid sequence comprises P469 of Xenopus Axin, or a homolog thereof. In some embodiments, a provided amino acid sequence comprises M481 of Xenopus Axin, or a homolog thereof.

In some embodiments, a provided amino acid sequence comprises H476, D474, I472, L473, V477, V480, P469 and M481 of Xenopus Axin. In some embodiments, a provided amino acid sequence comprises L473, D474, and H476 of Xenopus Axin. In some embodiments, a provided amino acid sequence comprises H476 of Xenopus Axin. In some embodiments, a provided amino acid sequence comprises D474 of Xenopus Axin. In some embodiments, a provided amino acid sequence comprises I472 of Xenopus Axin. In some embodiments, a provided amino acid sequence comprises L473 of Xenopus Axin. In some embodiments, a provided amino acid sequence comprises V477 of Xenopus Axin. In some embodiments, a provided amino acid sequence comprises V480 of Xenopus Axin. In some embodiments, a provided amino acid sequence comprises P469 of Xenopus Axin. In some embodiments, a provided amino acid sequence comprises M481 of Xenopus Axin.

In some embodiments, a provided amino acid sequence is one that, when incorporated into a stapled peptide, the stapled peptide interacts with beta-catenin. In some embodiments, a provided amino acid sequence is one that, when incorporated into a stapled peptide, the stapled peptide interacts with beta-catenin and competes with beta-catenin interaction with Axin. In some embodiments, a provided amino acid sequence is one that, when incorporated into a stapled peptide, the stapled peptide interacts with beta-catenin and competes with beta-catenin interaction with FITC-StAx-33 from Grossmann et al. PNAS 109 17942-17947, and/or FITC-bA-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 3) (hydrocarbon staple formed by two S5 via olefin metathesis). Various assays for assessing interactions with beta-catenin can be utilized in accordance with the present disclosure, including those described in the examples of the present disclosure.

In some embodiments, a provided amino acid sequence is homologous to a sequence of Axin. In some embodiments, a provided amino acid sequence is homologous to a sequence of the beta-catenin binding region of Axin. In some embodiments, a provided amino acid sequence is homologous to a sequence of Axin that interacts with beta-catenin. In some embodiments, a provided amino acid sequence is homologous to a sequence of an Axin helix that interacts with beta-catenin. In some embodiments, a provided amino acid sequence is homologous to a sequence of a peptide described in Table 1. In some embodiments, a provided amino acid sequence is homologous to a sequence of a peptide described in Xing et al.

In some embodiments, a provided amino acid sequence is homologous to a reference sequence in that the two sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical. In some embodiments, a provided amino acid sequence is homologous to a reference sequence in that the two sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% similar (e.g., containing residues with related chemical properties at corresponding positions). In some embodiments, two residues are considered similar is both of them are hydrophobic, hydrophilic, polar, non-polar, acidic or basic. In some embodiments, two residues are considered similar in that one residue is a homolog of the other residue. In some embodiments, a percentage is at least 25%. In some embodiments, a percentage is at least 30%. In some embodiments, a percentage is at least 35%. In some embodiments, a percentage is at least 40%. In some embodiments, a percentage is at least 45%. In some embodiments, a percentage is at least 50%. In some embodiments, a percentage is at least 55%. In some embodiments, a percentage is at least 60%. In some embodiments, a percentage is at least 65%. In some embodiments, a percentage is at least 70%. In some embodiments, a percentage is at least 75%. In some embodiments, a percentage is at least 80%. In some embodiments, a percentage is at least 85%. In some embodiments, a percentage is at least 90%. In some embodiments, a percentage is at least 91%. In some embodiments, a percentage is at least 92%. In some embodiments, a percentage is at least 93%. In some embodiments, a percentage is at least 94%. In some embodiments, a percentage is at least 95%. In some embodiments, a percentage is at least 96%. In some embodiments, a percentage is at least 97%. In some embodiments, a percentage is at least 98%. In some embodiments, a percentage is at least 99%.

Provided amino acid sequences and stapled peptides can be various lengths, e.g., 2-100, 5-50, 5-40, 5-30, a range from and including 2, 3, 4, 5, 6, or 7 to and including 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 38, 29, or 30 amino acid residues.

In some embodiments, a length is at least 5 amino acid residues. In some embodiments, a length is at least 6 amino acid residues. In some embodiments, a length is at least 7 amino acid residues. In some embodiments, a length is at least 8 amino acid residues. In some embodiments, a length is at least 9 amino acid residues. In some embodiments, a length is at least 10 amino acid residues. In some embodiments, a length is at least 11 amino acid residues. In some embodiments, a length is at least 12 amino acid residues. In some embodiments, a length is at least 13 amino acid residues. In some embodiments, a length is at least 14 amino acid residues. In some embodiments, a length is at least 15 amino acid residues. In some embodiments, a length is at least 16 amino acid residues. In some embodiments, a length is at least 17 amino acid residues. In some embodiments, a length is at least 18 amino acid residues. In some embodiments, a length is at least 19 amino acid residues. In some embodiments, a length is at least 20 amino acid residues. In some embodiments, a length is at least 21 amino acid residues. In some embodiments, a length is at least 22 amino acid residues. In some embodiments, a length is at least 23 amino acid residues. In some embodiments, a length is at least 24 amino acid residues. In some embodiments, a length is at least 25 amino acid residues.

In some embodiments, a length is 5 amino acid residues. In some embodiments, a length is 6 amino acid residues. In some embodiments, a length is 7 amino acid residues. In some embodiments, a length is 8 amino acid residues. In some embodiments, a length is 9 amino acid residues. In some embodiments, a length is 10 amino acid residues. In some embodiments, a length is 11 amino acid residues. In some embodiments, a length is 12 amino acid residues. In some embodiments, a length is 13 amino acid residues. In some embodiments, a length is 14 amino acid residues. In some embodiments, a length is 15 amino acid residues. In some embodiments, a length is 16 amino acid residues. In some embodiments, a length is 17 amino acid residues. In some embodiments, a length is 18 amino acid residues. In some embodiments, a length is 19 amino acid residues. In some embodiments, a length is 20 amino acid residues. In some embodiments, a length is 21 amino acid residues. In some embodiments, a length is 22 amino acid residues. In some embodiments, a length is 23 amino acid residues. In some embodiments, a length is 24 amino acid residues. In some embodiments, a length is 25 amino acid residues.

In some embodiments, a length is no more than 17 amino acid residues. In some embodiments, a length is no more than 18 amino acid residues. In some embodiments, a length is no more than 19 amino acid residues. In some embodiments, a length is no more than 20 amino acid residues. In some embodiments, a length is no more than 21 amino acid residues. In some embodiments, a length is no more than 22 amino acid residues. In some embodiments, a length is no more than 23 amino acid residues. In some embodiments, a length is no more than 24 amino acid residues. In some embodiments, a length is no more than 25 amino acid residues. In some embodiments, a length is no more than 26 amino acid residues. In some embodiments, a length is no more than 27 amino acid residues. In some embodiments, a length is no more than 28 amino acid residues. In some embodiments, a length is no more than 29 amino acid residues. In some embodiments, a length is no more than 30 amino acid residues. In some embodiments, a length is no more than 35 amino acid residues. In some embodiments, a length is no more than 40 amino acid residues. In some embodiments, a length is no more than 50 amino acid residues.

Both naturally occurring and non-naturally occurring amino acids can be utilized in accordance with the present disclosure. In some embodiments, an amino acid is a compound comprising an amino group that can form an amide group with a carboxyl group and a carboxyl group.

In some embodiments, an amino acid is a compound having the structure of formula A-I.

NH(R^a1)-L^a1-C(R^a2)(R^a3)-L^a2-COOH, A-I

or a salt thereof, wherein:

each of Rai, R^a2, R^a3is independently -L^a-R′;

each of L^a, L^a1and L^a2is independently L;

each R′ is independently —R, —C(O)R, —CO₂R, or —SO₂R;

two R groups are optionally and independently taken together to form a covalent bond, or:

In some embodiments, L^a1is a covalent bond. In some embodiments, a compound of formula A-1 is of the structure NH(R^a1)—C(R^a2)(R^a3)-L^a2-COOH.

In some embodiments, L^a2is a covalent bond. In some embodiments, a compound of formula A-1 is of the structure NH(R^a1)—C(R^a2)(R^a3)-L^a2-COOH.

In some embodiments, L^a1is a covalent bond and L^a2is a covalent bond. In some embodiments, a compound of formula A-1 is of the structure NH(R^a1)—C(R^a)(R^a3)—COOH.

In some embodiments, L^ais a covalent bond. In some embodiments, R′ is R. In some embodiments, R^a1is R, wherein R is as described in the present disclosure. In some embodiments, R^a2is R, wherein R is as described in the present disclosure. In some embodiments, R^a3is R, wherein R is as described in the present disclosure. In some embodiments, each of R^a1, R^a2, and R^a3is independently R, wherein R is as described in the present disclosure.

In some embodiments, R^a1is hydrogen. In some embodiments, R^a2is hydrogen. In some embodiments, R^a3is hydrogen. In some embodiments, R^a1is hydrogen, and at least one of R^a2and R^a3is hydrogen. In some embodiments, R^a1is hydrogen, one of R^a2and R^a3is hydrogen, and the other is not hydrogen.

In some embodiments, R^a2is -L^a-R, wherein R is as described in the present disclosure. In some embodiments, R^a2is -L^a-R, wherein R is an optionally substituted group selected from C_3-30cycloaliphatic, C_5-30aryl, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R^a2is -L^a-R, wherein R is an optionally substituted group selected from C_6-30aryl and 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R′ is a side chain of an amino acid. In some embodiments, R^a2is a side chain of a standard amino acid.

In some embodiments, R^a3is -L^a-R, wherein R is as described in the present disclosure. In some embodiments, R^a3is -L^a-R, wherein R is an optionally substituted group selected from C_3-30cycloaliphatic, C_5-30aryl, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R^a3is -L^a-R, wherein R is an optionally substituted group selected from C_6-30aryl and 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R^a3is a side chain of an amino acid. In some embodiments, R^a3is a side chain of a standard amino acid.

In some embodiments, in an amino acid, neither of R^a2and R^a3is hydrogen, e.g., as in certain amino acids exemplified in the present disclosure for stapling. In some embodiments, one or both of R^a2and R^a3comprise an olefin group. An amino acid residue comprising an amino group may form a staple with another amino acid residue comprising an olefin group through, e.g., olefin metathesis of the olefin groups. In some embodiments, one of R^a2and R^a3comprises an olefin group. In some embodiments, one of R^a2and R^a3comprises an olefin group, and the other is optionally substituted C_1-4alkyl. In some embodiments, one of R^a2and R^a3comprises an olefin group, and the other is methyl. In some embodiments, both R^a2and R^a3comprise an olefin group. In some embodiments, an olefin group is a terminal olefin group. In some embodiments, an olefin group is a terminal olefin group as in an allyl group. In some embodiments, an olefin group is a terminal olefin group as in an allyloxycarbonyl group. In some embodiments, R^a2is an alkenyl group comprising a terminal olefin. In some embodiments, R^a3is an alkenyl group comprising a terminal olefin. In some embodiments, R^a2is —(CH₂)_1-10—CH═CH₂. In some embodiments, R^a2is —CH₂—CH═CH₂. In some embodiments, R^a2is —(CH₂)₂—CH═CH₂. In some embodiments, R^a2is —(CH₂)₃—CH═CH₂. In some embodiments, R^a2is —(CH₂)₄—CH═CH₂. In some embodiments, R^a2is —(CH₂)₅—CH═CH₂. In some embodiments, R^a2is —(CH₂)₆—CH═CH₂. In some embodiments, R^a2is —(CH₂)₇—CH═CH₂. In some embodiments, R^a2is —(CH₂)s-CH═CH₂. In some embodiments, R^a3is —(CH₂)_1-10—CH═CH₂. In some embodiments, R^a3is —CH₂—CH═CH₂. In some embodiments, R^a3is —(CH₂)₂—CH═CH₂. In some embodiments, R^a3is —(CH₂)₃—CH═CH₂. In some embodiments, R^a3is —(CH₂)₄—CH═CH₂. In some embodiments, R^a3is —(CH₂)₅—CH═CH₂. In some embodiments, R^a3is —(CH₂)₆—CH═CH₂. In some embodiments, R^a3is —(CH₂)₇—CH═CH₂. In some embodiments, R^a3is —(CH₂)s-CH═CH₂.

In some embodiments, R^a2and R^a3are the same. In some embodiments, R^a2and R^a3are different.

In some embodiments, L^ais L, wherein L is as described in the present disclosure. In some embodiments, L^a1is L, wherein L is as described in the present disclosure. In some embodiments, L^a2is L, wherein L is as described in the present disclosure.

In some embodiments, L is a covalent bond, or an optionally substituted, bivalent C_1-20, e.g., C₁, C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, C₁₆, C₁₇, C₁₈, C₁₉, or C₂₀aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, L is a covalent bond. In some embodiments, L is an optionally substituted, bivalent C₁-C₂₀aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, L is an optionally substituted, bivalent C₁-C₁₅aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, L is an optionally substituted, bivalent C₁-C₁₀aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—.

In some embodiments, at least one methylene group is replaced. In some embodiments, L is an optionally substituted, bivalent C₃-C₂₀aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, L is an optionally substituted, bivalent C₃-C₁₅aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, L is an optionally substituted, bivalent C₃-C₁₀aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—.

In some embodiments, L is an optionally substituted C_1-20aliphatic wherein at least one methylene unit is replaced with —N(R′)—. In some embodiments, L is an optionally substituted C_2-20aliphatic wherein at least one methylene unit is replaced with —N(R′)—. In some embodiments, L is an optionally substituted C_3-20aliphatic wherein at least one methylene unit is replaced with —N(R′)—. In some embodiments, L^ais L, wherein L is an optionally substituted C_3-10aliphatic wherein at least one methylene unit is replaced with —N(R′)—. In some embodiments, only one methylene unit is replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, —N(R′)— is —N(O(CO)OR), wherein R is as described in the present disclosure. In some embodiments, —N(R′)— is -NAlloc-. In some embodiments, L is optionally substituted C_1-6alkylene. In some embodiments, L is —(CH₂)₂—. In some embodiments, L is —(CH₂)₃—. In some embodiments, L is —(CH₂)₄—. In some embodiments, L is —(CH₂)₅—. In some embodiments, L is —(CH₂)₆—.

In some embodiments, one of R^2aand R^3ais -L-R′, wherein at least one methylene unit of L is replaced with —N(R′)—, wherein each of the variables is independently as described in the present disclosure. In some embodiments, both the R′ of —N(R′)— and the other of R^2aand R^3aare R and are taken together with their intervening atoms to form an optionally substituted ring as described in the present disclosure. In some embodiments, a formed ring has no additional heteroatom ring atoms other than the nitrogen atom. In some embodiments, a formed ring is saturated.

In some embodiments, one of R^2aand R^3ais -L-R′, wherein at least one methylene unit of L is replaced with —N(R′)C(O)O—, wherein each of the variables is independently as described in the present disclosure. In some embodiments, both the R′ of —N(R′)C(O)O— and the other of R^2aand R^3aare R and are taken together with their intervening atoms to form an optionally substituted ring as described in the present disclosure. In some embodiments, a formed ring has no additional heteroatom ring atoms other than the nitrogen atom. In some embodiments, a formed ring is saturated.

In some embodiments, one of R^2aand R^3ais —CH₂N(Alloc)CH₃. In some embodiments, one of R^2aand R^3ais —(CH₂)₂N(Alloc)CH₃. In some embodiments, one of R^2aand R^3ais —(CH₂)₃N(Alloc)CH₃.

In some embodiments, two or more of R^a1, R^a2, and R^a3are R and are taken together to form an optionally substituted ring as described in the present disclosure.

In some embodiments, R^a1and one of R^a2and R^a3are R and are taken together to form an optionally substituted 3-6 membered ring having no additional ring heteroatom other than the nitrogen atom to which R^a1is bonded to. In some embodiments, a formed ring is a 5-membered ring as in proline.

In some embodiments, R^a2and R^a3are R and are taken together to form an optionally substituted 3-6 membered ring as described in the present disclosure. In some embodiments, R^a2 and R^a3are R and are taken together to form an optionally substituted 3-6 membered ring having one or more nitrogen ring atom. In some embodiments, R^a2and R^a3are R and are taken together to form an optionally substituted 3-6 membered ring having one and no more than one ring heteroatom which is a nitrogen atom. In some embodiments, a ring is a saturated ring. In some embodiments, the nitrogen atom is optionally substituted with an alloc group (—N(Alloc)-).

In some embodiments, each -Cy- is independently an optionally substituted bivalent group selected from a C_3-20cycloaliphatic ring, a C_6-20aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, -Cy- is an optionally substituted ring as described in the present disclosure, for example, for R and Cy^L, but is bivalent.

In some embodiments, -Cy- is monocyclic. In some embodiments, -Cy- is bicyclic. In some embodiments, -Cy- is polycyclic. In some embodiments, -Cy- is saturated. In some embodiments, -Cy- is partially unsaturated. In some embodiments, -Cy- is aromatic. In some embodiments, -Cy- comprises a saturated cyclic moiety. In some embodiments, -Cy-comprises a partially unsaturated cyclic moiety. In some embodiments, -Cy- comprises an aromatic cyclic moiety. In some embodiments, -Cy- comprises a combination of a saturated, a partially unsaturated, and/or an aromatic cyclic moiety. In some embodiments, -Cy- is 3-membered. In some embodiments, -Cy- is 4-membered. In some embodiments, -Cy- is 5-membered. In some embodiments, -Cy- is 6-membered. In some embodiments, -Cy- is 7-membered. In some embodiments, -Cy- is 8-membered. In some embodiments, -Cy- is 9-membered. In some embodiments, -Cy- is 10-membered. In some embodiments, -Cy- is 11-membered. In some embodiments, -Cy- is 12-membered. In some embodiments, -Cy- is 13-membered. In some embodiments, -Cy- is 14-membered. In some embodiments, -Cy- is 15-membered. In some embodiments, -Cy- is 16-membered. In some embodiments, -Cy- is 17-membered. In some embodiments, -Cy- is 18-membered. In some embodiments, -Cy- is 19-membered. In some embodiments, -Cy- is 20-membered.

In some embodiments, -Cy- is an optionally substituted bivalent C_3-20cycloaliphatic ring. In some embodiments, -Cy- is an optionally substituted bivalent, saturated C_3-20cycloaliphatic ring. In some embodiments, -Cy- is an optionally substituted bivalent, partially unsaturated C_3-20cycloaliphatic ring. In some embodiments, -Cy-H is optionally substituted cycloaliphatic as described in the present disclosure, for example, cycloaliphatic embodiments for R.

In some embodiments, -Cy- is an optionally substituted C_6-20aryl ring. In some embodiments, -Cy- is optionally substituted phenylene. In some embodiments, -Cy- is optionally substituted 1,2-phenylene. In some embodiments, -Cy- is optionally substituted 1,3-phenylene. In some embodiments, -Cy- is optionally substituted 1,4-phenylene. In some embodiments, -Cy- is an optionally substituted bivalent naphthalene ring. In some embodiments, -Cy-H is optionally substituted aryl as described in the present disclosure, for example, aryl embodiments for R.

In some embodiments, -Cy- is an optionally substituted bivalent 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, -Cy- is an optionally substituted bivalent 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, -Cy- is an optionally substituted bivalent 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from oxygen, nitrogen, sulfur. In some embodiments, -Cy- is an optionally substituted bivalent 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, sulfur. In some embodiments, -Cy- is an optionally substituted bivalent 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, nitrogen, sulfur. In some embodiments, -Cy- is an optionally substituted bivalent 5-6 membered heteroaryl ring having one heteroatom independently selected from oxygen, nitrogen, sulfur. In some embodiments, -Cy-H is optionally substituted heteroaryl as described in the present disclosure, for example, heteroaryl embodiments for R.

In some embodiments, -Cy- is an optionally substituted bivalent 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, -Cy- is an optionally substituted bivalent 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, -Cy- is an optionally substituted bivalent 3-6 membered heterocyclyl ring having 1-4 heteroatoms independently selected from oxygen, nitrogen, sulfur. In some embodiments, -Cy- is an optionally substituted bivalent 5-6 membered heterocyclyl ring having 1-4 heteroatoms independently selected from oxygen, nitrogen, sulfur. In some embodiments, -Cy- is an optionally substituted bivalent 5-6 membered heterocyclyl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, sulfur. In some embodiments, -Cy- is an optionally substituted bivalent 5-6 membered heterocyclyl ring having 1-2 heteroatoms independently selected from oxygen, nitrogen, sulfur. In some embodiments, -Cy- is an optionally substituted bivalent 5-6 membered heterocyclyl ring having one heteroatom independently selected from oxygen, nitrogen, sulfur. In some embodiments, -Cy- is an optionally substituted saturated bivalent heterocyclyl group. In some embodiments, -Cy- is an optionally substituted partially unsaturated bivalent heterocyclyl group. In some embodiments, -Cy-H is optionally substituted heterocyclyl as described in the present disclosure, for example, heterocyclyl embodiments for R.

In some embodiments, R′ is —R, —C(O)R, —C(O)OR, or —S(O)₂R, wherein R is as described in the present disclosure. In some embodiments, R′ is R, wherein R is as described in the present disclosure. In some embodiments, R′ is —C(O)R, wherein R is as described in the present disclosure. In some embodiments, R′ is —C(O)OR, wherein R is as described in the present disclosure. In some embodiments, R′ is —S(O)₂R, wherein R is as described in the present disclosure. In some embodiments, R′ is hydrogen. In some embodiments, R′ is not hydrogen. In some embodiments, R′ is R, wherein R is optionally substituted C_1-20aliphatic as described in the present disclosure. In some embodiments, R′ is R, wherein R is optionally substituted C_1-20heteroaliphatic as described in the present disclosure. In some embodiments, R′ is R, wherein R is optionally substituted C_6-20aryl as described in the present disclosure. In some embodiments, R′ is R, wherein R is optionally substituted C_6-20arylaliphatic as described in the present disclosure. In some embodiments, R′ is R, wherein R is optionally substituted C_6-20arylheteroaliphatic as described in the present disclosure. In some embodiments, R′ is R, wherein R is optionally substituted 5-20 membered heteroaryl as described in the present disclosure. In some embodiments, R′ is R, wherein R is optionally substituted 3-20 membered heterocyclyl as described in the present disclosure. In some embodiments, two or more R′ are R, and are optionally and independently taken together to form an optionally substituted ring as described in the present disclosure.

In some embodiments, each R is independently —H, or an optionally substituted group selected from C_1-30aliphatic, C_1-30heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C_6-30aryl, C_6-30arylaliphatic, C_6-30arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or

two R groups are optionally and independently taken together to form a covalent bond, or:

In some embodiments, each R is independently —H, or an optionally substituted group selected from C_1-20aliphatic, C_1-20heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C_6-20aryl, C_6-20arylaliphatic, C_6-20arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-20 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-20 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-20 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-20 membered monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

In some embodiments, R is hydrogen. In some embodiments, R is not hydrogen. In some embodiments, R is an optionally substituted group selected from C_1-30aliphatic, C_1-30heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C_6-30aryl, a 5-30 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-30 membered heterocyclic ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

In some embodiments, R is hydrogen or an optionally substituted group selected from C_1-20aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, an 8-10 membered bicyclic saturated, partially unsaturated or aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In some embodiments, R is optionally substituted C_1-30aliphatic. In some embodiments, R is optionally substituted C_1-20aliphatic. In some embodiments, R is optionally substituted C_1-15aliphatic. In some embodiments, R is optionally substituted C_1-10aliphatic. In some embodiments, R is optionally substituted C_1-6aliphatic. In some embodiments, R is optionally substituted C_1-6alkyl. In some embodiments, R is optionally substituted hexyl, pentyl, butyl, propyl, ethyl or methyl. In some embodiments, R is optionally substituted hexyl. In some embodiments, R is optionally substituted pentyl. In some embodiments, R is optionally substituted butyl. In some embodiments, R is optionally substituted propyl. In some embodiments, R is optionally substituted ethyl. In some embodiments, R is optionally substituted methyl. In some embodiments, R is hexyl. In some embodiments, R is pentyl. In some embodiments, R is butyl. In some embodiments, R is propyl. In some embodiments, R is ethyl. In some embodiments, R is methyl. In some embodiments, R is isopropyl. In some embodiments, R is n-propyl. In some embodiments, R is tert-butyl. In some embodiments, R is sec-butyl. In some embodiments, R is n-butyl. In some embodiments, R is —(CH₂)₂CN.

In some embodiments, R is optionally substituted C_3-30cycloaliphatic. In some embodiments, R is optionally substituted C_3-20cycloaliphatic. In some embodiments, R is optionally substituted C_3-10cycloaliphatic. In some embodiments, R is optionally substituted cyclohexyl. In some embodiments, R is cyclohexyl. In some embodiments, R is optionally substituted cyclopentyl. In some embodiments, R is cyclopentyl. In some embodiments, R is optionally substituted cyclobutyl. In some embodiments, R is cyclobutyl. In some embodiments, R is optionally substituted cyclopropyl. In some embodiments, R is cyclopropyl.

In some embodiments, R is an optionally substituted 3-30 membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 3-membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 4-membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 5-membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 6-membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 7-membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is optionally substituted cycloheptyl. In some embodiments, R is cycloheptyl. In some embodiments, R is optionally substituted cyclohexyl. In some embodiments, R is cyclohexyl. In some embodiments, R is optionally substituted cyclopentyl. In some embodiments, R is cyclopentyl. In some embodiments, R is optionally substituted cyclobutyl. In some embodiments, R is cyclobutyl. In some embodiments, R is optionally substituted cyclopropyl. In some embodiments, R is cyclopropyl.

In some embodiments, when R is or comprises a ring structure, e.g., cycloaliphatic, cycloheteroaliphatic, aryl, heteroaryl, etc., the ring structure can be monocyclic, bicyclic or polycyclic. In some embodiments, R is or comprises a monocyclic structure. In some embodiments, R is or comprises a bicyclic structure. In some embodiments, R is or comprises a polycyclic structure.

In some embodiments, R is optionally substituted C_1-30heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R is optionally substituted C_1-20heteroaliphatic having 1-10 heteroatoms. In some embodiments, R is optionally substituted C_1-20heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus or silicon, optionally including one or more oxidized forms of nitrogen, sulfur, phosphorus or selenium. In some embodiments, R is optionally substituted C_1-30heteroaliphatic comprising 1-10 groups independently selected from

embedded image

In some embodiments, R is optionally substituted C_6-30aryl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl. In some embodiments, R is substituted phenyl.

In some embodiments, R is an optionally substituted 8-10 membered bicyclic saturated, partially unsaturated or aryl ring. In some embodiments, R is an optionally substituted 8-10 membered bicyclic saturated ring. In some embodiments, R is an optionally substituted 8-10 membered bicyclic partially unsaturated ring. In some embodiments, R is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, R is optionally substituted naphthyl.

In some embodiments, R is optionally substituted 5-30 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R is optionally substituted 5-30 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, R is optionally substituted 5-30 membered heteroaryl ring having 1-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R is optionally substituted 5-30 membered heteroaryl ring having 1-5 heteroatoms independently selected from oxygen, nitrogen, and sulfur.

In some embodiments, R is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an unsubstituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, sulfur, and oxygen. In some embodiments, R is a substituted 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an unsubstituted 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, sulfur, and oxygen.

In some embodiments, R is an optionally substituted 5-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. In some embodiments, R is an optionally substituted 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In some embodiments, R is an optionally substituted 5-membered monocyclic heteroaryl ring having one heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, R is selected from optionally substituted pyrrolyl, furanyl, or thienyl.

In some embodiments, R is an optionally substituted 5-membered heteroaryl ring having two heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 5-membered heteroaryl ring having one nitrogen atom, and an additional heteroatom selected from sulfur or oxygen. Example R groups include but are not limited to optionally substituted pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl or isoxazolyl.

In some embodiments, R is an optionally substituted 5-membered heteroaryl ring having three heteroatoms independently selected from nitrogen, oxygen, and sulfur. Example R groups include but are not limited to optionally substituted triazolyl, oxadiazolyl or thiadiazolyl.

In some embodiments, R is an optionally substituted 5-membered heteroaryl ring having four heteroatoms independently selected from nitrogen, oxygen, and sulfur. Example R groups include but are not limited to optionally substituted tetrazolyl, oxatriazolyl and thiatriazolyl.

In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having 1-4 nitrogen atoms. In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having 1-3 nitrogen atoms. In other embodiments, R is an optionally substituted 6-membered heteroaryl ring having 1-2 nitrogen atoms. In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having four nitrogen atoms. In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having three nitrogen atoms. In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having two nitrogen atoms. In certain embodiments, R is an optionally substituted 6-membered heteroaryl ring having one nitrogen atom. Example R groups include but are not limited to optionally substituted pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, or tetrazinyl.

In certain embodiments, R is an optionally substituted 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In other embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1 heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted indolyl. In some embodiments, R is an optionally substituted azabicyclo[3.2.1]octanyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted azaindolyl. In some embodiments, R is an optionally substituted benzimidazolyl. In some embodiments, R is an optionally substituted benzothiazolyl. In some embodiments, R is an optionally substituted benzoxazolyl. In some embodiments, R is an optionally substituted indazolyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having one heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted indolyl. In some embodiments, R is optionally substituted benzofuranyl. In some embodiments, R is optionally substituted benzo[b]thienyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having two heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted azaindolyl. In some embodiments, R is optionally substituted benzimidazolyl. In some embodiments, R is optionally substituted benzothiazolyl. In some embodiments, R is optionally substituted benzoxazolyl. In some embodiments, R is an optionally substituted indazolyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having three heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted oxazolopyridiyl, thiazolopyridinyl or imidazopyridinyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having four heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted purinyl, oxazolopyrimidinyl, thiazolopyrimidinyl, oxazolopyrazinyl, thiazolopyrazinyl, imidazopyrazinyl, oxazolopyridazinyl, thiazolopyridazinyl or imidazopyridazinyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having five heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In some embodiments, R is optionally substituted 1,4-dihydropyrrolo[3,2-b]pyrrolyl, 4H-furo[3,2-b]pyrrolyl, 4H-thieno[3,2-b]pyrrolyl, furo[3,2-b]furanyl, thieno[3,2-b]furanyl, thieno[3,2-b]thienyl, 1H-pyrrolo[1,2-a]imidazolyl, pyrrolo[2,1-b]oxazolyl or pyrrolo[2,1-b]thiazolyl. In some embodiments, R is optionally substituted dihydropyrroloimidazolyl, 1H-furoimidazolyl, 1H-thienoimidazolyl, furooxazolyl, furoisoxazolyl, 4H-pyrrolooxazolyl, 4H-pyrroloisoxazolyl, thienooxazolyl, thienoisoxazolyl, 4H-pyrrolothiazolyl, furothiazolyl, thienothiazolyl, 1H-imidazoimidazolyl, imidazooxazolyl or imidazo[5,1-b]thiazolyl.

In certain embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In other embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having 1 heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted quinolinyl. In some embodiments, R is an optionally substituted isoquinolinyl. In some embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted quinazoline or a quinoxaline.

In some embodiments, R is 3-30 membered heterocyclic ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R is 3-30 membered heterocyclic ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, R is 3-30 membered heterocyclic ring having 1-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R is 3-30 membered heterocyclic ring having 1-5 heteroatoms independently selected from oxygen, nitrogen, and sulfur.

In some embodiments, R is an optionally substituted 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an unsubstituted 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 5-7 membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 5-6 membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 5-membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 6-membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 7-membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted 3-membered heterocyclic ring having one heteroatom selected from nitrogen, oxygen or sulfur. In some embodiments, R is optionally substituted 4-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted 5-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted 7-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In some embodiments, R is an optionally substituted 3-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 4-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 7-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In some embodiments, R is an optionally substituted 4-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is nitrogen. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is oxygen. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is sulfur. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having 2 oxygen atoms. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having 2 nitrogen atoms. In some embodiments, R is an optionally substituted 4-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is nitrogen. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is oxygen. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is sulfur. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having 2 oxygen atoms. In some embodiments, R is an optionally substituted 4-membered partially unsaturated heterocyclic ring having 2 nitrogen atoms.

In some embodiments, R is an optionally substituted 5-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5-membered partially unsaturated heterocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom. In some embodiments, R is an optionally substituted 5-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is nitrogen. In some embodiments, R is an optionally substituted 5-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is oxygen. In some embodiments, R is an optionally substituted 5-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is sulfur. In some embodiments, R is an optionally substituted 5-membered partially unsaturated heterocyclic ring having 2 oxygen atoms. In some embodiments, R is an optionally substituted 5-membered partially unsaturated heterocyclic ring having 2 nitrogen atoms.

In some embodiments, R is an optionally substituted 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 6-membered partially unsaturated heterocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 6-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom. In some embodiments, R is an optionally substituted 6-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is nitrogen. In some embodiments, R is an optionally substituted 6-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is oxygen. In some embodiments, R is an optionally substituted 6-membered partially unsaturated heterocyclic ring having no more than 1 heteroatom, wherein the heteroatom is sulfur. In some embodiments, R is an optionally substituted 6-membered partially unsaturated heterocyclic ring having 2 oxygen atoms. In some embodiments, R is an optionally substituted 6-membered partially unsaturated heterocyclic ring having 2 nitrogen atoms.

In certain embodiments, R is a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is optionally substituted oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepaneyl, aziridineyl, azetidineyl, pyrrolidinyl, piperidinyl, azepanyl, thiiranyl, thietanyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, thiepanyl, dioxolanyl, oxathiolanyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, dithiolanyl, dioxanyl, morpholinyl, oxathianyl, piperazinyl, thiomorpholinyl, dithianyl, dioxepanyl, oxazepanyl, oxathiepanyl, dithiepanyl, diazepanyl, dihydrofuranonyl, tetrahydropyranonyl, oxepanonyl, pyrolidinonyl, piperidinonyl, azepanonyl, dihydrothiophenonyl, tetrahydrothiopyranonyl, thiepanonyl, oxazolidinonyl, oxazinanonyl, oxazepanonyl, dioxolanonyl, dioxanonyl, dioxepanonyl, oxathiolinonyl, oxathianonyl, oxathiepanonyl, thiazolidinonyl, thiazinanonyl, thiazepanonyl, imidazolidinonyl, tetrahydropyrimidinonyl, diazepanonyl, imidazolidinedionyl, oxazolidinedionyl, thiazolidinedionyl, dioxolanedionyl, oxathiolanedionyl, piperazinedionyl, morpholinedionyl, thiomorpholinedionyl, tetrahydropyranyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrothiophenyl, or tetrahydrothiopyranyl.

In certain embodiments, R is an optionally substituted 5-6 membered partially unsaturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted tetrahydropyridinyl, dihydrothiazolyl, dihydrooxazolyl, or oxazolinyl group.

In some embodiments, R is an optionally substituted 7-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted indolinyl. In some embodiments, R is optionally substituted isoindolinyl. In some embodiments, R is optionally substituted 1, 2, 3, 4-tetrahydroquinolinyl. In some embodiments, R is optionally substituted 1, 2, 3, 4-tetrahydroisoquinolinyl. In some embodiments, R is an optionally substituted azabicyclo[3.2.1]octanyl.

In some embodiments, R is an optionally substituted 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having two heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted 1,4-dihydropyrrolo[3,2-b]pyrrolyl, 4H-furo[3,2-b]pyrrolyl, 4H-thieno[3,2-b]pyrrolyl, furo[3,2-b]furanyl, thieno[3,2-b]furanyl, thieno[3,2-b]thienyl, 1H-pyrrolo[1,2-a]imidazolyl, pyrrolo[2,1-b]oxazolyl or pyrrolo[2,1-b]thiazolyl. In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having three heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted dihydropyrroloimidazolyl, 1H-furoimidazolyl, 1H-thienoimidazolyl, furooxazolyl, furoisoxazolyl, 4H-pyrrolooxazolyl, 4H-pyrroloisoxazolyl, thienooxazolyl, thienoisoxazolyl, 4H-pyrrolothiazolyl, furothiazolyl, thienothiazolyl, 1H-imidazoimidazolyl, imidazooxazolyl or imidazo[5,1-b]thiazolyl. In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having four heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having five heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In other embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having one heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted indolyl. In some embodiments, R is optionally substituted benzofuranyl. In some embodiments, R is optionally substituted benzo[b]thienyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having two heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted azaindolyl. In some embodiments, R is optionally substituted benzimidazolyl. In some embodiments, R is optionally substituted benzothiazolyl. In some embodiments, R is optionally substituted benzoxazolyl. In some embodiments, R is an optionally substituted indazolyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having three heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted oxazolopyridiyl, thiazolopyridinyl or imidazopyridinyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having four heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted purinyl, oxazolopyrimidinyl, thiazolopyrimidinyl, oxazolopyrazinyl, thiazolopyrazinyl, imidazopyrazinyl, oxazolopyridazinyl, thiazolopyridazinyl or imidazopyridazinyl. In certain embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having five heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In certain embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In other embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having one heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted quinolinyl. In some embodiments, R is optionally substituted isoquinolinyl. In some embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having two heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted quinazolinyl, phthalazinyl, quinoxalinyl or naphthyridinyl. In some embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having three heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted pyridopyrimidinyl, pyridopyridazinyl, pyridopyrazinyl, or benzotriazinyl. In some embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having four heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted pyridotriazinyl, pteridinyl, pyrazinopyrazinyl, pyrazinopyridazinyl, pyridazinopyridazinyl, pyrimidopyridazinyl or pyrimidopyrimidinyl. In some embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having five heteroatoms independently selected from nitrogen, oxygen, and sulfur.

In some embodiments, R is optionally substituted C_6-30arylaliphatic. In some embodiments, R is optionally substituted C_6-20arylaliphatic. In some embodiments, R is optionally substituted C_6-10arylaliphatic. In some embodiments, an aryl moiety of the arylaliphatic has 6, 10, or 14 aryl carbon atoms. In some embodiments, an aryl moiety of the arylaliphatic has 6 aryl carbon atoms. In some embodiments, an aryl moiety of the arylaliphatic has 10 aryl carbon atoms. In some embodiments, an aryl moiety of the arylaliphatic has 14 aryl carbon atoms. In some embodiments, an aryl moiety is optionally substituted phenyl.

In some embodiments, R is optionally substituted C_6-30arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R is optionally substituted C_6-30arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, R is optionally substituted C_6-20arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R is optionally substituted C_6-20arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, R is optionally substituted C_6-10arylheteroaliphatic having 1-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R is optionally substituted C_6-10arylheteroaliphatic having 1-5 heteroatoms independently selected from oxygen, nitrogen, and sulfur.

In some embodiments, two R groups are optionally and independently taken together to form a covalent bond. In some embodiments, —C═O is formed. In some embodiments, —C═C— is formed. In some embodiments, —C≡C— is formed.

In some embodiments, two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-20 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-10 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-6 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-3 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-5 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-3 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

In some embodiments, two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-20 membered monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-10 membered monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-10 membered monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-6 membered monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-3 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-5 membered monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-3 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

In some embodiments, heteroatoms in R groups, or in the structures formed by two or more R groups taken together, are selected from oxygen, nitrogen, and sulfur. In some embodiments, a formed ring is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20-membered. In some embodiments, a formed ring is saturated. In some embodiments, a formed ring is partially saturated. In some embodiments, a formed ring is aromatic. In some embodiments, a formed ring comprises a saturated, partially saturated, or aromatic ring moiety. In some embodiments, a formed ring comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 aromatic ring atoms. In some embodiments, a formed contains no more than 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 aromatic ring atoms. In some embodiments, aromatic ring atoms are selected from carbon, nitrogen, oxygen and sulfur.

In some embodiments, a ring formed by two or more R groups (or two or more groups selected from R and variables that can be R) taken together is a C_3-30cycloaliphatic, C_6-30aryl, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, ring as described for R, but bivalent or multivalent.

In some embodiments, an amino acid of formula A-I is a compound having the structure of formula A-II:

NH(R^a1)-L^a1-C(-L^a-CH═CH₂)(R^a3)-L^a2-COOH, A-II

or a salt thereof, wherein each variable is independently as described in the present disclosure.

In some embodiments, an amino acid of formula A-I is a compound having the structure of formula A-III:

NH(R^a1)—C(-L^a-CH═CH₂)(R^a3)—COOH, A-III

or a salt thereof, wherein each variable is independently as described in the present disclosure.

In some embodiments, L^acomprises at least one —N(R′)— wherein R′ is independently as described in the present disclosure.

In some embodiments, an amino acid of formula A-I is a standard amino acid. In some embodiments, an amino acid of formula A-I is selected from Tables A-I, A-II, and A-III:

TABLE A-I

Exemplary amino acids (Fmoc-Protected).

embedded image

TABLE A-II

Exemplary amino acids (Fmoc-Protected).

embedded image

TABLE A-III

Exemplary amino acids (Fmoc-Protected).

embedded image

In some embodiments, an amino acid is an alpha-amino acid. In some embodiments, an amino acid is an L-amino acid. In some embodiments, an amino acid is a D-amino acid. In some embodiments, the alpha-carbon of an amino acid is achiral.

In some embodiments, an amino acid is a beta-amino acid. In some embodiments, an amino acid is beta-alanine.

In some embodiments, an amino acid is one whose residue is incorporated in a peptide in Table 1.

In some embodiments, a provided amino acid sequence contains two or more amino acid residues whose side chains are linked together to form one or more staples. In some embodiments, a provided amino acid sequence contains two or more amino acid residues, each of which independently has a side chain comprising an olefin. In some embodiments, a provided amino acid sequence contains two or more amino acid residues, each of which independently has a side chain comprising a terminal olefin. In some embodiments, a provided amino acid sequence contains two and no more than two amino acid residues, each of which independently has a side chain comprising an olefin. In some embodiments, a provided amino acid sequence contains two and no more than two amino acid residues, each of which independently has a side chain comprising a terminal olefin. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid that comprises an olefin and a nitrogen atom other than the nitrogen atom of its amino group. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid that comprises a terminal olefin and a nitrogen atom other than the nitrogen atom of its amino group. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid that has a side chain than comprises a terminal olefin and a nitrogen atom. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid of formula A-I, wherein R^a2comprising an olefin and a —N(R′)— moiety, wherein R′ is as described in the present disclosure (including, in some embodiments, optionally taken together with R^a3and their intervening atoms to form an optionally substituted ring as described in the present disclosure). In some embodiments, R^a2comprising a terminal olefin and a —N(R′)— moiety wherein R′ is as described in the present disclosure. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid selected from Table A-I. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid selected from Table A-II. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid selected from Table A-III. In some embodiments, two olefins from two side chains are linked together through olefin metathesis to form a staple. In some embodiments, a staple is preferably formed by side chains of amino acid residues that are not at the corresponding positions of the Axin residues that interact with beta-catenin. In some embodiments, a formed staple does not disrupt interaction between the peptide and beta-catenin.

In some embodiments, the present disclosure provides a peptide comprising:

[X¹]_p1[X²]_p2—X³X⁴X⁵X⁶X⁷X⁸X⁹X¹⁰—[X¹¹]_p11[X¹²]_p12[X¹³]_p13,

wherein:

each of p1, p2, p11, p12 and p13 is independently 0 or 1;

each of X, X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹⁰, X¹¹, X¹², and X¹³is independently an amino acid residue;

at least two of X, X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹⁰, X¹¹, X¹², and X¹³comprise side chains that are optionally linked together to form a staple.

In some embodiments, a provided peptide is a stapled peptide, and at least two of X¹to X¹³comprise side chains that are linked together to form a staple. In some embodiments, a provided peptide is an unstapled peptide, wherein at least two of X¹to X¹³comprise side chains that can be linked together to form a staple. In some embodiments, a stapled peptide, or an unstapled peptide once stapled, interact with beta-catenin at one or more beta-catenin sites that interact with Axin. In some embodiments, a stapled peptide, or an unstapled peptide once stapled, interact with beta-catenin and compete with beta-catenin interaction with Axin or an Axin peptide.

In some embodiments, each of X¹to X¹³is independently an amino acid residue of an amino acid having the structure of formula A-I.

In some embodiments, Xⁱand X^i+m, each independently comprises a side chain that comprises an olefin, and the two side chains can be linked together to form a staple, e.g., a staple as described in the present disclosure, through olefin metathesis of the two olefins. In some embodiments, both of the olefins are terminal olefins. In some embodiments, m is an integer of 3-12, and i is an integer of 1-18. In some embodiments, m is an integer of 3-8, and i is an integer of 1-13. In some embodiments, at least one of Xⁱand X^i+mcomprises a side chain comprising an olefin and a nitrogen atom. In some embodiments, at least one of Xⁱand X^i+mcomprises —C(R^2a)(R^3a) being —C(-L^a-R′)(R^3a), wherein at least one methylene unit of L^ais replaced with —N(R′)— and R′ comprises an olefin. In some embodiments, at least one of Xⁱand X^i+mcomprises —C(R^2a)(R^3a) being —C(-L^a-CH═CH₂)(R^3a), wherein at least one methylene unit of L^ais replaced with —N(R′)—.

In some embodiments, i is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17. In some embodiments, i is 1. In some embodiments, i is 2. In some embodiments, i is 3. In some embodiments, i is 4. In some embodiments, i is 5. In some embodiments, i is 6. In some embodiments, i is 7. In some embodiments, i is 8. In some embodiments, i is 9. In some embodiments, i is 10. In some embodiments, i is 11. In some embodiments, i is 12. In some embodiments, i is 13. In some embodiments, i is 14. In some embodiments, i is 15. In some embodiments, i is 16. In some embodiments, i is 17. In some embodiments, i is 18.

In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9. In some embodiments, m is 10. In some embodiments, m is 11. In some embodiments, m is 12.

In some embodiments, each of Xⁱand X^i+mis independently selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, M_I. In some embodiments, at least one of Xⁱand X^i+mis independently selected from M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, M_I. In some embodiments, each of Xⁱand X^i+mis independently selected from M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, M_I.

In some embodiments, X³is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, and M_I. In some embodiments, X³is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, and S₈. In some embodiments, wherein X³is an amino acid residue of R₈. In some embodiments, wherein X³is an amino acid residue of M_G. In some embodiments, wherein X³is an amino acid residue of R4. In some embodiments, X¹⁰is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, and M_I. In some embodiments, X¹⁰is a residue of an amino acid selected from M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, and M_I. In some embodiments, X¹⁰is a residue of R or a homolog thereof. In some embodiments, X¹⁰is a residue of R.

In some embodiments, X¹is a residue of an amino acid selected from P, A, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y, and α-methyl proline. In some embodiments, X¹is a residue of an amino acid selected from P, A, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, and Y. In some embodiments, X¹is a residue of an amino acid selected from P, K, N, Q, R, Y, and α-methyl proline. In some embodiments, X¹is a residue of an amino acid P. In some embodiments, X²is a residue of an amino acid selected from A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y. In some embodiments, X²is a residue of an amino acid selected from A, D, E, K, N, Q, and R. In some embodiments, X²is a residue of A. In some embodiments, X⁴is a residue of an amino acid selected from I, F, H, L, V, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine. In some embodiments, X⁴is a residue of an amino acid selected from I, F, H, L, and V. In some embodiments, X⁴is a residue of an amino acid selected from I, L, V, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, and alpha-neopentylglycine. In some embodiments, X⁴is a residue of I. In some embodiments, X⁵is a residue of an amino acid selected from L, F, H, I, V, alpha-methyl leucine, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine. In some embodiments, X⁵is a residue of an amino acid selected from L, F, H, I, and V. In some embodiments, X⁵is a residue of an amino acid selected from L, I, V, alpha-methyl leucine, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine. In some embodiments, X⁵is a residue of L. In some embodiments, X⁶is a residue of an amino acid selected from D, A, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, methionine sulfone, 2-aminoadipic acid, aspartic acid beta-methylester, aspartic acid beta-cyclohexylester, aspartic acid beta-benzylester, glutamic acid beta-methylester, glutamic acid beta-cyclohexylester, and glutamic acid beta-benzyl ester. In some embodiments, X⁶is a residue of an amino acid selected from D, A, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y. In some embodiments, X⁶is a residue of an amino acid selected from D, E, H, N, Q, S, T, Y, methionine sulfone, 2-aminoadipic acid, aspartic acid beta-methylester, aspartic acid beta-cyclohexylester, aspartic acid beta-benzylester, glutamic acid beta-methylester, glutamic acid beta-cyclohexylester, and glutamic acid beta-benzyl ester. In some embodiments, X⁶is a residue of an amino acid selected from D, N, and T. In some embodiments, X⁷is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, M_I, A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y and alpha-methyl alanine. In some embodiments, X⁷is a residue of an amino acid selected from A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y and alpha-methyl alanine. In some embodiments, X⁷is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, and M_I. In some embodiments, X⁷is a residue of an amino acid selected from A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y. In some embodiments, X⁷is a residue of an amino acid selected from A, D, E, I, K, L, N, Q, R, S, T, V, W, Y and alpha-methyl alanine. In some embodiments, X⁷is a A or alpha-methyl alanine residue. In some embodiments, X⁸is a residue of an amino acid selected from H, F, I, L, N, Q, V, 1-methylhistidine, 3-methylhistidine, 3-(2-pyridyl)alanine, 3-(3-pyridyl)alanine, 3-(4-pyridyl)alanine, beta-2-furylalanine, beta-2-thienylalanine, 3-(2-tetrazolyl)alanine), and beta-4-thiazolylalanine. In some embodiments, X⁸is a residue of an amino acid selected from H, F, I, L, N, Q, and V. In some embodiments, X⁸is a residue of an amino acid selected from H, N, Q, 1-methylhistidine, 3-methylhistidine, 3-(2-pyridyl)alanine, 3-(3-pyridyl)alanine, 3-(4-pyridyl)alanine, beta-2-furylalanine, beta-2-thienylalanine, 3-(2-tetrazolyl)alanine), and beta-4-thiazolylalanine. In some embodiments, X⁸is a H residue. In some embodiments, X⁹is a residue of an amino acid selected from I, V, F, H, L, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine. In some embodiments, X⁹is a residue of an amino acid selected from I, V, F, H, and L. In some embodiments, X⁹is a residue of an amino acid selected from I, V, L, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine. In some embodiments, X⁹is a residue of an amino acid selected from I and V. In some embodiments, X¹¹is a residue of an amino acid selected from R, A, D, E, F, H, I, K, L, M, N, P, Q, S, T, V, W, Y, 3-(1-naphthylalanine), 2-aminoadipic acid, asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine, N-epsilon-methyllysine, N-epsilon-dimethyllysine, and N-epsilon-trimethyllysine. In some embodiments, X¹¹is a residue of an amino acid selected from R, A, D, E, F, H, I, K, L, M, N, P, Q, S, T, V, W, and Y. In some embodiments, X¹¹is a residue of an amino acid selected from R, A, E, F, K, Q, S, V, Y, 3-(1-naphthylalanine), 2-aminoadipic acid, asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine, N-epsilon-methyllysine, N-epsilon-dimethyllysine, and N-epsilon-trimethyllysine. In some embodiments, X¹¹is a residue of an amino acid selected from R, A, F, K, S, V, 3-(1-naphthylalanine), asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine, and N-epsilon-methyllysine. In some embodiments, X¹²is a residue of an amino acid selected from V, F, H, I, L, alpha-methyl valine, alpha methyl leucine, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine. In some embodiments, X¹²is a residue of an amino acid selected from V, F, H, I, and L. In some embodiments, X¹²is a residue of an amino acid selected from I, A, L, V, alpha-methylleucine, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, alpha-neopentylglycine, O-propargylserine, L-octylglycine, and L-alloisoleucine. In some embodiments, X¹²is a residue of an amino acid selected from V, alpha-methyl valine, and alpha methyl leucine. In some embodiments, X¹³is a residue of an amino acid selected from W, A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, Y, d-tryptophan, alpha-methyl tryptophan, 3-(1-naphthylalanine), 3-(2-naphthylalanine), 4-chlorotryptophan, 5-chlorotryptophan, 6-chlorotryptophan, 7-chlorotryptophan, 4-bromotryptophan, 5-bromotryptophan, 6-bromotryptophan, 7-bromotryptophan, 4-fluorotryptophan, 5-fluorotryptophan, 6-fluorotryptophan, 7-fluorotryptophan, 1-methyltryptophan, 2-methyltryptophan, 4-methyltryptophan, 5-methyltryptophan, 6-methyltryptophan, 7-methyltryptophan, 2-hydroxytryptophan, 4-hydroxytryptophan, 5-hydroxytryptophan, 6-hydroxytryptophan, 7-hydroxytryptophan, 5-methoxytryptophan, 7-azatryptophan, 3-benzothienylalanine, and 4-phenyl-L-phenylalanine. In some embodiments, X¹³is a residue of an amino acid selected from W, A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and Y. In some embodiments, X¹³is a residue of an amino acid selected from W, D, E, F, Y, d-tryptophan, alpha-methyl tryptophan, 3-(1-naphthylalanine), 3-(2-naphthylalanine), 5-chlorotryptophan, 6-chlorotryptophan, 7-chlorotryptophan, 5-bromotryptophan, 6-bromotryptophan, 7-bromotryptophan, 5-fluorotryptophan, 6-fluorotryptophan, 7-fluorotryptophan, 1-methyltryptophan, 2-methyltryptophan, 5-methyltryptophan, 6-methyltryptophan, 7-methyltryptophan, 2-hydroxytryptophan, 5-hydroxytryptophan, 6-hydroxytryptophan, 7-hydroxytryptophan, 5-methoxytryptophan, 7-azatryptophan, and 3-benzothienylalanine. In some embodiments, X¹³is a residue of an amino acid selected from W, D-tryptophan, and alpha-methyl tryptophan.

In some embodiments, a provided peptide comprises SILDAHIQRVW (SEQ ID NO: 4) or a homolog thereof, therein at least two amino acid residues of SILDAHIQRVW (SEQ ID NO: 4) or a homolog thereof is independently replaced with Xⁱand X^i+m. In some embodiments, a provided peptide comprising XⁱILDAHIX^i+mRVW (SEQ ID NO: 5) or a homolog thereof. In some embodiments, the side chains of Xⁱand X^i+mare linked together through olefin metathesis to form a staple, e.g., one described in the present disclosure. In some embodiments, one or more, or more than half, or all of I, L, D, H, and V, corresponding to I472, L473, D474, H476, and V480 of Xenopus Axin are not replaced or replaced with a homolog that has similar properties (e.g., a basic residue with a basic homolog, an acid residue with an acidic homolog, a hydrophobic residue with a hydrophobic homolog, and/or an aromatic residue with an aromatic homolog). In some embodiments, one or more, or more than half, or all of I, L, D, and H, corresponding to I472, L473, D474, and H476 of Xenopus Axin are not replaced. In some embodiments, one of I, L, D, and H, corresponding to I472, L473, D474, and H476 of Xenopus Axin is not replaced. In some embodiments, two of I, L, D, and H, corresponding to I472, L473, D474, and H476 of Xenopus Axin are not replaced. In some embodiments, three of I, L, D, and H, corresponding to I472, L473, D474, and H476 of Xenopus Axin are not replaced. In some embodiments, four of I, L, D, and H, corresponding to I472, L473, D474, and H476 of Xenopus Axin are not replaced. In some embodiments, all replacement, if any, are each independently replaced with a homolog that has similar properties (e.g., a basic residue with a basic homolog, an acid residue with an acidic homolog, a hydrophobic residue with a hydrophobic homolog, and/or an aromatic residue with an aromatic homolog). In some embodiments, all replacement, if any, are each independently replaced with a homolog, wherein if a basic residue is replaced, it is replaced with a basic homolog; if an acid residue, with an acidic homolog; if a hydrophobic residue, with a hydrophobic homolog, and if an aromatic residue, with an aromatic homolog.

In some embodiments, a provide peptide has a sequence that is at least 50%, 60%, 70%, 80%, 90%, or 95% homologous to PAR₈ILDAHVM_BRVW (SEQ ID NO: 6). In some embodiments, a provide peptide has a sequence that is at least 50%, 60%, 70%, 80%, 90%, or 95% homologous to AR₈ILDAHIM_BRVW (SEQ ID NO: 7). In some embodiments, a provide peptide has a sequence that is at least 50%, 60%, 70%, 80%, 90%, or 95% homologous to AM_GILDAHIM_BRVW (SEQ ID NO: 8). In some embodiments, the homology is at least 50%. In some embodiments, the homology is at least 60%. In some embodiments, the homology is at least 70%. In some embodiments, the homology is at least 80%. In some embodiments, the homology is at least 80%. In some embodiments, the homology is at least 95%.

Exemplary peptides are extensively described in the present disclosure, e.g., in the Tables, Examples, etc. In some cases, a “-” may be included in a compound (e.g., unstapled peptide, stapled peptide, etc.) ID number after “FP”. Unless otherwise specified, a number with a “-” after “FP” and a number without a “-” after “FP” refer to the same compound. For example, unless otherwise specified, FP-0996 (with a “-” after “FP”) and FP0996 (without a “-” after “FP”) refer to the same compound (in this case, the same peptide). In some embodiments, a provided peptide is a peptide of Table 1. In some embodiments, a provided stapled peptide is a peptide of Table 1. In some embodiments, a provided peptide is a peptide that can undergo olefin metathesis to form a peptide of Table 1. In some embodiments, a provided stapled peptide is FPO217c. In some embodiments, a provided stapled peptide is FP0597c.

TABLE 1

Exemplary peptides.

Part A:

ID*
SEQ ID NO:
Sequence

FP0001c
9
Ac-P-Q-M_C-I-L-D-A-H-V-S₈-R-V-L-NH2

FP0003c
10
Ac-P-A-M_C-I-L-D-A-H-V-S₈-R-V-L-NH2

FP0005c
11
Ac-P-A-M_C-I-L-D-A-H-V-S₈-R-V-W-NH2

FP0006a
12
Ac-P-A-M_C-I-L-D-A-H-V-S₈-R-V-W-NH2

FP0007c
13
Ac-P-A-M_C-I-L-D-A-H-V-S₈-R-W-NH2

FP0009c
14
Ac-P-A-M_C-I-A-D-A-H-V-S₈-R-V-W-NH2

FP0011c
15
Ac-P-Q-R₈-I-L-D-A-H-V-M_B-R-V-L-NH2

FP0025c
16
Ac-P-A-R₈-I-L-D-A-H-V-M_B-R-V-W-NH2

FP0098
17
Ac-P-A-S-I-L-D-A-H-V-Q-R-V-W-NH2

FP0099
18
Ac-P-A-M_C-I-L-D-A-H-V-S₈-R-V-W-NH2

FP0110
19
Ac-P-E-S-I-L-D-E-H-V-Q-R-V-nL-K-NH2

FP0212s Isomer 2
20
Ac-P-A-R₅-I-L-D-A-H-V-S₈-R-V-W-NH2

FP0216c
21
Ac-P-A-R₈-I-L-T-A-H-I-M_B-R-V-W-NH2

FP0217a
22
Ac-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0217c
23
Ac-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

c14-FP0217a
24
Myr-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

c14-FP0217c
25
Myr-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

c16-FP0217a
26
Pal-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0217c_bAfree
27
bA-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0217c_btn
28
Btn-PEG3-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0217c_c18a
29
C18a-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0217rc
30
Ac-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0217s Isomer 1
31
Ac-A-R₈-I-L-D-A-H-I-S₅-R-V-W-NH2

FP0217s Isomer 2
32
Ac-A-R₈-I-L-D-A-H-I-S₅-R-V-W-NH2

FP0217u
33
Ac-A-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0218c
34
Ac-A-R₈-I-L-N-A-H-I-M_B-R-V-W-NH2

FP0219c
35
Ac-A-R₈-I-L-T-A-H-I-M_B-R-V-W-NH2

FP0220c
36
Ac-R₈-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0221c
37
Ac-R₈-I-L-N-A-H-I-M_B-R-V-W-NH2

FP0222c
38
Ac-R₈-I-L-T-A-H-I-M_B-R-V-W-NH2

FP0223a
39
Ac-P-A-M_A-I-L-D-A-H-V-S₈-R-V-W-NH2

FP0224a
40
Ac-P-A-R₈-I-L-D-A-H-I-M_A-R-V-W-NH2

FP0243c
41
Ac-A-M_A-I-L-pff-A-H-I-S₈-ADMA-V-W-NH2

FP0244c
42
Ac-A-M_A-I-L-pff-A-H-I-S₈-Y-V-W-NH2

FP0247c
43
Ac-A-M_A-I-L-ADMA-A-H-I-S₈-ADMA-V-W-NH2

FP0249c
44
Ac-A-R₈-I-L-SDMA-A-H-I-M_A-ADMA-V-W-NH2

FP0250c
45
Ac-A-M_A-I-L-ADMA-A-H-I-S₈-SDMA-V-W-NH2

FP0253c
46
Ac-A-R₈-I-L-N-A-H-I-M_A-pff-V-W-NH2

FP0264c
47
Ac-A-M_A-I-L-pff-A-H-I-S₈-A-V-W-NH2

FP0265c
48
Ac-A-R₈-I-L-Y-A-H-I-M_A-Y-V-W-NH2

FP0268c
49
Ac-A-M_A-I-L-N-A-H-I-S₈-ADMA-V-W-NH2

FP0269c
50
Ac-A-R₈-I-L-ADMA-A-H-I-M_A-N-V-W-NH2

FP0270c
51
Ac-A-M_A-I-L-ADMA-A-H-I-S₈-N-V-W-NH2

FP0271c
52
Ac-A-M_A-I-L-N-A-H-I-S₈-SDMA-V-W-NH2

FP0272c
53
Ac-A-R₈-I-L-ADMA-A-H-I-M_A-L-V-W-NH2

FP0273c
54
Ac-A-M_A-I-L-SDMA-A-H-I-S₈-L-V-W-NH2

FP0274c
55
Ac-A-M_A-I-L-ADMA-A-H-I-S₈-L-V-W-NH2

FP0278c
56
Ac-A-M_A-I-L-Q-A-H-I-S₈-R-V-W-NH2

FP0279c
57
Ac-A-R₈-I-L-N-A-H-I-M_A-Y-V-W-NH2

FP0280c
58
Ac-A-M_A-I-L-Y-A-H-I-S₈-N-V-W-NH2

FP0281c
59
Ac-A-R₈-I-L-Y-A-H-I-M_A-N-V-W-NH2

FP0282c
60
Ac-A-M_A-I-L-N-A-H-I-S₈-Y-V-W-NH2

FP0284c
61
Ac-A-M_A-I-L-SDMA-A-H-I-S₈-A-V-W-NH2

FP0285c
62
Ac-A-M_A-I-L-D-A-H-I-S₈-R-V-W-NH2

FP0286c
63
Ac-A-M_A-I-L-N-A-H-I-S₈-R-V-W-NH2

FP0290c
64
Ac-A-M_A-I-L-N-A-H-I-S₈-cpa-V-W-NH2

FP0292c
65
Ac-A-R₈-I-L-D-A-H-I-M_A-Q-V-W-NH2

FP0293c
66
Ac-A-M_A-I-L-D-A-H-I-S₈-Q-V-W-NH2

FP0295c
67
Ac-A-R₈-I-L-Q-A-H-I-M_A-N-V-W-NH2

FP0296c
68
Ac-A-M_A-I-L-Q-A-H-I-S₈-N-V-W-NH2

FP0298c
69
Ac-A-M_A-I-L-Q-A-H-I-S₈-T-V-W-NH2

FP0299c
70
Ac-A-R₈-I-L-Q-A-H-I-M_A-T-V-W-NH2

FP0300c
71
Ac-A-M_A-I-L-D-A-H-I-S₈-N-V-W-NH2

FP0302c
72
Ac-A-M_A-I-L-N-A-H-I-S₈-L-V-W-NH2

FP0306c
73
Ac-A-M_A-I-L-T-A-H-I-S₈-N-V-W-NH2

FP0317a
74
Dodec-P-A-R₈-I-L-D-A-H-V-M_B-R-V-W-NH2

FP0318a
75
Dec-P-A-R₈-I-L-D-A-H-V-M_B-R-V-W-NH2

FP0318c
76
Dec-P-A-R₈-I-L-D-A-H-V-M_B-R-V-W-NH2

FP0321c
77
Bua-P-A-R₈-I-L-D-A-H-V-M_B-R-V-W-NH2

FP0324c
78
0ct-P-A-R₈-I-L-D-A-H-V-M_B-R-V-W-1NH2

FP0325a
79
Hex-P-A-R₈-I-L-D-A-H-V-M_B-R-V-W-NH2

FP0325c
80
Hex-P-A-R₈-I-L-D-A-H-V-M_B-R-V-W-NH2

FP0327c
81
Ac-P-A-R₈-I-A-D-A-H-V-M_B-R-V-W-NH2

FP0327c
81
Ac-P-A-R₈-I-A-D-A-H-V-M_B-R-V-W-NH2

FP0335a
82
Ac-A-M_E-I-L-D-A-H-I-S₈-R-V-W-NH2

FP0335c Isomer 1
83
Ac-A-M_E-I-L-D-A-H-I-S₈-R-V-W-NH2

FP0335c Isomer 2
84
Ac-A-M_E-I-L-D-A-H-I-S₈-R-V-W-NH2

FP0336c
85
Ac-A-M_E-I-L-4FF-A-H-I-S₈-Y-V-W-NH2

FP0338c
86
Ac-A-R₈-I-L-D-A-H-I-M_D-R-V-W-NH2

FP0344c
87
Ac-A-R₈-I-L-4FF-A-H-I-M_B-R-V-W-NH2

FP0345c
88
Ac-A-M_A-I-L-4FF-A-H-I-S₈-Y-V-W-NH2

FP0346c
89
Ac-A-R₈-I-L-4FF-A-H-I-M_A-4FF-V-W-NH2

FP0349c
90
Ac-A-R₈-I-L-MeY-A-H-I-M_A-4FF-V-W-NH2

FP0350c
91
Ac-A-R₈-I-L-F-A-H-I-M_B-R-V-W-NH2

FP0352c
92
Ac-A-R₈-I-L-F-A-H-I-M_A-4FF-V-W-NH2

FP0353c
93
Ac-A-R₈-I-L-1NapA-A-H-I-M_B-R-V-W-NH2

FP0354c
94
Ac-A-M_A-I-L-1NapA-A-H-I-S₈-Y-V-W-NH2

FP0355c
95
Ac-A-R8-I-L-1NapA-A-H-I-M_A-4FF-V-W-NH2

FP0357c
96
Ac-A-M_A-I-L-V-A-H-I-S₈-Y-V-W-NH2

FP0365c
97
Ac-A-R₈-I-L-D-A-H-I-M_B-1NapA-V-W-NH2

FP0365c Isomer 1
98
Ac-A-R₈-I-L-D-A-H-I-M_B-1NapA-V-W-NH2

FP0365c Isomer 2
99
Ac-A-R₈-I-L-D-A-H-I-M_B-1NapA-V-W-NH2

FP0368c
100
Ac-A-R₈-I-L-D-A-H-I-M_B-V-V-W-NH2

FP0369c
101
Ac-A-M_A-I-L-4FF-A-H-I-S₈-V-V-W-NH2

FP0371c
102
Ac-A-R₈-I-L-D-A-H-I-M_B-F-V-W-NH2

FP0380c
103
Ac-A-R₈-I-L-D-A-H-I-M_B-R-Cha-W-NH2

FP0383c
104
Ac-A-R₈-I-L-D-A-H-Cha-M_B-R-V-W-NH2

FP0391c
105
Ac-A-R₈-I-L-2NapA-A-H-I-M_A-4FF-V-W-NH2

FP0395c
106
Ac-A-R₈-I-L-Cha-A-H-I-M_B-R-V-W-NH2

FP0405c
107
Ac-A-R₈-A-L-D-A-H-I-M_B-R-V-W-NH2

FP0406c
108
Ac-A-R₈-I-A-D-A-H-I-M_B-R-V-W-NH2

FP0407c
109
Ac-A-R₈-I-L-A-A-H-I-M_B-R-V-W-NH2

FP0408c
110
Ac-A-R₈-I-L-D-A-A-I-M_B-R-V-W-NH2

FP0409a
111
Ac-A-R₈-I-L-D-A-H-A-M_B-R-V-W-NH2

FP0409c
112
Ac-A-R₈-I-L-D-A-H-A-M_B-R-V-W-NH2

FP0409c_free
113
A-R₈-I-L-D-A-H-A-M_B-R-V-W-NH2

c16-FP0409a
114
Pal-A-R₈-I-L-D-A-H-A-M_B-R-V-W-NH2

c16-FP0409c
115
Pal-A-R₈-I-L-D-A-H-A-M_B-R-V-W-NH2

FP0410c
116
Ac-A-R₈-I-L-D-A-H-I-M_B-A-V-W-NH2

FP0411c
117
Ac-A-R₈-I-L-D-A-H-I-M_B-R-A-W-NH2

FP0412c
118
Ac-A-R₈-I-L-D-A-H-I-M_B-R-V-A-NH2

FP0495a
119
Ac-A-R₇-I-L-D-A-H-I-M_D-R-V-W-NH2

FP0495c
120
Ac-A-R₇-I-L-D-A-H-I-M_D-R-V-W-NH2

FP0501c
121
Ac-A-R₅-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0502a
122
Ac-A-R₆-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0502c Isomer 1
123
Ac-A-R₆-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0502c Isomer 2
124
Ac-A-R₆-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0503a
125
Ac-A-R₇-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0503c
126
Ac-A-R₇-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0506a
127
Ac-A-M_I-I-L-D-A-H-I-S₅-R-V-W-NH2

FP0506c Isomer 1
128
Ac-A-M_I-I-L-D-A-H-I-S₅-R-V-W-NH2

FP0506c Isomer 2
129
Ac-A-M_I-I-L-D-A-H-I-S₅-R-V-W-NH2

FP0507a
130
Ac-A-M_I-I-L-D-A-H-I-S₆-R-V-W-NH2

FP0507c
131
Ac-A-M_I-I-L-D-A-H-I-S₆-R-V-W-NH2

FP0509a
132
Ac-A-R₄-I-L-D-A-H-I-M_H-R-V-W-NH2

FP0509c
133
Ac-A-R₄-I-L-D-A-H-I-M_H-R-V-W-NH2

FP0510a
134
Ac-A-R₅-I-L-D-A-H-I-M_H-R-V-W-NH2

FP0510c Isomer 1
135
Ac-A-R₅-I-L-D-A-H-I-M_H-R-V-W-NH2

FP0510c Isomer 2
136
Ac-A-R₅-I-L-D-A-H-I-M_H-R-V-W-NH2

FP0511a
137
Ac-A-R₆-I-L-D-A-H-I-M_H-R-V-W-NH2

FP0511c Isomer 1
138
Ac-A-R₆-I-L-D-A-H-I-M_H-R-V-W-NH2

FP0511c Isomer 2
139
Ac-A-R₆-I-L-D-A-H-I-M_H-R-V-W-NH2

FP0516a Isomer 1
140
Ac-A-R₇-I-L-D-A-H-I-M_A-R-V-W-NH2

FP0516a Isomer 2
141
Ac-A-R₇-I-L-D-A-H-I-M_A-R-V-W-NH2

FP0516c
142
Ac-A-R₇-I-L-D-A-H-I-M_A-R-V-W-NH2

FP0536c
143
Ac-A-R₈-I-L-D-A-thi-I-M_B-R-V-W-NH2

FP0537c
144
Ac-A-R₈-I-L-D-A-3pyr-I-M_B-R-V-W-NH2

FP0538c
145
Ac-A-R₈-I-L-D-A-4pyr-I-M_B-R-V-W-NH2

FP0539c
146
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-R-V-W-NH2

FP0539c Isomer 1
147
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-R-V-W-NH2

FP0539c Isomer 2
148
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-R-V-W-NH2

FP0540c
149
Ac-A-R₈-I-L-D-A-F-I-M_B-R-V-W-NH2

FP054 lc
150
Ac-A-R₈-I-L-D-A-fur-I-M_B-R-V-W-NH2

FP0542c
151
Ac-A-R₈-I-L-D-A-H-I-M_B-S-V-W-NH2

FP0554c Isomer 1
152
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-A-V-W-NH2

FP0554c Isomer 2
153
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-A-V-W-NH2

FP0555c Isomer 1
154
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-F-V-W-NH2

FP0555c Isomer 2
155
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-F-V-W-NH2

FP0556c Isomer 1
156
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-I-V-W-NH2

FP0556c Isomer 2
157
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-I-V-W-NH2

FP0557c Isomer 1
158
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-L-V-W-NH2

FP0557c Isomer 2
159
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-L-V-W-NH2

FP0558c Isomer 1
160
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-N-V-W-NH2

FP0558c Isomer 2
161
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-N-V-W-NH2

FP0559c Isomer 1
162
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Q-V-W-NH2

FP0559c Isomer 2
163
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Q-V-W-NH2

FP0560c Isomer 1
164
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-S-V-W-NH2

FP0560c Isomer 2
165
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-S-V-W-NH2

FP0561c Isomer 1
166
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-T-V-W-NH2

FP0561c Isomer 2
167
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-T-V-W-NH2

FP0562c Isomer 1
168
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-V-V-W-NH2

FP0562c Isomer 2
169
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-V-V-W-NH2

FP0563c Isomer 1
170
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-W-V-W-NH2

FP0563c Isomer 2
171
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-W-V-W-NH2

FP0564c Isomer 1
172
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Y-V-W-NH2

FP0564c Isomer 2
173
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Y-V-W-NH2

FP0565c Isomer 1
174
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Cba-V-W-NH2

FP0565c Isomer 2
175
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Cba-V-W-NH2

FP0566c Isomer 1
176
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Cha-V-W-NH2

FP0567c Isomer 1
177
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Nva-V-W-NH2

FP0567c Isomer 2
178
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Nva-V-W-NH2

FP0568c Isomer 1
179
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-tLeu-V-W-NH2

FP0568c Isomer 2
180
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-tLeu-V-W-NH2

FP0569c Isomer 1
181
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-fur-V-W-NH2

FP0569c Isomer 2
182
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-fur-V-W-NH2

FP0570c Isomer 1
183
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Aib-V-W-NH2

FP0570c Isomer 2
184
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-Aib-V-W-NH2

FP0571c Isomer 1
185
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-thi-V-W-NH2

FP0571c Isomer 2
186
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-thi-V-W-NH2

FP0572c Isomer 1
187
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-2pyr-V-W-NH2

FP0573c Isomer 1
188
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-3pyr-V-W-NH2

FP0573c Isomer 2
189
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-3pyr-V-W-NH2

FP0574c Isomer 1
190
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-cpa-V-W-NH2

FP0574c Isomer 2
191
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-cpa-V-W-NH2

FP0575c Isomer 1
192
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-MeY-V-W-NH2

FP0575c Isomer 2
193
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-MeY-V-W-NH2

FP0576c Isomer 1
194
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-4FF-V-W-NH2

FP0576c Isomer 2
195
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-4FF-V-W-NH2

FP0577c Isomer 1
196
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-1NapA-V-W-NH2

FP0578c Isomer 1
197
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-4MeF-V-W-NH2

FP0578c Isomer 2
198
Ac-A-R₈-I-L-D-A-2pyr-I-M_B-4MeF-V-W-NH2

FP0587c
199
Ac-A-M_I-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0588c
200
Ac-A-M_I-I-L-D-A-H-I-M_G-R-V-W-NH2

FP0594c
201
Ac-A-M_G-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0596c
202
Ac-A-M_G-I-L-D-A-H-I-M_E-R-V-W-NH2

FP0597c
203
Ac-A-M_G-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0597c_c12
204
Dodec-A-M_G-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0597c_c8
205
Oct-A-M_G-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0598c
206
Ac-A-M_G-I-L-D-A-H-I-M_C-R-V-W-NH2

FP0601c
207
Ac-A-M_E-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0604c
208
Ac-A-M_E-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0605c
209
Ac-A-M_E-I-L-D-A-H-I-M_C-R-V-W-NH2

FP0611c
210
Ac-A-M_A-I-L-D-A-H-I-M_F-R-V-W-NH2

FP0616c
211
Ac-A-M_A-I-L-D-A-H-I-M_C-R-V-W-NH2

FP0617c
212
Ac-A-M_A-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0625c
213
Ac-A-M_A-I-L-D-A-H-I-M_I-R-V-W-NH2

FP0626c
214
Ac-A-M_F-I-L-D-A-H-I-M_B-R-V-W-NH2

FP0628_aib
215
Ac-A-Aib-I-L-D-A-H-I-Aib-R-V-W-NH2

FP0629c
216
Ac-A-R₈-I-L-M2O-A-H-I-M_B-R-V-W-NH2

FP0630c
217
Ac-A-R₈-I-L-D-A-H-I-M_B-R-V-dW-NH2

FP0631c
218
Ac-A-R₈-I-L-D-A-H-I-M_B-R-V-aMeW-NH2

FP0632c
219
Ac-A-R₈-I-L-D-A-H-I-M_B-R-aMeV-W-NH2

FP0633c
220
Ac-A-R₈-I-L-D-A-H-I-M_B-R-aMeL-W-NH2

FP0634c
221
Ac-A-R₈-I-L-D-A-H-I-M_B-hArg-V-W-NH2

FP0635c
222
Ac-A-R₈-I-L-D-A-H-I-M_B-K-V-W-NH2

FP0636c
223
Ac-A-R₈-I-L-D-A-H-I-M_B-lmeK-V-W-NH2

FP0639c
224
Ac-A-R₈-I-L-D-A-H-I-M_B-ADMA-V-W-NH2

FP0640c
225
Ac-A-R₈-I-L-D-A-H-I-M_B-SDMA-V-W-NH2

FP0644c
226
Ac-A-R₈-I-aMeL-D-A-H-I-M_B-R-V-W-NH2

FP0645c
227
Ac-A-R₈-I-L-D-Aib-H-I-M_B-R-V-W-NH2

FP0721a
228
Ac-P-Q-M_A-I-L-D-R₄-H-V-R-R-V-W-R-NH2

FP0721c
229
Ac-P-Q-M_A-I-L-D-R₄-H-V-R-R-V-W-R-NH2

FP0723a
230
Ac-P-Q-M_A-I-L-D-R₅-H-V-R-R-V-W-R-NH2

FP0723c
231
Ac-P-Q-M_A-I-L-D-R₅-H-V-R-R-V-W-R-NH2

FP0724c
232
Ac-P-Q-M_A-I-L-D-S₅-H-V-R-R-V-W-R-NH2

FP0725a
233
Ac-P-Q-M_A-I-L-D-R₆-H-V-R-R-V-W-R-NH2

FP0725c
234
Ac-P-Q-M_A-I-L-D-R₆-H-V-R-R-V-W-R-NH2

FP0727c
235
Ac-P-Q-M_A-I-L-D-R₇-H-V-R-R-V-W-R-NH2

FP0728c
236
Ac-P-Q-M_A-I-L-D-S₇-H-V-R-R-V-W-R-NH2

FP0731c
237
Ac-P-Q-R₄-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0733c
238
Ac-P-Q-R₅-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0734a
239
Ac-P-Q-S₅-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0734c
240
Ac-P-Q-S₅-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0735a
241
Ac-P-Q-R₆-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0735c
242
Ac-P-Q-R₆-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0736a
243
Ac-P-Q-S₆-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0736c
244
Ac-P-Q-S₆-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0738a
245
Ac-P-Q-S₇-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0738c
246
Ac-P-Q-S₇-I-L-D-M_A-H-V-R-R-V-W-R-NH2

FP0743a
247
Ac-P-Q-M_C-I-L-D-R₅-H-V-R-R-V-W-R-NH2

FP0743c
248
Ac-P-Q-M_C-I-L-D-R₅-H-V-R-R-V-W-R-NH2

FP0745a
249
Ac-P-Q-M_C-I-L-D-R₆-H-V-R-R-V-W-R-NH2

FP0745c
250
Ac-P-Q-M_C-I-L-D-R₆-H-V-R-R-V-W-R-NH2

FP0751a
251
Ac-P-Q-M_B-I-L-D-S₅-H-V-R-R-V-W-R-NH2

FP0751c
252
Ac-P-Q-M_B-I-L-D-S₅-H-V-R-R-V-W-R-NH2

FP0752c
253
Ac-P-Q-M_B-I-L-D-S₆-H-V-R-R-V-W-R-NH2

FP0753a
254
Ac-P-Q-M_B-I-L-D-S₇-H-V-R-R-V-W-R-NH2

FP0758a
255
Ac-P-Q-R₅-I-L-D-M_B-H-V-R-R-V-W-R-NH2

FP0758c
256
Ac-P-Q-R₅-I-L-D-M_B-H-V-R-R-V-W-R-NH2

FP0761c
257
Ac-P-Q-S₆-I-L-D-M_B-H-V-R-R-V-W-R-NH2

FP0763a
258
Ac-P-Q-S₇-I-L-D-M_B-H-V-R-R-V-W-R-NH2

FP0763c
259
Ac-P-Q-S₇-I-L-D-M_B-H-V-R-R-V-W-R-NH2

FP0765c
260
Ac-P-Q-R₄-I-L-D-M_C-H-V-R-R-V-W-R-NH2

FP0766c
261
Ac-P-Q-R₅-I-L-D-M_C-H-V-R-R-V-W-R-NH2

FP0767a
262
Ac-P-Q-R₆-I-L-D-M_C-H-V-R-R-V-W-R-NH2

FP0767c
263
Ac-P-Q-R₆-I-L-D-M_C-H-V-R-R-V-W-R-NH2

FP0768a
264
Ac-P-Q-R₇-I-L-D-M_C-H-V-R-R-V-W-R-NH2

FP0768c
265
Ac-P-Q-R₇-I-L-D-M_C-H-V-R-R-V-W-R-NH2

FP0776c
266
Ac-P-Q-R₅-I-L-D-M_G-H-V-R-R-V-W-R-NH2

FP0776a
267
Ac-P-Q-R₅-I-L-D-M_G-H-V-R-R-V-W-R-NH2

FP0777c
268
Ac-P-Q-R₅-I-L-D-M_I-H-V-R-R-V-W-R-NH2

FP0777a
269
Ac-P-Q-R₅-I-L-D-M_I-H-V-R-R-V-W-R-NH2

FP0778c
270
Ac-P-Q-M_D-I-L-D-S₅-H-V-R-R-V-W-R-NH2

FP0779c
271
Ac-P-Q-M_F-I-L-D-S₅-H-V-R-R-V-W-R-NH2

FP0780c
272
Ac-P-Q-M_H-I-L-D-S₅-H-V-R-R-V-W-R-NH2

FP0782c
273
Ac-P-Q-M_G-I-L-D-R₅-H-V-R-R-V-W-R-NH2

FP0783c
274
Ac-P-Q-M_I-I-L-D-R₅-H-V-R-R-V-W-R-NH2

FP0783a
275
Ac-P-Q-M_I-I-L-D-R₅-H-V-R-R-V-W-R-NH2

FP0787s
276
Ac-P-Q-S₅-I-L-D-S₅-H-V-R-R-V-W-R-NH2

*u: unstapled;

a, c and s: stapled, typically (i, i + 4) and (i, i + 7). Some stapled peptides may contain two or more staples. For c, comprising a carbamate staple which

comprises —N(R’)—C(O)—O—. For s, comprising a hydrocarbon staple which comprises neither —N(R')—C(O)—O— nor —N(R'). For a, compris-

ing an amino staple which comprises —N(R')— which is not part of —N(R')—C(O)—O— (can be formed by removal of CO₂from

—N(R')—C(O)—O—). As appreciated by those skilled in the art, a staple formed by two side chains each independently having the structure of

—L^a—CH═CH₂has the structure of —L^a—CH═CH—L^a—, wherein the two L^aare the same or different. For amino linker, —N(R')—C(O)—O— in

L^aof the corresponding carbamate linker is replaced with —N(R')—;

r: olefin (—CH═CH—) in staple formed by metathesis reduced to —CH₂—CH₂— (e.g., in rc). Non-natural amino acids (or protected form thereof) or

modifications (or reagents for introducing the modifications) in Table 1 (unless otherwise noted, all amino acids, if applicable, are L-amino acids):

Myr = myristoyl

Pal = palmitoyl

Ac = acetyl

nL = norleucine

bA = beta-alanine

Btn = biotin

PEG3 = CAS# 557756-85-1

C18a = CAS# 871-70-5

pff = pentafluorophenylalanine

ADMA = asymmetric dimethylarginine

SDMA = symmetric dimethylarginine

cpa = 3-cyclopropylalanine

Dodec = dodecanoyl

Dec = decanoyl

Bua = butyryl

Oct = octyl

Hex = hexyl

4FF = 4-fluorophenylalanine

MeY = O-methyl tyrosine

1NapA = 3-(1-naphthyl)-L-alanine

2NapA = 3-(2-naphthyl)-L-alanine

Cha = 3-cyclohexyl-L-alanine

thi = beta-2-thienylalanine

2pyr = 3-(2-pyridyl)-L-alanine

3pyr = 3-(3-pyridyl)-L-alanine

4pyr =3-(4-pyridyl)-L-alanine

fur = 2-furyl-L-alanine

cba = 3-cyclobutylalanine

Nva = norvaline

tLeu = tert-leucine

4MeF = 4-methyl-L-phenylalanine

Aib = aminoisobutyric acid

M2O = methionine sulfone

dW = D-tryptophan

aMeW = alpha-methyl-L-tryptophan

aMeV = alpha-methyl-L-valine

aMeL = alpha-methyl-L-leucine

hArg = homoarginine

lmeK = N-epsilon-methyl-L-lysine

FITC = fluorescein isothiocyanate

NHBut = aminobutyric acid

NHHex = aminohexanoic acid

NHOct = aminooctanoic acid

AzWT = azetidine-2-carboxylic acid

Bip = 4-phenyl-L-phenylalanine

5ClW = 5-chloro-L-tryptophan

HOW= 5-hydroxy-L-tryptophan

H2W= 2,3-dihydro-L-tryptophan

F3MeF = 4-trifluoromethyl-L-phenylalanine

4ClF = 4-chloro-L-phenylalanine

embedded image

Part B - Amino acid sequence the same as FP0217.

Amino Acid
Amino Acid 2

1
(i + 7
ID
Carbamate Staple

Monomer A
S₈
FP0512c

embedded image

Monomer A
S₇
FP0513c

embedded image

Monomer A
S₆
FP0514c

embedded image

R₈
Monomer A
FP0515c

embedded image

R₇
Monomer A
FP0516c

embedded image

R₆
Monomer A
FP0517c

embedded image

Monomer E
S₈
FP0335c

embedded image

Monomer E
S₇
FP0492c

embedded image

Monomer E
S₆
FP0491c

embedded image

Monomer E
S₅
FP0490c

embedded image

R₈
Monomer D
FP0338c

embedded image

R₇
Monomer D
FP0495c

embedded image

R₆
Monomer D
FP0494c

embedded image

R₅
Monomer D
FP0493c

embedded image

Monomer G
S₇
FP0499c

embedded image

Monomer G
S₆
FP0498c

embedded image

Monomer G
S₅
FP0497c

embedded image

Monomer G
S₄
FP0496c

embedded image

R₇
Monomer F
FP0503c

embedded image

R₆
Monomer F
FP0502c

embedded image

R₅
Monomer F
FP0501c

embedded image

R₄
Monomer F
FP0500c

embedded image

Monomer I
S₆
FP0507c

embedded image

Monomer I
S₅
FP0506c

embedded image

Monomer I
S₄
FP0505c

embedded image

Monomer I
S₃
FP0504c

embedded image

Monomer C
S₈
FP0496c

embedded image

Monomer C
S₇
FP0485c

embedded image

Monomer C
S₆
FP0484c

embedded image

Monomer C
S₅
FP0483c

embedded image

R₈
Monomer B
FP0217c

embedded image

R₇
Monomer B
FP0489c

embedded image

R₆
Monomer B
FP0488c

embedded image

R₅
Monomer B
FP0487c

embedded image

R₃
Monomer H
FP0508c

embedded image

R₄
Monomer H
FP0509c

embedded image

R₅
Monomer H
FP0510c

embedded image

R₆
Monomer H
FP0511c

embedded image

Monomer G
S₇
FP0520c

embedded image

R₇
Monomer F
FP0521c

embedded image

Monomer I
S₆
FP0522c

embedded image

R₆
Monomer H
FP0523c

embedded image

Monomer A
Monomer B
FP0617c

embedded image

Monomer A
Monomer C
FP0616c

embedded image

Monomer A
Monomer A
FP0615c

embedded image

Monomer A
Monomer F
FP0611c

embedded image

Monomer A
Monomer E
FP0623c

embedded image

Monomer A
Monomer G
FP0624c

embedded image

Monomer A
Monomer I
FP0625c

embedded image

Monomer I
Monomer A
FP0529c

embedded image

Monomer G
Monomer A
FP0599c

embedded image

Monomer E
Monomer A
FP0606c

embedded image

Monomer F
Monomer A
FP0627c

embedded image

Monomer C
Monomer A
FP0618c

embedded image

Monomer B
Monomer A
FP0619c

embedded image

Monomer B
Monomer B
FP0613c

embedded image

Monomer B
Monomer F
FP0609c

embedded image

Monomer C
Monomer F
FP0610c

embedded image

Monomer C
Monomer C
FP0612c

embedded image

Monomer C
Monomer B
FP0614c

embedded image

Monomer C
Monomer E
FP0620c

embedded image

Monomer C
Monomer G
FP0621c

embedded image

Monomer C
Monomer I
FP0622c

embedded image

Monomer I
Monomer F
FP0587c

embedded image

Monomer I
Monomer G
FP0588c

embedded image

Monomer I
Monomer E
FP0589c

embedded image

Monomer I
Monomer B
FP0590c

embedded image

Monomer I
Monomer C
FP0591c

embedded image

Monomer I
Monomer I
FP0593c

embedded image

Monomer G
Monomer F
FP0594c

embedded image

Monomer G
Monomer G
FP0595c

embedded image

Monomer G
Monomer E
FP0596c

embedded image

Monomer G
Monomer B
FP0597c

embedded image

Monomer G
Monomer C
FP0598c

embedded image

Monomer G
Monomer I
FP0600c

embedded image

Monomer E
Monomer F
FP0601c

embedded image

Monomer E
Monomer G
FP0602c

embedded image

Monomer E
Monomer E
FP0603c

embedded image

Monomer E
Monomer B
FP0604c

embedded image

Monomer E
Monomer C
FP0605c

embedded image

Monomer E
Monomer I
FP0607c

embedded image

Monomer F
Monomer F
FP0608c

embedded image

Monomer F
Monomer B
FP0626c

embedded image

Amino Acid 1
Amino Acid 2
ID

(i position)
(i + 7 position)
(Carbamate)
ID
Amino Staple

R₇
Monomer A
FP0516c
FP0516a

embedded image

Monomer E
S₈
FP0335c
FP0335a

embedded image

R₈
Monomer D
FP0338c
FP0338a

embedded image

R₇
Monomer D
FP0495c
FP0495a

embedded image

R₇
Monomer F
FP0503c
FP0503a

embedded image

R₆
Monomer F
FP0502c
FP0502a

embedded image

Monomer I
S₆
FP0507c
FP0507a

embedded image

Monomer I
S₅
FP0506c
FP0506a

embedded image

R₈
Monomer B
FP0217c
FP0217a

embedded image

R₄
Monomer H
FP0509c
FP0509a

embedded image

R₅
Monomer H
FP0510c
FP0510a

embedded image

R₆
Monomer H
FP0511c
FP0511a

embedded image

b. Staples

In some embodiments, a staple is a linker that can link one amino acid residue to another amino acid residue through bonding to peptide backbone atoms of the amino acid residues and, as is understood by those skilled in the art, is not through the peptide backbone between the linked amino acid residues. In some embodiments, a staple bonds to the peptide backbone by replacing one or more hydrogen and/or substituents (e.g., side chains, O, etc.) on peptide backbone atoms (e.g., C, N, etc.).

In some embodiments, a staple may contribute to one or more properties and/or activities of a stapled peptide, reportedly through stabilization of alpha-helix formed by a stapled peptide. Various types of staples have been reported and may be utilized in accordance with the present disclosure, for example, those described in U.S. Pat. No. 9,617,309, US 2015-0225471, US 2016-0024153, US 2016-0215036, US2016-0244494, WO2017/062518, Azzarito et al, Nature Chemistry 5: 161-173 (2013), etc., the staples of each of which are incorporated herein by reference.

In some embodiments, the present disclosure provides the insights that structural elements of staples (e.g., chemistry [e.g., hydrocarbon, non-hydrocarbon (e.g., comprising one or more heteroatoms or heteroatom-containing moieties such as amino, carbamate, etc.)], stereochemistry [e.g., stereochemistry of backbone atoms that staples are connected to (e.g., if staples are connected to alpha-carbon atoms of amino acid residues, such carbon atoms being chiral (R S) or achiral)], positioning (to what amino acid residues/backbone atoms staples are connected), sizes (length of staples), etc.) can have significant impact on properties and/or activities, and can be employed to design and/or optimize stapled peptides having significantly improved properties and/or activities (e.g., increased solubility, increased cell permeability, increased stability, increased selectivity, lowered toxicity, increased activity, etc.).

In some embodiments, a provided staple is a hydrocarbon staple. In some embodiments, a hydrocarbon staple comprises no chain heteroatoms wherein a chain of a staple is the shortest covalent connection within the staple from one end of the staple to the other end of the staple.

In some embodiments, a provided staple is a non-hydrocarbon staple. In some embodiments, a non-hydrocarbon staple comprises one or more chain heteroatoms wherein a chain of a staple is the shortest covalent connection within the staple from one end of the staple to the other end of the staple. In some embodiments, a non-hydrocarbon staple is a carbamate staple in that it comprises a —N(R′)—C(O)—O— moiety in its chain. In some embodiments, a non-hydrocarbon staple is an amino staple in that it comprises a —N(R′)— moiety in its chain, wherein the —N(R′)— moiety is not part of —N(R′)—C(O)—O—. In some embodiments, a non-hydrocarbon staple is an amino staple in that it comprises a —N(R′)— moiety in its chain, wherein the —N(R′)-moiety is not bonded to a carbon atom that additionally forms a double bond with a heteroatom (e.g., —C(═O), —C(═S), —C(═N—R′), etc.).

In some embodiments, a provided stapled peptide comprises a staple which staple is L^s, wherein L^sis -L^s1-L^s2-L^s3-, each of L^s1, L^s2, and L^s3is independently L, wherein each L is independently as described in the present disclosure. In some embodiments, a provided staple is L^s.

In some embodiments, L^s1comprises at least one —N(R′)—, wherein R′ is as described in the present disclosure. In some embodiments, the —N(R′)— is bonded to two carbon atoms, wherein neither of the two carbon atoms forms a double bond with a heteroatom. In some embodiments, the —N(R′)— is not bonded to —C(O)—. In some embodiments, the —N(R′)— is not bonded to —C(S)—. In some embodiments, the —N(R′)— is not bonded to —C(═NR′)—. In some embodiments, L^s1is -L′-N(R′)—, wherein L′ is optionally substituted bivalent C₁-C₁₉aliphatic. In some embodiments, L^s1is -L′-N(CH₃)—, wherein L′ is optionally substituted bivalent C₁-C₁₉aliphatic.

In some embodiments, R′ is optionally substituted C_1-6alkyl. In some embodiments, R′ is C_1-6alkyl. In some embodiments, R′ is methyl. In some embodiments, the peptide backbone atom to which L^s1is bonded is also bonded to R¹, and R′ and R¹are both R and are taken together with their intervene atoms to form an optionally substituted ring as described in the present disclosure. In some embodiments, a formed ring has no additional ring heteroatoms in addition to the nitrogen atom to which R′ is bonded. In some embodiments, a formed ring is 3-membered. In some embodiments, a formed ring is 4-membered. In some embodiments, a formed ring is 5-membered. In some embodiments, a formed ring is 6-membered.

As defined herein, L′ is optionally substituted bivalent C₁-C₁₉aliphatic. In some embodiments, L′ is optionally substituted bivalent C₁-C₁₅aliphatic. In some embodiments, L′ is optionally substituted bivalent C₁-C₁₀aliphatic. In some embodiments, L′ is optionally substituted bivalent C₁-C₉aliphatic. In some embodiments, L′ is optionally substituted bivalent C₁-C₈aliphatic. In some embodiments, L′ is optionally substituted bivalent C₁-C₇aliphatic. In some embodiments, L′ is optionally substituted bivalent C₁-C₆aliphatic. In some embodiments, L′ is optionally substituted bivalent C₁-C₅aliphatic. In some embodiments, L′ is optionally substituted bivalent C₁-C₄aliphatic. In some embodiments, L′ is optionally substituted alkylene. In some embodiments, L′ is optionally substituted alkenylene. In some embodiments, L′ is unsubstituted alkylene. In some embodiments, L′ is —CH₂—. In some embodiments, L′ is —(CH₂)₂—. In some embodiments, L′ is —(CH₂)₃—. In some embodiments, L′ is —(CH₂)₄—. In some embodiments, L′ is —(CH₂)₅—. In some embodiments, L′ is —(CH₂)₆—. In some embodiments, L′ is —(CH₂)₇—. In some embodiments, L′ is —(CH₂)s-. In some embodiments, L′ is bonded to a peptide backbone atom. In some embodiments, L′ is optionally substituted alkenylene. In some embodiments, L′ is unsubstituted alkenylene. In some embodiments, L′ is —CH₂—CH═CH—CH₂—.

In some embodiments, L^s1comprises at least one —N(R′)C(O)—, wherein R′ is as described in the present disclosure. In some embodiments, L^s1is -L′-N(R′)C(O)—, wherein each of L′ and R′ is independently as described in the present disclosure. In some embodiments, L^s1is -L′-N(CH₃)C(O)—, wherein L′ is independently as described in the present disclosure.

In some embodiments, L^s1is a covalent bond.

In some embodiments, L^s1is L′, wherein L′ is as described in the present disclosure.

In some embodiments, L^s2is L, wherein L is as described in the present disclosure. In some embodiments, L^s2is L′, wherein L′ is as described in the present disclosure. In some embodiments, L^s2comprises —CH₂—CH═CH—CH₂—. In some embodiments, L^s2is —CH₂—CH═CH—CH₂—. In some embodiments, L^s2comprises —(CH₂)₄—. In some embodiments, L^s2is —(CH₂)₄—.

In some embodiments, L^s3comprises at least one —N(R′)—, wherein R′ is as described in the present disclosure. In some embodiments, the —N(R′)— is bonded to two carbon atoms, wherein neither of the two carbon atoms forms a double bond with a heteroatom. In some embodiments, the —N(R′)— is not bonded to —C(O)—. In some embodiments, the —N(R′)— is not bonded to —C(S)—. In some embodiments, the —N(R′)— is not bonded to —C(═NR′)—. In some embodiments, L^s3is -L′-N(R′)—, wherein L′ is optionally substituted bivalent C₁-C₁₉aliphatic. In some embodiments, L^s3is -L′-N(CH₃)—, wherein L′ is optionally substituted bivalent C₁-C₁₉aliphatic.

In some embodiments, L^s3comprises at least one —N(R′)C(O)—, wherein R′ is as described in the present disclosure. In some embodiments, L^s3is -L′-N(R′)C(O)—, wherein each of L′ and R′ is independently as described in the present disclosure. In some embodiments, L^s3is -L′-N(CH₃)C(O)—, wherein L′ is independently as described in the present disclosure.

In some embodiments, L^s3is L′, wherein L′ is as described in the present disclosure. In some embodiments, L^s3is optionally substituted alkylene. In some embodiments, L^s3is unsubstituted alkylene.

In some embodiments, L^scomprises at least one —N(R′)—, wherein R′ is as described in the present disclosure. In some embodiments, the —N(R′)— is bonded to two carbon atoms, wherein neither of the two carbon atoms forms a double bond with a heteroatom. In some embodiments, the —N(R′)— is not bonded to —C(O)—. In some embodiments, the —N(R′)— is not bonded to —C(S)—. In some embodiments, the —N(R′)— is not bonded to —C(═NR′)—. In some embodiments, L^scomprises at least one —N(R′)C(O)—, wherein R′ is as described in the present disclosure.

In some embodiments, L comprises at least one —N(R′)—, wherein R′ is as described in the present disclosure. In some embodiments, the —N(R′)— is bonded to two carbon atoms, wherein neither of the two carbon atoms forms a double bond with a heteroatom. In some embodiments, the —N(R′)— is not bonded to —C(O)—. In some embodiments, the —N(R′)— is not bonded to —C(S)—. In some embodiments, the —N(R′)— is not bonded to —C(═NR′)—. In some embodiments, L is -L′-N(R′)—, wherein L′ is optionally substituted bivalent C₁-C₁₉aliphatic. In some embodiments, L is -L′-N(CH₃)—, wherein L′ is optionally substituted bivalent C₁-C₁₉aliphatic.

In some embodiments, L comprises at least one —N(R′)C(O)—, wherein R′ is as described in the present disclosure. In some embodiments, L is -L′-N(R′)C(O)—, wherein each of L′ and R′ is independently as described in the present disclosure. In some embodiments, L is -L′-N(CH₃)C(O)—, wherein L′ is independently as described in the present disclosure.

In some embodiments, L is L′, wherein L′ is as described in the present disclosure. In some embodiments, L is optionally substituted alkylene. In some embodiments, L is unsubstituted alkylene.

In some embodiments, L is optionally substituted bivalent C₁-C₁₅aliphatic. In some embodiments, L is optionally substituted bivalent C₁-C₁₀aliphatic. In some embodiments, L is optionally substituted bivalent C₁-C₉aliphatic. In some embodiments, L is optionally substituted bivalent C₁-C₈aliphatic. In some embodiments, L is optionally substituted bivalent C₁-C₇aliphatic. In some embodiments, L is optionally substituted bivalent C₁-C₆aliphatic. In some embodiments, L is optionally substituted bivalent C₁-C₅aliphatic. In some embodiments, L is optionally substituted bivalent C₁-C₄aliphatic. In some embodiments, L is optionally substituted alkylene. In some embodiments, L is optionally substituted alkenylene. In some embodiments, L is unsubstituted alkylene. In some embodiments, L is —CH₂—. In some embodiments, L is —(CH₂)₂—. In some embodiments, L is —(CH₂)₃—. In some embodiments, L is —(CH₂)₄—. In some embodiments, L is —(CH₂)₅—. In some embodiments, L is —(CH₂)₆—. In some embodiments, L is —(CH₂)₇—. In some embodiments, L is —(CH₂)s-. In some embodiments, L is bonded to a peptide backbone atom. In some embodiments, L is optionally substituted alkenylene. In some embodiments, L is unsubstituted alkenylene. In some embodiments, L is —CH₂—CH═CH—CH₂—.

In some embodiments, one end of a staple is connected to an atom Aⁿ¹of the peptide backbone, wherein Aⁿ¹is optionally substituted with R¹and is an atom of an amino acid residue at amino acid position n¹of the peptide from the N-terminus, and the other end is connected to an atom A²of the peptide backbone, wherein A²is optionally substituted with R²(in some embodiments, R¹and/or R²is R which can be hydrogen) and is an atom of an amino acid residue at amino acid position n²of the peptide from the N-terminus, wherein each of n¹and n²is independently an integer, and n²=n¹+m, wherein m is 3-12.

In some embodiments, Aⁿ¹is a carbon atom. In some embodiments, Aⁿ¹is achiral. In some embodiments, Aⁿ¹is chiral. In some embodiments, Aⁿ¹is R. In some embodiments, Aⁿ¹is S.

In some embodiments, Aⁿ²is a carbon atom. In some embodiments, Aⁿ²is achiral. In some embodiments, Aⁿ²is chiral. In some embodiments, Aⁿ²is R. In some embodiments, Aⁿ²is S.

In some embodiments, Aⁿ¹is achiral and A²is achiral. In some embodiments, Aⁿ¹is achiral and A²is R. In some embodiments, Aⁿ¹is achiral and A²is S. In some embodiments, Aⁿ¹is R and Aⁿ²is achiral. In some embodiments, Aⁿ¹is R and Aⁿ²is R. In some embodiments, Aⁿ¹is R and Aⁿ²is S. In some embodiments, Aⁿ¹is S and A²is achiral. In some embodiments, Aⁿ¹is S and Aⁿ²is R. In some embodiments, Aⁿ¹is S and A²is S.

In some embodiments, provided stereochemistry at staple-backbone connection points and/or combinations thereof, optionally together with one or more structural elements of provided peptide, e.g., staple chemistry (hydrocarbon, non-hydrocarbon), staple length, etc. can provide various benefits, such as improved preparation yield, purity, and/or selectivity, improved properties (e.g., improved solubility, improved stability, lowered toxicity, improved selectivities, etc.), improved activities, etc. In some embodiments, provided stereochemistry and/or stereochemistry combinations are different from those typically used, e.g., those of U.S. Pat. No. 9,617,309, US 2015-0225471, US 2016-0024153, US 2016-0215036, US2016-0244494, WO2017/062518, and provided one or more of benefits described in the present disclosure.

In some embodiments, a staple can be of various lengths, in some embodiments, as represent by the number of chain atoms of a staple. In some embodiments, a chain of a staple is the shortest covalent connection in the staple from a first end (connection point with a peptide backbone) of a staple to a second end of the staple, wherein the first end and the second end are connected to two different peptide backbone atoms. In some embodiments, a staple comprises 5-30 chain atoms, e.g., 5, 6, 7, 8, 9, or 10 to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 chain atoms. In some embodiments, a staple comprises 5 chain atoms. In some embodiments, a staple comprises 6 chain atoms. In some embodiments, a staple comprises 7 chain atoms. In some embodiments, a staple comprises 8 chain atoms. In some embodiments, a staple comprises 9 chain atoms. In some embodiments, a staple comprises 10 chain atoms. In some embodiments, a staple comprises 11 chain atoms. In some embodiments, a staple comprises 12 chain atoms. In some embodiments, a staple comprises 13 chain atoms. In some embodiments, a staple comprises 14 chain atoms. In some embodiments, a staple comprises 15 chain atoms. In some embodiments, a staple comprises 16 chain atoms. In some embodiments, a staple comprises 17 chain atoms. In some embodiments, a staple comprises 18 chain atoms. In some embodiments, a staple comprises 19 chain atoms. In some embodiments, a staple comprises 20 chain atoms. In some embodiments, a staple has a length of 5 chain atoms. In some embodiments, a staple has a length of 6 chain atoms. In some embodiments, a staple has a length of 7 chain atoms. In some embodiments, a staple has a length of 8 chain atoms. In some embodiments, a staple has a length of 9 chain atoms. In some embodiments, a staple has a length of 10 chain atoms. In some embodiments, a staple has a length of 11 chain atoms. In some embodiments, a staple has a length of 12 chain atoms. In some embodiments, a staple has a length of 13 chain atoms. In some embodiments, a staple has a length of 14 chain atoms. In some embodiments, a staple has a length of 15 chain atoms. In some embodiments, a staple has a length of 16 chain atoms. In some embodiments, a staple has a length of 17 chain atoms. In some embodiments, a staple has a length of 18 chain atoms. In some embodiments, a staple has a length of 19 chain atoms. In some embodiments, a staple has a length of 20 chain atoms. In some embodiments, a staple has a length of 8-15 chain atoms. In some embodiments, a staple has 8-12 chain atoms. In some embodiments, a staple has 9-12 chain atoms. In some embodiments, a staple has 9-10 chain atoms. In some embodiments, a staple has 8-10 chain atoms. In some embodiments, length of a staple can be adjusted according to the distance of the amino acid residues it connects, for example, a longer staple may be needed for a (i, i+7) staple than a (i, i+4) staple. Staple lengths may be otherwise described. For example, in some embodiments, staple lengths may be described as the total number of chain atoms and non-chain ring atoms, where a non-chain ring atom is an atom of the staple which forms a ring with one or more chain atoms but is not a chain atom in that it is not within the shortest covalent connection from a first end of the staple to a second end of the staple. In some embodiments, staples formed using Monomer A (which comprises a azetidine moiety), Monomer B (which comprises a pyrrolidine moiety), and/or Monomer C (which comprises a pyrrolidine moiety) may comprise one or two non-chain ring atoms as illustrated in the exemplary stapled peptides.

In some embodiments, a staple has no heteroatoms in its chain. In some embodiments, a staple comprises at least one heteroatom in its chain. In some embodiments, a staple comprises at least one nitrogen atom in its chain.

In some embodiments, a staple is L^s, wherein L^sis an optionally substituted, bivalent C_8-14aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, a staple is L^s, wherein L^sis an optionally substituted, bivalent C_9-13aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, a staple is L^s, wherein L^sis an optionally substituted, bivalent C_10-15aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, a staple is L^s, wherein L^sis an optionally substituted, bivalent C_11-14aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—. In some embodiments, a staple is a (i, i+4) staple in that not including the two amino acid residues that are directly connected to the staple, there are three amino acid residues between the two amino acid residues that are directly connected to the staple. In some embodiments, a staple is a (i, i+7) staple in that not including the two amino acid residues that are directly connected to the staple, there are six amino acid residues between the two amino acid residues that are directly connected to the staple.

In some embodiments, for each of L^s, L^s1, L^s2, and L^s3, any replacement of methylene units, if any, is replaced with —N(R′)— or —N(R′)—C(O)—.

In some embodiments, an olefin in a staple is a Z-olefin. In some embodiments, an olefin in a staple in an E-olefin. In some embodiments, a provided composition comprises stapled peptides comprising a staple that contains a Z-olefin and stapled peptides comprising a staple that contains an E-olefin. In some embodiments, a provided composition comprises stapled peptides comprising a staple that contains a Z-olefin. In some embodiments, a provided composition comprises stapled peptides comprising a staple that contains an E-olefin. In some embodiments, otherwise identical stapled peptides that differ only in the E Z configuration of staple olefin demonstrate different properties and/or activities as demonstrated herein. In some embodiments, stapled peptides with E-olefin in a staple may provide certain desirable properties and/or activities given the context. In some embodiments, stapled peptides with Z-olefin in a staple may provide certain desirable properties and/or activities given the context.

In some embodiments, two staples may be bonded to the same atom of the peptide backbone, forming a “stitch” structure.

In some embodiments, a staple is Pro-lock in that one end of the staple is bonded to the alpha-carbon of a proline residue.

In some embodiments, an exemplary staple is a staple as illustrated below in Tables S-1, S-2, S-3, and S-4 (with exemplary peptide backbone illustrated for clarity (can be applied to other peptide backbone), X being amino acid residues). In some embodiments, the olefin is Z. In some embodiments, the olefin is E. In some embodiments, an (i, i+4) staple is selected from Table S-1. In some embodiments, an (i, i+4) staple is selected from Table S-2. In some embodiments, an (i, i+7) staple is selected from Table S-3. In some embodiments, an (i, i+7) staple is selected from Table S-4.

TABLE S-1

Exemplary staples.

embedded image

TABLE S-2

Exemplary staples.

embedded image

TABLE S-3

Exemplary staples.

embedded image

TABLE S-4

Exemplary staples.

embedded image

c. Modifications and Conjugations

In some embodiments, a provided peptide is optionally modified at its backbone, side chain, N-terminus and/or C-terminus, and is optionally conjugated to a second entity. Various modifications and/or conjugations are known in the art and can be utilized in accordance with the present disclosure.

In some embodiments, a provided peptide is capped. In some embodiments, a provided peptide is capped at the N-terminus. In some embodiments, a provided peptide is capped by an amidation reaction which convert the N-terminal —NH₂into an amide. In some embodiments, the capping is acetylation.

In some embodiments, a modification and/or conjugation is to incorporate a targeting moiety, e.g., those can facilitate delivery to certain cells, organs, and/or organisms.

In some embodiments, a second entity is a ligand, e.g., a ligand for a protein receptor or an enzyme. In some embodiments, a ligand is a carbohydrate. In some embodiments, a modification is glycosylation. In some embodiments, a second entity for conjugation is a carbohydrate. In some embodiments, a carbohydrate is GalNac. In some embodiments, a second entity is a protein ligand.

In some embodiments, a provided peptide is conjugated to a lipid moiety, e.g., through coupling with a fatty acid with an N-terminus. In some embodiments, a lipid moiety is or comprises an optionally substituted C₅-C₁₀₀aliphatic. In some embodiments, a lipid moiety is or comprises an unsubstituted C₅-C₁₀₀aliphatic. In some embodiments, a lipid moiety is decanoyl, dodecanoyl, myristoyl, octyl, or palmitoyl.

In some embodiments, a provided peptide is conjugated to a degradation signal/entity. In some embodiments, a provided peptide is conjugated to a ligand for an E3 ubiquitin ligase.

In some embodiments, a provided peptide is conjugated to another peptide or protein. In some embodiments, a provided peptide is conjugated to another stapled peptide that interacts with beta-catenin at a different site than the provide peptide. In some embodiments, a provided peptide is conjugated to another stapled peptide that interacts with beta-catenin but does not compete with the provided peptide for beta-catenin binding.

In some embodiments, a provided stapled peptide comprises a helix in its 3-dimensional structure. In some embodiments, a provided stapled peptide can form an alpha-helix.

d. Properties and Activities

As demonstrated in the present disclosure, provided technologies can significantly improve properties and/or activities of stapled peptides.

In some embodiments, a provided peptide can form a helix structure.

In some embodiments, a provided peptide binds to beta-catenin. In some embodiments, a provided peptide has a Kd of no greater than 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, or 10 uM for beta-catenin. In some embodiments, a provided peptide has a Kd of no greater than 0.01 uM. In some embodiments, a provided peptide has a Kd of no greater than 0.05 uM. In some embodiments, a provided peptide has a Kd of no greater than 0.1 uM. In some embodiments, a provided peptide has a Kd of no greater than 0.2 uM. In some embodiments, a provided peptide has a Kd of no greater than 0.5 uM. In some embodiments, a provided peptide has a Kd of no greater than 1 uM. Various technologies can be utilized in accordance with the present disclosure to assess Kd, for example, fluorescence polarization, surface plasmon resonance, TR-FRET, etc.

In some embodiments, provided technologies provide improved stability. One challenge of using peptide as therapeutics is that peptides can be readily degraded when administered to a subject. Among other things, the present disclosure provides stapled peptides with greatly improved pharmacokinetics profiles. In some embodiments, provided stapled peptides have significantly improved half-life.

In some embodiments, provided technologies greatly improved solubility of stapled peptides. Among other things, the present disclosure recognize that a significant challenge of using stapled peptides is that stapled peptides, for example, those comprising hydrocarbon staples, may have low solubility in aqueous solutions, thereby complicating formulation and delivery. In some embodiments, the present disclosure provides stapled peptides with staples comprising —N(R′)— and/or —N(R′)—C(O)— moieties, which have improved solubility compared to stapled peptides that are otherwise identical but comprise hydrocarbon staples instead of staples comprising —N(R′)— and/or —N(R′)—C(O)— moieties. In some embodiments, provided stapled peptides comprising staples that comprise —N(R′)— and/or —N(R′)—C(O)— moieties have a solubility of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 uM in DPBS (per liter, 8 g sodium chloride, 0.2 g potassium phosphate, monobasic, 1.15 g sodium phosphate, dibasic, and 0.2 g potassium chloride). In some embodiments, the solubility is at least 1 uM in DPBS. In some embodiments, the solubility is at least 2 uM in DPBS. In some embodiments, the solubility is at least 3 uM in DPBS. In some embodiments, the solubility is at least 4 uM in DPBS. In some embodiments, the solubility is at least 5 uM in DPBS. In some embodiments, the solubility is at least 6 uM in DPBS. In some embodiments, the solubility is at least 7 uM in DPBS. In some embodiments, the solubility is at least 8 uM in DPBS. In some embodiments, the solubility is at least 9 uM in DPBS. In some embodiments, the solubility is at least 10 uM in DPBS. In some embodiments, the solubility is at least 20 uM in DPBS. In some embodiments, the solubility is at least 30 uM in DPBS. In some embodiments, the solubility is at least 40 uM in DPBS. In some embodiments, the solubility is at least 50 uM in DPBS. In some embodiments, the solubility is at least 60 uM in DPBS. In some embodiments, the solubility is at least 70 uM in DPBS. In some embodiments, the solubility is at least 80 uM in DPBS. In some embodiments, the solubility is at least 90 uM in DPBS. In some embodiments, the solubility is at least 100 uM in DPBS. In some embodiments, the solubility is at least 120 uM in DPBS. In some embodiments, the solubility is at least 150 uM in DPBS. In some embodiments, the solubility is at least 180 uM in DPBS. In some embodiments, the solubility is at least 200 uM in DPBS. In some embodiments, the solubility is at least 220 uM in DPBS. In some embodiments, the solubility is at least 250 uM in DPBS. In some embodiments, provided stapled peptides can achieve improved properties and/or activities using fewer acidic or basic amino acid residues, which, among other things, are often used to improve solubility (e.g., FP0597c v. StAx-35R, removal of the C-terminal R). Various methods can be utilized in accordance with the present disclosure to assess solubility, including those described in the examples.

Among other things, the present disclosure provides methods for improving solubility of stapled peptides. In some embodiments, the present disclosure encompasses the recognition and positioning of a staple can be utilized to modulate solubility. In some embodiments, the present disclosure provides methods for increasing or decreasing solubility of a stapled peptide by adjusting positioning of a staple. As demonstrate herein, structural similarly or otherwise identical stapled peptides can have greatly increased solubility (e.g., see FP0597c (98 uM) v. 7 FPO217c (7 uM)).

In some embodiments, provided stapled peptides with provided structural features, e.g., non-hydrocarbon staples (e.g., those comprising one or more staples that comprises one or more —N(R′)—C(O)— or —N(R′)—), staple positioning, connection stereochemistry, etc., provides improved properties and/or activities, e.g., increased cell permeability, increased cellular activities, etc., compared to an appropriate reference peptide which in some embodiments, is an unstapled peptide having the same sequence, or in some embodiments, is a stapled peptide that is otherwise identical but have a different type of staple, e.g., a hydrocarbon staple. For example, as reported in Grossmann et al. PNAS 109 17942-17947, a hydrocarbon-stapled peptide, StAx-33, (Ac-PEG1-PQS₅ILDS₅HVRRVWR (SEQ ID NO: 277)), was not cell-permeable and did not exhibit cell-based activity; to obtain a cell-permeable stapled peptide with cell-based activity, 3 amino acids were added to the N-terminus of the peptide and one other Q→R mutation was made. However, these modifications can negatively impact other properties of the peptide. For example, the resulting peptide StAx-35R (Ac-PEG1-RRWPRS₅ILDS₅HVRRVWR (SEQ ID NO: 278)) had a reduced affinity compared to StAx-33. In some embodiments, provided stapled peptides can achieve improved properties and/or activities without using conjugation with other entries, e.g., PEG as in StAx-33 and StAx-35R (e.g., FP0597c v. StAx-35R). In some embodiments, provided stapled peptides can achieve improved properties and/or activities using a shorter amino acid sequence (e.g., FP0597c or FP0025c v. StAx-35R). In some embodiments, provided stapled peptides can achieve improved properties and/or activities using fewer acidic or basic amino acid residues, which, among other things, are often used to improve solubility (e.g., FP0597c or FP0025c v. StAx-35R). In a competition fluorescence polarization assay, FP0025c displaced a labeled probe from the axin site of beta-catenin with an EC₅₀<100 nM and showed better than 50% inhibition of signal at 10 μM in a beta-catenin luciferase reporter assay.

In some embodiments, provided stapled peptides provide selectivity in various aspects. In some embodiments, provided stapled peptides selectively interacts with beta-catenin sites that interact with Axin over those sites that interact with BCL9. In some embodiments, provided stapled peptides competes with FITC-PEG1-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 1), (with a hydrocarbon staple formed by two S5 via olefin metathesis) for interaction with beta-catenin, but not or to a significantly less extent with Ac-LSQEQLEHRERSLQTLRDIQRML-(2-Nal)-βA₂-K(FAM)-NH₂(SEQ ID NO: 279). In some embodiments, provided stapled peptides competes with FITC-bA-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 3) (with a hydrocarbon staple formed by two S5 via olefin metathesis) for interaction with beta-catenin, but not or to a significantly less extent with Ac-LSQEQLEHRERSLQTLRDIQRML-(2-Nal)-βA₂-K(FAM)-NH₂(SEQ ID NO: 279). In some embodiments, a reference stapled peptide that interacts with beta-catenin at sites that that interact with Axin is FITC-PEG1-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 1) (hydrocarbon staple formed by two S5 via olefin metathesis). In some embodiments, a reference stapled peptide that interacts with beta-catenin at sites that interact with Axin is FITC-bA-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 3) (hydrocarbon staple formed by two S5 via olefin metathesis). In some embodiments, a reference stapled peptide that interacts with beta-catenin at sites that interact with BCL9 is Ac-LSQEQLEHRERSLQTLRDIQRML-(2-Nal)-βA₂-K(FAM)-NH₂(SEQ ID NO: 279). In some embodiments, a significantly less extent is EC50, e.g., as measured by competition assays described in the present disclosure, that is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 100, 200, 300, 400, or 500 fold higher. In some embodiments, a fold is 5 fold. In some embodiments, a fold is 10 fold. In some embodiments, a fold is 20 fold. In some embodiments, a fold is 50 fold. In some embodiments, a fold is 100 fold. In some embodiments, a fold is 500 fold.

In some embodiments, provided stapled peptides provide more specific modulation of beta-catenin target gene expression compared to a reference Wnt pathway modulator (e.g., IWR-1, ICG-001, etc.). In some embodiments, provided stapled peptides decrease expression levels of one or more beta-catenin target genes in a type of cells that comprises aberrant Wnt/beta-catenin signaling pathway, while a reference Wnt pathway modulator does not do so or do so to a less extent. In some embodiments, provided stapled peptides do not decrease, or decrease to much less extent, expression levels of one or more beta-catenin target genes compared to a reference agent in a type of cells that comprises wild-type Wnt/beta-catenin signaling pathway.

In some embodiments, provided stapled peptides have low toxicity, e.g., non-specific toxicity, compared to an appropriate reference peptide. In some embodiments, a reference peptide is a stapled peptide that interacts with one or more beta-catenin sites that interact with Axin and comprises a hydrocarbon staple, e.g., WO2017062518. In some embodiments, a provided stapled peptide has less than 10%, 15%, 20%, 25%, 30%, 40%, 50% non-specific cytotoxicity at a concentration of no less than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 uM as measured by a LDH release assay compared to an appreciate positive reference. In some embodiments, a provided stapled peptide comprises a staple comprising a —N(R′)— or —N(R′)—C(O)— moiety, and has lower non-specific cytotoxicity compared to a peptide comprising a hydrocarbon staple but is otherwise of the identical structure when assayed under a comparable condition.

In some embodiments, provided stapled peptides modulate one or more functions of beta-catenin. In some embodiments, provided stapled peptides modulate one or more functions of beta-catenin associated with Axin binding. In some embodiments, provided stapled peptides modulate one or more functions of beta-catenin associated with interactions at one or more sites that interact with Axin. In some embodiments, provided stapled peptides modulate beta-catenin target gene expression. In some embodiments, provided stapled peptides inhibit cancer cell growth. In some embodiments, provided stapled peptides provide increased activities compared to an appropriate reference agent. In some embodiments, a reference agent is a stapled peptide. In some embodiments, a reference agent is a stapled peptide that interacts with beta-catenin sites that interact with Axin.

4. Production of Stapled Peptides

Various technologies are known in the art can be utilized in accordance with the present disclosure to prepare provided stapled peptides, including those described in the methods. In many embodiments, peptides are prepared on solid phase on a synthesizer using, typically, Fmoc chemistry. In some embodiments, staples are formed by olefin metathesis. In some embodiments, a product double bond of metathesis is reduced/hydrogenated. In some embodiments, CO₂are extruded from a carbamate moiety of a staple. In some embodiments, provided stapled peptides are further modified, and/or conjugated to other entities. Conditions and/or reagents of these reactions are widely know in the art and can be performed in accordance with the present disclosure to provide stapled peptides.

Properties and/or activities of provided stapled peptides can be readily assessed in accordance with the present disclosure, for example, through use of one or more methods described in the examples.

In some embodiments, the present disclosure encompasses the recognition that structural elements of staples, e.g., size, chemistry, stereochemistry, etc., can significantly impact yields and/or purity of stapling through olefin metathesis. As illustrated by exemplary data provided in the present disclosure, staples having certain structural elements, e.g., size, chemistry, stereochemistry, etc., and/or combination thereof, can facilitate production of provided stapled peptides including higher yields, purity, and selectivity, etc. In some embodiments, the present disclosure provides beneficial structural elements, e.g., size, chemistry, stereochemistry, etc., and/or combination thereof, for example, those exemplified in the examples.

In some embodiments, the present disclosure provides the recognition that catalysts other than Grubbs I may provide better results, e.g., yield, purity, selectivity, etc. for olefin metathesis. In some embodiments, the present disclosure demonstrates that Hoveyda-Grubbs II catalyst may provide better results, e.g., yield, purity, selectivity, etc. for olefin metathesis. In some embodiments, the present disclosure provides methods for preparing a provided stapled peptide, comprising providing a Hoveyda-Grubbs II in an olefin metathesis reaction.

In some embodiments, technologies for preparing and/or assessing provided stapled peptides include those described in U.S. Pat. No. 9,617,309, US 2015-0225471, US 2016-0024153, US 2016-0215036, US2016-0244494, WO2017/062518, etc.

In some embodiments, a provided agent, e.g, a provided peptide, has a purity of 60%-100%. In some embodiments, a provided agent has a purity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, a purity is at least 60%. In some embodiments, a purity is at least 70%. In some embodiments, a purity is at least 80%. In some embodiments, a purity is at least 85%. In some embodiments, a purity is at least 90%. In some embodiments, a purity is at least 91%. In some embodiments, a purity is at least 92%. In some embodiments, a purity is at least 93%. In some embodiments, a purity is at least 94%. In some embodiments, a purity is at least 95%. In some embodiments, a purity is at least 96%. In some embodiments, a purity is at least 97%. In some embodiments, a purity is at least 98%. In some embodiments, a purity is at least 99%. In some embodiments, a purity is at least 99.5%.

In some embodiments, provided methods provide high yields. In some embodiments, a yield is 50%-100%. In some embodiments, a yield is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In some embodiments, a yield is at least 60%. In some embodiments, a yield is at least 65%. In some embodiments, a yield is at least 70%. In some embodiments, a yield is at least 75%. In some embodiments, a yield is at least 80%. In some embodiments, a yield is at least 85%. In some embodiments, a yield is at least 90%. In some embodiments, a yield is at least 91%. In some embodiments, a yield is at least 92%. In some embodiments, a yield is at least 93%. In some embodiments, a yield is at least 94%. In some embodiments, a yield is at least 95%. In some embodiments, a yield is at least 96%. In some embodiments, a yield is at least 97%. In some embodiments, a yield is at least 98%. In some embodiments, a yield is at least 99%.

In some embodiments, a provided method delivers high E/Z selectivity for olefin. In some embodiments, provided selectivity favors the E isomer. In some embodiments, provided selectivity favors the Z isomer. In some embodiments, a E:Z ratio is at least 1:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, or 100:1. In some embodiments, a Z:E ratio is at least 1:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 80:1, 90:1, 95:1, 99:1, or 100:1. In some embodiments, a ratio is at least 1:1. In some embodiments, a ratio is at least 1.5:1. In some embodiments, a ratio is at least 2:1. In some embodiments, a ratio is at least 3:1. In some embodiments, a ratio is at least 4:1. In some embodiments, a ratio is at least 5:1. In some embodiments, a ratio is at least 6:1. In some embodiments, a ratio is at least 7:1. In some embodiments, a ratio is at least 8:1. In some embodiments, a ratio is at least 9:1. In some embodiments, a ratio is at least 10:1. In some embodiments, a ratio is at least 20:1. In some embodiments, a ratio is at least 30:1. In some embodiments, a ratio is at least 40:1. In some embodiments, a ratio is at least 50:1. In some embodiments, a ratio is at least 80:1. In some embodiments, a ratio is at least 90:1. In some embodiments, a ratio is at least 95:1. In some embodiments, a ratio is at least 99:1. In some embodiments, a ratio is at least 100:1.

In some embodiments, a provide method comprises a period of time at a temperature higher than room temperature. In some embodiments, a temperature is about 25-200° C. In some embodiments, a temperature is about 25° C. In some embodiments, a temperature is about 30° C. In some embodiments, a temperature is about 35° C. In some embodiments, a temperature is about 40° C. In some embodiments, a temperature is about 45° C. In some embodiments, a temperature is about 50° C. In some embodiments, a temperature is about 55° C. In some embodiments, a temperature is about 60° C. In some embodiments, a temperature is about 65° C. In some embodiments, a temperature is about 70° C. In some embodiments, a temperature is about 75° C. In some embodiments, a temperature is about 80° C. In some embodiments, a temperature is about 85° C. In some embodiments, a temperature is about 90° C. In some embodiments, a temperature is about 95° C. In some embodiments, a temperature is about 100° C. In some embodiments, a temperature is about 150° C. In some embodiments, a temperature is higher than about 150° C.

5. Uses

Among other things, provided stapled peptides interacts with beta-catenin. In some embodiments, a condition, disorder, or disease is associated with one or more components involved in Wnt/beta-catenin signaling. In some embodiments, a condition, disorder, or disease is associated with one or more beta-catenin functions. In some embodiments, a condition disorder or disease is associated with interactions between beta-catenin and one or more beta-catenin sites that interact with one or more proteins in Wnt/beta-catenin signaling. In some embodiments, provided stapled peptides compete with and/or otherwise interfere with or reduce binding between beta-catenin and Axin. In some embodiments, a condition disorder or disease is associated with interactions between beta-catenin and one or more beta-catenin sites that interact with Axin. In some embodiments, a condition, disorder, or disease is associated with interactions with and one or more proteins that compete with Axin for interaction with beta-catenin. In some embodiments, a provided stapled peptide antagonizes beta-catenin interaction with another protein, such as TCF, whose one or more binding sites overlap with, or are in close proximity to, one or more beta-catenin sites that interact with Axin or a provided stapled peptide. In some embodiments, a condition, disorder, or disease is associated with interactions between beta-catenin and Axin. In some embodiments, provided stapled peptides interacts with beta-catenin at one or more beta-catenin sites that interacts with Axin. In some embodiments, provided stapled peptides inhibit one or more Axin activities. In some embodiments, provided stapled peptides inhibit one or more Wnt/beta-catenin pathway activities.

In some embodiments, provided stapled peptides is useful for preventing and/or treating one or more beta-catenin-associated conditions, disorders, and/or diseases. In some embodiments, the present disclosure provides a method for preventing or treating a beta-catenin-associated condition, disorder or disease, comprising administering to a subject susceptible to or suffering from provided stapled peptide or a pharmaceutical composition thereof.

In some embodiments, a condition, disorder, or disease is selected from cancer, cardiac disease, dilated cardiomyopathy, fetal alcohol syndrome, depression, and diabetes.

In some embodiments, a condition, disorder, or disease is a heart condition, disorder, or disease.

In some embodiments, a condition, disorder, or disease is cancer. In some embodiments a cancer is selected from: colon cancer, colorectal cancer, rectal cancer, prostate cancer familial adenomatous polyposis (FAP), Wilms Tumor, melanoma, hepatocellular carcinoma, ovarian cancer, endometrial cancer, medulloblastoma pilomatricomas, primary hetpatocellular carcinoma, ovarial carcinoma, breast cancer, lung cancer, glioblastoma, pliomatrixoma, medulloblastoma, thyroid tumors, ovarian neoplasms. In some embodiments, a cancer is colorectal cancer. In some embodiments, a cancer is hepatocellular cancer. In some embodiments, a cancer is prostate cancer. In some embodiments, a cancer is melanoma.

In some embodiments, a provided stapled peptide is administered in combination with an additional agent. In some embodiments, a provided stapled peptide is administered prior to, concurrently with, or subsequent to an additional agent. In some embodiments, a provided stapled peptide is administered at the same time as an additional agent. In some embodiments, an additional agent is a therapeutic agent. In some embodiments, an additional agent may optionally be formulated with a provided stapled peptide in the same pharmaceutical composition.

In some embodiments, an additional agent is a checkpoint inhibitor, an EGFR inhibitor, a VEGF inhibitor, a VEGFR inhibitor, a kinase inhibitor, or an anti-cancer drug.

In some embodiments, an additional agent is a checkpoint inhibitor. In some embodiments, an additional agent is an immune oncology agent. In some embodiments, an additional agent is an antibody against a checkpoint molecules. In some embodiments, an additional agent is an antibody of PD1, PDL-1, CTLA4, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG3, TIM-s, C10orf54, etc. In some embodiments, an antibody is an anti-PD1 antibody. In some embodiments, an antibody is an anti-PD-L1 antibody. In some embodiments, an antibody is an anti-CTLA4.

In some embodiments, an additional agent is an EGFR inhibitor, e.g., erlotinib, gefitinib, lapatinib, panitumumab, vandetanib, cetuximab, etc.

In some embodiments, an additional agent is an VEGF and/or VEGFR inhibitor, e.g., pazopanib, bevacizumab, sorafenib, sunitinib, axitinib, ponatinib, regorafenib, vandetanib, cabozantinib, ramucirumab, lenvatinib, ziv-aflibercept, etc.

In some embodiments, an additional agent is a kinase inhibitor. In some embodiments, an additional therapeutic agent is a chemotherapeutic agent. In some embodiments, an additional therapeutic agent is an anti-cancer drug, e.g., cyclophosphamide, methotrexate, 5-fluorouracil (5-FU), doxorubicin, mustine, vincristine, procarbazine, prednisolone, dacarbazine, bleomycin, etoposide, cisplatin, epirubicin, capecitabine, folinic acid, actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bortezomib, carboplatin, chlorambucil, cytarabine, daunorubicin, docetaxel, doxifluridine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, mechlorethamine, mercaptopurine, mitoxantrone, paclitaxel, pemetrexed, teniposide, tioguanine, topotecan, valrubicin, vinblastine, vindesine, vinorelbine, oxaliplatin, etc.

In some embodiments, an additional agent is a stapled peptide. In some embodiments, an additional agent is a stapled peptide that interacts with beta-catenin that does not compete with binding between beta-catenin and Axin. In some embodiments, an additional agent is a stapled peptide that interacts with beta-catenin at one or more sites that interacts with BCL9.

In some embodiments, a provided stapled peptide is administered in combination with an additional therapy. In some embodiments, an additional therapy is radiation therapy. In some embodiments, an additional therapy is surgery.

6. Example Embodiments

Among other things, the present disclosure provides the following Example Embodiments:

1. A peptide comprising:

[X¹]_p1[X²]_p2—X³X⁴X⁵X⁶X⁷X⁸X⁹X¹⁰—[X¹¹]_p11[X¹²]_p12[X¹³]_p13,

wherein:

each of p1, p2, p11, p12 and p13 is independently 0 or 1;

each of X, X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹⁰, X¹¹, X¹², and X¹³is independently an amino acid residue;

at least two of X, X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹⁰, X¹¹, X¹², and X¹³comprise side chains that are optionally linked together to form a staple.

2. The peptide of embodiment 1, wherein at least two of X¹to X¹³each independently comprise a side chain that comprise an olefin, wherein the two olefins can be connected together by olefin metathesis to form a staple.

3. The peptide of any one of the preceding embodiments, wherein side chains of the at least two of X¹to X¹³are connected to form a staple.

4. The peptide of any one of the preceding embodiments, wherein each of X¹to X¹³is independently a residue of an amino acid having the structure of formula A-I.

5. The peptide of any one of the preceding embodiments, wherein each of X¹to X¹³is independently a residue of an amino acid having the structure of formula A-I and is an alpha amino acid.

6. The peptide of any one of the preceding embodiments, wherein each of p1, p2, p11, p12 and p13 is independently 0.

7. The peptide of any one of embodiments 1-5, wherein each of p1, p2, p11, p12 and p13 is independently 1.

8. The peptide of any one of embodiments 1-5, wherein each of p1 is 0.

9. The peptide of any one of the preceding embodiments, wherein X³is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, and M_I.

10. The peptide of any one of the preceding embodiments, wherein X³is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, and S₈.

11. The peptide of any one of the preceding embodiments, wherein X³is an amino acid residue of R₈.

12. The peptide of any one of embodiments 1-9, wherein X³is an amino acid residue of M_G.

13. The peptide of any one of embodiments 1-9, wherein X³is an amino acid residue of R₄.

14. The peptide of any one of the preceding embodiments, X¹⁰is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, and M_I.

15. The peptide of any one of the preceding embodiments, X¹⁰is a residue of an amino acid selected from M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, and M_I.

16. The peptide of any one of embodiments 1-13, wherein X¹⁰is a residue of R or a homolog thereof.

17. The peptide of any one of embodiments 1-13, wherein X¹⁰is a residue of R.

18. The peptide of any one of the preceding embodiments, wherein the peptide comprises at least one residue of R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, or S₈.

19. The peptide of any one of the preceding embodiments, wherein the peptide comprises at least one residue of M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, or M_I.

20. The peptide of any one of the preceding embodiments, wherein a side chain of X³and a side chain of X¹⁰are taken together to form a staple.

21. The peptide of any one of the preceding embodiments, wherein X¹is a residue of an amino acid selected from P, A, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y, and α-methyl proline.

22. The peptide of any one of the preceding embodiments, wherein X¹is a residue of an amino acid selected from P, A, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, and Y.

23. The peptide of embodiment 21, wherein X¹is a residue of an amino acid selected from P, K, N, Q, R, Y, and α-methyl proline.

24. The peptide of embodiment 21, wherein X¹is a residue of an amino acid P.

25. The peptide of any one of the preceding embodiments, wherein X²is a residue of an amino acid selected from A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y.

26. The peptide of embodiment 25, wherein X²is a residue of an amino acid selected from A, D, E, K, N, Q, and R.

27. The peptide of embodiment 25, wherein X²is a residue of A.

28. The peptide of any one of the preceding embodiments, wherein X⁴is a residue of an amino acid selected from I, F, H, L, V, homoleucine,tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine.

29. The peptide of any one of the preceding embodiments, wherein X⁴is a residue of an amino acid selected from I, F, H, L, and V.

30. The peptide of embodiment 28, wherein X⁴is a residue of an amino acid selected from I, L, V, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, and alpha-neopentylglycine.

31. The peptide of embodiment 28, wherein X⁴is a residue of I.

32. The peptide of any one of the preceding embodiments, wherein X⁵is a residue of an amino acid selected from L, F, H, I, V, alpha-methyl leucine, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine.

33. The peptide of any one of the preceding embodiments, wherein X⁵is a residue of an amino acid selected from L, F, H, I, and V.

34. The peptide of embodiment 32, wherein X⁵is a residue of an amino acid selected from L, I, V, alpha-methyl leucine, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine.

35. The peptide of embodiment 32, wherein X⁵is a residue of L.

36. The peptide of any one of the preceding embodiments, wherein X⁶is a residue of an amino acid selected from D, A, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y, methionine sulfone, 2-aminoadipic acid, aspartic acid beta-methylester, aspartic acid beta-cyclohexylester, aspartic acid beta-benzylester, glutamic acid beta-methylester, glutamic acid beta-cyclohexylester, and glutamic acid beta-benzyl ester.

37. The peptide of any one of the preceding embodiments, wherein X⁶is a residue of an amino acid selected from D, A, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y.

38. The peptide of embodiment 36, wherein X⁶is a residue of an amino acid selected from D, E, H, N, Q, S, T, Y, methionine sulfone, 2-aminoadipic acid, aspartic acid beta-methylester, aspartic acid beta-cyclohexylester, aspartic acid beta-benzylester, glutamic acid beta-methylester, glutamic acid beta-cyclohexylester, and glutamic acid beta-benzyl ester.

39. The peptide of embodiment 36, wherein X⁶is a residue of an amino acid selected from D, N, and T.

40. The peptide of any one of the preceding embodiments, wherein X⁷is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, M_I, A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y and alpha-methyl alanine.

41. The peptide of any one of the preceding embodiments, wherein X⁷is a residue of an amino acid selected from A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y and alpha-methyl alanine.

42. The peptide of embodiment 40, wherein X⁷is a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, and M_I.

43. The peptide of embodiment 40, wherein X⁷is a residue of an amino acid selected from A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y.

44. The peptide of embodiment 40, wherein X⁷is a residue of an amino acid selected from A, D, E, I, K, L, N, Q, R, S, T, V, W, Y and alpha-methyl alanine.

45. The peptide of embodiment 40, wherein X⁷is a A or alpha-methyl alanine residue.

46. The peptide of any one of the preceding embodiments, wherein X⁸is a residue of an amino acid selected from H, F, I, L, N, Q, V, 1-methylhistidine, 3-methylhistidine, 3-(2-pyridyl)alanine, 3-(3-pyridyl)alanine, 3-(4-pyridyl)alanine, beta-2-furylalanine, beta-2-thienylalanine, 3-(2-tetrazolyl)alanine), and beta-4-thiazolylalanine.

47. The peptide of any one of the preceding embodiments, wherein X⁸is a residue of an amino acid selected from H, F, I, L, N, Q, and V.

48. The peptide of embodiment 46, wherein X⁸is a residue of an amino acid selected from H, N, Q, 1-methylhistidine, 3-methylhistidine, 3-(2-pyridyl)alanine, 3-(3-pyridyl)alanine, 3-(4-pyridyl)alanine, beta-2-furylalanine, beta-2-thienylalanine, 3-(2-tetrazolyl)alanine), and beta-4-thiazolylalanine.

49. The peptide of embodiment 46, wherein X⁸is a H residue.

50. The peptide of any one of the preceding embodiments, wherein X⁹is a residue of an amino acid selected from I, V, F, H, L, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine.

51. The peptide of any one of the preceding embodiments, wherein X⁹is a residue of an amino acid selected from I, V, F, H, and L.

52. The peptide of embodiment 50, wherein X⁹is a residue of an amino acid selected from I, V, L, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine.

53. The peptide of embodiment 50, wherein X⁹is a residue of an amino acid selected from I and V.

54. The peptide of any one of the preceding embodiments, wherein X¹¹is a residue of an amino acid selected from R, A, D, E, F, H, I, K, L, M, N, P, Q, S, T, V, W, Y, 3-(1-naphthylalanine), 2-aminoadipic acid, asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine, N-epsilon-methyllysine, N-epsilon-dimethyllysine, and N-epsilon-trimethyllysine.

55. The peptide of any one of the preceding embodiments, wherein X¹¹is a residue of an amino acid selected from R, A, D, E, F, H, I, K, L, M, N, P, Q, S, T, V, W, and Y.

56. The peptide of embodiment 54, wherein X¹¹is a residue of an amino acid selected from R, A, E, F, K, Q, S, V, Y, 3-(1-naphthylalanine), 2-aminoadipic acid, asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine, N-epsilon-methyllysine, N-epsilon-dimethyllysine, and N-epsilon-trimethyllysine.

57. The peptide of embodiment 54, wherein X¹¹is a residue of an amino acid selected from R, A, F, K, S, V, 3-(1-naphthylalanine), asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine, and N-epsilon-methyllysine.

58. The peptide of any one of the preceding embodiments, wherein X¹²is a residue of an amino acid selected from V, F, H, I, L, alpha-methyl valine, alpha methyl leucine, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, and alpha-neopentylglycine.

59. The peptide of any one of the preceding embodiments, wherein X¹²is a residue of an amino acid selected from V, F, H, I, and L.

60. The peptide of embodiment 58, wherein X¹²is a residue of an amino acid selected from I, A, L, V, alpha-methylleucine, homoleucine, tert-leucine, 3-cyclopropylalanine, 3-cyclobutylalanine, 3-cyclopentylalanine, 3-cyclohexylalanine, alpha-neopentylglycine, O-propargylserine, L-octylglycine, and L-alloisoleucine.

61. The peptide of embodiment 58, wherein X¹²is a residue of an amino acid selected from V, alpha-methyl valine, and alpha methyl leucine.

62. The peptide of any one of the preceding embodiments, wherein X¹³is a residue of an amino acid selected from W, A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, Y, d-tryptophan, alpha-methyl tryptophan, 3-(1-naphthylalanine), 3-(2-naphthylalanine), 4-chlorotryptophan, 5-chlorotryptophan, 6-chlorotryptophan, 7-chlorotryptophan, 4-bromotryptophan, 5-bromotryptophan, 6-bromotryptophan, 7-bromotryptophan, 4-fluorotryptophan, 5-fluorotryptophan, 6-fluorotryptophan, 7-fluorotryptophan, 1-methyltryptophan, 2-methyltryptophan, 4-methyltryptophan, 5-methyltryptophan, 6-methyltryptophan, 7-methyltryptophan, 2-hydroxytryptophan, 4-hydroxytryptophan, 5-hydroxytryptophan, 6-hydroxytryptophan, 7-hydroxytryptophan, 5-methoxytryptophan, 7-azatryptophan, 3-benzothienylalanine, and 4-phenyl-L-phenylalanine.

63. The peptide of any one of the preceding embodiments, wherein X¹³is a residue of an amino acid selected from W, A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and Y.

64. The peptide of embodiment 62, wherein X¹³is a residue of an amino acid selected from W, D, E, F, Y, d-tryptophan, alpha-methyl tryptophan, 3-(1-naphthylalanine), 3-(2-naphthylalanine), 5-chlorotryptophan, 6-chlorotryptophan, 7-chlorotryptophan, 5-bromotryptophan, 6-bromotryptophan, 7-bromotryptophan, 5-fluorotryptophan, 6-fluorotryptophan, 7-fluorotryptophan, 1-methyltryptophan, 2-methyltryptophan, 5-methyltryptophan, 6-methyltryptophan, 7-methyltryptophan, 2-hydroxytryptophan, 5-hydroxytryptophan, 6-hydroxytryptophan, 7-hydroxytryptophan, 5-methoxytryptophan, 7-azatryptophan, and 3-benzothienylalanine.

65. The peptide of embodiment 62, wherein X¹³is a residue of an amino acid selected from W, D-tryptophan, and alpha-methyl tryptophan.

66. The peptide of any one of the preceding embodiments, wherein the peptide comprising a (i, i+4) staple wherein, not including the two amino acid residues that are directly connected to the staple, there are three amino acid residues between the two amino acid residues that are directly connected to the staple.

67. The peptide of any one of the preceding embodiments, wherein the peptide comprising a (i, i+7) staple wherein, not including the two amino acid residues that are directly connected to the staple, there are six amino acid residues between the two amino acid residues that are directly connected to the staple.

68. The peptide of any one of the preceding embodiments, wherein the staple is formed by olefin metathesis of two terminal olefins each of which is independently of a side chain of an amino acid residue.

69. The peptide of any one of the preceding embodiments, wherein the staple is formed by olefin metathesis of two terminal olefins each of which is independently of a side chain of a residue of an amino acid selected from R₄, R₅, R₆, R₇, R₈, S₄, S₅, S₆, S₇, S₈, M_A, M_B, M_C, M_D, M_E, M_F, M_G, M_H, and M_I.

70. The peptide of any one of the preceding embodiments, wherein the peptide comprises one and no more than one staple.

71. The peptide of any one of the preceding embodiments, wherein the peptide comprises two or more staples.

72. The peptide of embodiment 71, wherein at least two staples are bonded to the same peptide backbone atom.

73. The peptide of embodiment 71, wherein none of the staples are bonded to the same peptide backbone atom.

74. The peptide of any one of the preceding embodiments, wherein a staple is bonded to a peptide backbone atom of amino acid residue 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17.

75. The peptide of any one of the preceding embodiments, wherein a staple is L^s, wherein L^sis an optionally substituted, bivalent C_1-50aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—;

each R′ is independently —R, —C(O)R, —CO₂R, or —SO₂R;

two R groups are optionally and independently taken together to form a covalent bond, or:

76. A peptide having the structure of:

embedded image

or a salt thereof, wherein

each of R^a, R¹, R², R³, and R⁴is independently R′;

R^bis R′, —OR′ or —N(R′)₂;

each of X is independently an amino acid residue;

each of a, b, c, s, and d is independently 1-20;

each of C¹and C²is independently a carbon atom;

each L^sis independently -L^s1-L^s2-L^s3-, wherein L^s1is bonded to C¹and L^s3is bonded to C²;

each of L^s1, L^s2, and L^s3is independently L;

each R′ is independently —R, —C(O)R, —CO₂R, or —SO₂R;

two R groups are optionally and independently taken together to form a covalent bond, or:

77. The peptide of embodiment 76, wherein the sum of all a, b, c, and d is 5 to 70.

78. The peptide of embodiment 77, wherein the sum of all a, b, c, and d is 10 to 20.

79. The peptide of any one of embodiments 76-78, wherein a is 1-20.

80. The peptide of any one of embodiments 76-79, wherein b is 2-6.

81. The peptide of any one of embodiments 76-80, wherein c is 1-20.

82. The peptide of any one of embodiments 76-81, wherein d is 1-20.

83. The peptide of any one of embodiments 76-82, wherein the peptide is a peptide of any one of embodiments 1-74.

84. A stapled peptide comprising a staple having the structure of L^s, wherein:

L^sis -L^s1-L^s2-L^s3-;

each of L^s1, L^s2, and L^s3is independently L;

each R′ is independently —R, —C(O)R, —CO₂R, or —SO₂R;

two R groups are optionally and independently taken together to form a covalent bond, or:

85. The peptide of embodiment 84, wherein:

one end of L^sis connected to an atom Aⁿ¹of the peptide backbone, wherein Aⁿ¹is bonded to R¹;

one end of L^sis connected to an atom Aⁿ²of the peptide backbone, wherein A²is bonded to R²;

each of R¹and R²is independently R′;

m is an integer of 1-12.

86. The peptide of embodiment 85, wherein each of Aⁿ¹and A²is independently a carbon atom.

87. The peptide of embodiment 85, wherein each of Aⁿ¹and A²is independently an alpha carbon atom.

88. The peptide of any one of embodiments 85-87, wherein m is 1.

89. The peptide of any one of embodiments 85-87, wherein m is 2.

90. The peptide of any one of embodiments 85-87, wherein m is 3.

91. The peptide of any one of embodiments 85-87, wherein m is 4.

92. The peptide of any one of embodiments 85-87, wherein m is 5.

93. The peptide of any one of embodiments 85-87, wherein m is 6.

94. The peptide of any one of embodiments 85-87, wherein m is 7.

95. The peptide of any one of embodiments 76-94, wherein C¹or Aⁿ¹has an R configuration.

96. The peptide of any one of embodiments 76-94, wherein C¹or Aⁿ¹has an S configuration.

97. The peptide of any one of embodiments 76-94, wherein C¹or Aⁿ¹is achiral.

98. The peptide of any one of embodiments 76-97, wherein C²or Aⁿ²has an R configuration.

99. The peptide of any one of embodiments 76-97, wherein C²or A²has an S configuration.

100. The peptide of any one of embodiments 76-97, wherein C²or A²is achiral.

101. The peptide of any one of embodiments 76-97, wherein C²or A²is achiral.

102. The peptide of any one of the preceding embodiments, wherein a staple is L^s, wherein L^sis an optionally substituted, bivalent C_8-14aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—.

103. The peptide of any one of the preceding embodiments, wherein a staple is L^s, wherein L^sis an optionally substituted, bivalent C_9-13aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—.

104. The peptide of any one of the preceding embodiments, wherein a staple is L^s, wherein L^sis an optionally substituted, bivalent C_10-15aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—.

105. The peptide of any one of the preceding embodiments, wherein a staple is L^s, wherein L^sis an optionally substituted, bivalent C_11-14aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with —C(R′)₂—, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O)₂—, —S(O)₂N(R′)—, —C(O)S—, or —C(O)O—.

106. The peptide of any one of embodiments 102-105, wherein the staple is a (i, i+4) staple.

107. The peptide of any one of embodiments 102-105, wherein the staple is a (i, i+7) staple.

108. The peptide of any one of the preceding embodiments, wherein for each of L^s, L^s1, L^s2and L^s3, any replacement of methylene units, if any, is replaced with —N(R′)— or —N(R′)—C(O)—.

109. The peptide of any one of the preceding embodiments, wherein a staple is a hydrocarbon staple.

110. The peptide of embodiment 109, wherein the hydrocarbon staple is L^s, wherein L^sis C_5-20bivalent aliphatic.

111. The peptide of any one of embodiments 1-108, wherein a staple comprises a —N(R′)-moiety.

112. The peptide of any one of embodiments 1-108, wherein a staple comprises a —N(R′)-moiety, wherein the —N(R′)— moiety is not bonded to a carbon atom that also forms a double bond with a heteroatom.

113. The peptide of any one of embodiments 1-108, wherein a staple comprises a —N(R′)-moiety, wherein the —N(R′)— moiety is not bonded to —C(O)—.

114. The peptide of any one of embodiments 1-108, wherein a staple comprises a —N(R′)—C(O)— moiety.

115. The peptide of any one of embodiments 75-108, wherein at least one methylene unit is replaced with —(NR′)—.

116. The peptide of any one of embodiments 75-108, wherein at least one methylene unit is replaced with —(NR′)—, wherein the —N(R′)— moiety is not bonded to —C(O)—.

117. The peptide of any one of embodiments 75-108, wherein at least one methylene unit is replaced with —(NR′)—C(O)—.

118. The peptide of any one of embodiments 111-117, wherein R′ of the —N(R′)— is R.

119. The peptide of any one of embodiments 111-117, wherein R′ of the —N(R′)— is optionally substituted C_1-6alkyl.

120. The peptide of any one of embodiments 111-117, wherein R′ of the —N(R′)— is methyl.

121. The peptide of any one of embodiments 75-120, wherein L^s1comprises at least one methylene units replaced with —N(R′)—.

122. The peptide of any one of embodiments 75-120, wherein L^s1comprises at least one methylene units replaced with —N(R′)—, wherein none of the neighboring methylene unit is replaced with —C(O)—.

123. The peptide of any one of embodiments 75-120, wherein L^s1comprises at least one —N(R′)C(O)O—.

124. The peptide of any one of embodiments 75-120, wherein L^s1is -L′-N(R′)—.

125. The peptide of any one of embodiments 75-120, wherein L^s1is -L′-N(R′)C(O)O—.

126. The peptide of any one of embodiments 124-125, wherein L′ is C_1-6alkylene.

127. The peptide of any one of embodiments 124-126, wherein L′ is bonded to a peptide backbone atom.

128. The peptide of any one of embodiments 75-120, wherein L^s1is optionally substituted C_1-10bivalent aliphatic.

129. The peptide of any one of embodiments 75-120, wherein L^s1is optionally substituted C_1-10bivalent alkylene.

130. The peptide of any one of embodiments 75-126, wherein L^s2is optionally substituted bivalent C₁-C₆aliphatic.

131. The peptide of any one of embodiments 75-126, wherein L^s2is —CH₂—CH═CH—CH₂—.

132. The peptide of any one of embodiments 75-126, wherein L^s2is -(E)-CH₂—CH═CH—CH₂—.

133. The peptide of any one of embodiments 75-126, wherein L^s2is —(Z)—CH₂—CH═CH—CH₂—.

134. The peptide of any one of embodiments 75-126, wherein L^s2is —(CH₂)₄—.

135. The peptide of any one of embodiments 75-134, wherein L^s3comprises at least one methylene units replaced with —N(R′)—.

136. The peptide of any one of embodiments 75-134, wherein L^s3comprises at least one methylene units replaced with —N(R′)—, wherein none of the neighboring methylene unit is replaced with —C(O)—.

137. The peptide of any one of embodiments 75-134, wherein L^s3comprises at least one —N(R′)C(O)O—.

138. The peptide of any one of embodiments 75-134, wherein L^s3is -L′-N(R′)—.

139. The peptide of any one of embodiments 75-134, wherein L^s3is -L′-N(R′)C(O)O—.

140. The peptide of any one of embodiments 138-139, wherein L′ is C_1-6alkylene.

141. The peptide of any one of embodiments 138-140, wherein L′ is bonded to a peptide backbone atom.

142. The peptide of any one of embodiments 75-134, wherein L^s3is optionally substituted C_1-10bivalent aliphatic.

143. The peptide of any one of embodiments 75-134, wherein L^s3is optionally substituted C_1-10bivalent alkylene.

144. The peptide of any one of embodiments 75-134, wherein L^s3is optionally substituted C_1-10bivalent alkylene.

145. The peptide of any one of embodiments 75-134, wherein L^sis a staple of Table S-1.

146. The peptide of any one of embodiments 75-134, wherein L^sis a staple of Table S-2.

147. The peptide of any one of embodiments 75-134, wherein L^sis a staple of Table S-3.

148. The peptide of any one of embodiments 75-134, wherein L^sis a staple of Table S-4.

149. The peptide of any one of the preceding embodiments, wherein a staple has 5-20 staple chain atoms, wherein the chain of the staple is the shortest covalent connection in the staple from a first end of a staple to a second end of the staple, wherein the first end and the second end connect to different peptide backbone atoms.

150. The peptide of embodiment 149, wherein a staple has 8 staple chain atoms.

151. The peptide of embodiment 149, wherein a staple has 9 staple chain atoms.

152. The peptide of embodiment 149, wherein a staple has 10 staple chain atoms.

153. The peptide of embodiment 149, wherein a staple has 11 staple chain atoms.

154. The peptide of embodiment 149, wherein a staple has 12 staple chain atoms.

155. The peptide of embodiment 149, wherein a staple has 13 staple chain atoms.

156. The peptide of embodiment 149, wherein a staple has 14 staple chain atoms.

157. The peptide of embodiment 149, wherein a staple has 15 staple chain atoms.

158. The peptide of embodiment 149, wherein a staple has 16 staple chain atoms.

159. The peptide of any one of embodiments 1-74, wherein the peptide is a peptide of any one of embodiments 75-158.

160. The peptide of any one of the preceding embodiments, wherein the peptide has a sequence that is at least 50%, 60%, 70%, 80%, 90%, or 95% homology with a peptide of Table 1.

161. The peptide of any one of the preceding embodiments, wherein the peptide is a peptide of Table 1.

162. The peptide of any one of the preceding embodiments, wherein the peptide can form a helix structure.

163. The peptide of any one of the preceding embodiments, wherein the peptide has a solubility of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 uM in DPBS (per liter, 8 g sodium chloride, 0.2 g potassium phosphate, monobasic, 1.15 g sodium phosphate, dibasic, and 0.2 g potassium chloride).

164. The peptide of embodiment 163, wherein the solubility is at least 1 uM.

165. The peptide of embodiment 163, wherein the solubility is at least 5 uM.

166. The peptide of embodiment 163, wherein the solubility is at least 10 uM.

167. The peptide of embodiment 163, wherein the solubility is at least 50 uM.

168. The peptide of embodiment 163, wherein the solubility is at least 100 uM.

169. The peptide of embodiment 163, wherein the solubility is at least 200 uM.

170. The peptide of any one of the preceding embodiments, wherein the peptide binds to beta-catenin.

171. The peptide of any one of the preceding embodiments, wherein the peptide has a Kd of no greater than 1, 2, 3, 4, 5, or 10 uM for beta-catenin.

172. The peptide of any one of the preceding embodiments, wherein the peptide has a Kd of no greater than 1 uM for beta-catenin.

173. The peptide of any one of embodiments 171-172, wherein the Kd is measured by fluorescence polarization, surface plasmon resonance, or TR-FRET.

174. The peptide of any one of the preceding embodiments, wherein the peptide has less than 10%, 15%, 20%, 25%, 30%, 40%, 50% non-specific cytotoxicity at a concentration of no less than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 uM as measured by a LDH release assay compared to an appreciate positive reference.

175. The peptide of any one of the preceding embodiments, wherein the peptide comprises a staple comprising a —N(R′)— or —N(R′)—C(O)— moiety, and has lower non-specific cytotoxicity compared to a peptide comprising a hydrocarbon staple but is otherwise of the identical structure when assayed under a comparable condition.

176. The peptide of any one of the preceding embodiments, wherein the peptide binds to beta-catenin selectively at sites that interact with Axin over sites that interacts with BCL9.

177. The peptide of any one of the preceding embodiments, wherein the peptide binds to beta-catenin selectively at sites that interact with Axin over sites that interacts with BCL9 as measured in an appropriate competition fluorescence polarization assay.

178. The peptide of any one of the preceding embodiments, wherein the peptide is conjugated with a second entity.

179. The peptide of embodiment 178, wherein the second entity is a label.

180. The peptide of embodiment 178, wherein the second entity a label selected from biotin and a fluorescence label.

181. The peptide of embodiment 178, wherein the second entity is a targeting moiety.

182. The peptide of embodiment 178 or 181, wherein the second entity is a carbohydrate moiety.

183. The peptide of embodiment 182, wherein the second entity is or comprises a GalNac moiety.

184. The peptide of embodiment 178, wherein the second entity is a lipid moiety.

185. The peptide of any one of the preceding embodiments, wherein each amino acid residue is independently a residue of an amino acid of formula A-I, A-II or A-III.

186. A pharmaceutical composition comprising a peptide of any one of the preceding embodiments and pharmaceutically acceptable carrier.

187. A method for modulating a function of beta-catenin, comprising contacting a system comprising beta-catenin with a peptide of any one of the preceding embodiments.

188. A method for modulating a function of Wnt signaling pathway, comprising contacting a system comprising the pathway with a peptide of any one of the preceding embodiments.

189. A method for modulating interaction of beta-catenin with Axin, comprising contacting a system comprising beta-catenin with a peptide of any one of the preceding embodiments.

190. A method for modulating expression of a nucleic acid sequence in a system, comprising contacting a system comprising beta-catenin a peptide of any one of the preceding embodiments; wherein expression of the nucleic acid sequence is associated with beta-catenin.

191. A method for modulating level of a product encoded by a nucleic acid sequence in a system, comprising contacting a system comprising beta-catenin a peptide of any one of the preceding embodiments;

wherein level of a product encoded by a nucleic acid sequence is associated with beta-catenin.

192. The peptide of embodiment 191, wherein the product is a protein.

193. The peptide of embodiment 191, wherein the product is mRNA.

194. A method for preventing or treating a beta-catenin-associated condition, disorder, or disease, comprising administering to a subject susceptible thereto or suffering therefrom a peptide or a composition of any one of the preceding embodiments.

195. The method of embodiment 194, wherein the condition, disorder, or disease is cancer.

196. The method of embodiment 195, wherein the cancer is colorectal cancer.

197. The method of embodiment 195, wherein the cancer is hepatocellular cancer.

198. The method of embodiment 195, wherein the cancer is prostate cancer.

199. The method of embodiment 195, wherein the cancer is melanoma.

200. The method of any one of embodiments 194-199, wherein the peptide or composition is administered prior to, concurrently with, or subsequent to an additional agent.

201. The method of embodiment 200, wherein the additional agent is an anti-cancer drug.

202. The method of embodiment 200, wherein the additional agent is a chemotherapy agent.

203. The method of embodiment 200, wherein the additional agent is an immuno oncology drug.

204. The method of embodiment 200, wherein the additional agent is a checkpoint inhibitor.

205. The method of embodiment 200, wherein the additional agent is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA4 antibody.

206. The method of embodiment 194, wherein the condition, disorder, or disease is a heart condition, disorder, or disease.

EXEMPLIFICATION

Non-limiting examples of provided technologies are described below. Those having ordinary skill in the art appreciates that various technologies can be utilized to prepare and access compounds, compositions and methods in accordance with the present disclosure.

Example 1. Exemplary Preparation of Provided Agents

Provided agents, e.g., stapled peptides, can be prepared using various technologies in accordance with the present disclosure, for example, methods as described herein. As appreciated by those skilled in the art, parameters of provided methods, e.g., steps, reagents, solvents, concentrations, temperatures, time, etc., may be optimized as desired.

In some embodiments, peptides can be prepared on a peptide synthesizer. For example, in some embodiments, provided peptides were typically synthesized on an Intavis Multipep RSi peptide synthesizer using Fmoc solid phase peptide chemistry on CEM ProTide Rink Amide resin (loading 0.55-0.8 mmol/g). In some embodiments, resin for synthesis is swelled in a suitable solvent, e.g., NMP, at a suitable temperature for a period of time (e.g., at 45 degrees for 20 minutes in a 5 mL or 2 mL plastic fritted reaction vessel). Amino acid residues are then added using peptide synthesis procedures (typically at 45 degrees; conditions can be adjusted as necessary). In some embodiments, provided stapled peptides, e.g., those described in Table 1, were prepared as described below.

Peptides were typically synthesized on an Intavis Multipep RSi peptide synthesizer using Fmoc solid phase peptide chemistry on CEM ProTide Rink Amide resin (loading 0.55-0.8 mmol/g). Resin for synthesis was swelled in NMP at 45 degrees for 20 minutes in a 5 mL or 2 mL plastic fritted reaction vessel. Amino acid residues were added using the following procedure (all steps at 45 degrees).

a) The Fmoc group was removed using one five-minute treatment and one ten-minute treatment with 20% Piperidine (v/v), 0.1 M HOBT in NMP.

b) The resin was washed eight times with NMP.

c) 5 equivalents of 0.5 M amino acid solution, 5 equivalents of 2 M DIC, and 5 equivalents of 0.5 M Oxyma were added to a preactivation vessel for one minute.

d) Reaction mixture was added to the reaction vessel and coupled for 30 minutes, vortexing intermittently.

e) Reaction vessel was washed once with NMP.

f) Steps c), d), and e) were repeated. In some embodiments, in the case of difficult positions, steps c), d), and e) were repeated twice.

g) Any unreacted amines were capped with 5% (v/v) acetic anhydride in NMP for two minutes.

h) The reaction vessels were washed, e.g., eight times with NMP.

Following the final residue, the Fmoc group was removed using the procedure from steps a) above and the peptides were typically capped (in some cases, were not capped so that the 5′-amino group can react with other entities as exemplified in the present disclosure), e.g., with 5% (v/v) acetic anhydride in NMP for 15 minutes at 45 degrees for Ac capping. The resin was washed 5 times with DCM.

Staples can be formed using various technologies in accordance with the present disclosure. In some embodiments, staples are formed by olefin metathesis. In some embodiments, two amino acid side chains each independently comprising an olefin (in some embodiments, terminal olefin) are reacted with each other under suitable olefin metathesis conditions so that olefin metathesis happens between the two side chains and a staple is formed. Many olefin metathesis conditions (e.g., catalyst, solvent, temperature, etc.) are known in the art and can be utilized in accordance with the present disclosure.

For example, in an exemplary procedure that was used to prepare provided staples, e.g., those in Table 1, resin with peptides, e.g., as prepared above, was swelled at 40 degrees in DCE for 20 minutes on the Intavis Multipep RSi. The peptides were treated with 30 mol % of a freshly prepared 5 mM solution of bis(tricyclohexvlphosphine)benzylidene ruthenium (IV) dichloride (Grubb's I) in DCE for one hour, with vortexing continuously. The treatment was repeated depending on e.g., conversion, purity, etc. The resin was then washed 5 times with DCM. The peptides were cleaved from the resin and de-protected using 95% trifluoroacetic acid, 2.5% triisopropylsilane, and 2.5% water for two and a half hours vortexing at room temperature. After TFA was evaporated under an inert atmosphere, e.g., nitrogen gas, the peptides were precipitated in a suitable solvent, e.g., tert-butyl methyl ether.

In some embodiments, Hoveyda-Grubbs catalyst may be used and may provide better yields, purity and/or selectivity.

Peptides can be further processed as desired. For example, in some embodiments, provided stapled peptides comprising an olefin in a staple can be subjected to a reduction (e.g., hydrogenation) condition, so that an olefin moiety in a staple is hydrogenated and converted into an alkane moiety. Described below is an exemplary procedure.

In an exemplary procedure for making FP0650rc, 100 umol FP0650c on peptide synthesis resin was swelled in N-methyl-2-pyrrolidone (NMP) in a Biotage Alstra microwave peptide synthesizer for 5 min at a temperature of, e.g., 50° C. The solvent was removed and 1.45 mL of 1.4 M piperidine (20 equivalents) in NMP was combined with 298 mg of 2,4,6-triisopropylbenzenesulfonyl hydrazide (20 equivalents) dissolved in 1.45 mL of NMP and subsequently added to the resin. The reaction was allowed to proceed at 50° C. for 2 hours and the resin was then washed 2× with NMP and 2× with 1,2-dichloroethane (DCE). If desired, the resin was then treated with freshly prepared reaction solution according to the above steps (in some cases, two or more additional times) until the reaction was complete (as monitored by LC/MS after analytical cleavage of a few beads of resin). After the reaction was complete, FP0650rc was cleaved from the resin and purified.

In some embodiments, provided stapled peptides comprises one or more amino staples which comprises an amino moiety (e.g., —N(R′)—, wherein R′ is as described in the present disclosure, and the —N(R′)— is not bonded to —C(O)— groups). In some embodiments, a staple comprising an amino moiety is prepared from extraction of CO₂from an appropriate staple comprising a corresponding carbamate moiety (e.g., converting —N(R′)—C(O)—O— to —N(R′)—). An exemplary procedure for preparing peptides comprising an amino staple (e.g., those in Table 1) through, e.g., CO₂extrusion, is described below.

Stapled peptides comprising carbamate staples were treated with 80 mol % of freshly prepared 10 mM solution of tetrakis(triphenylphosphine) palladium (0) in DCM for 90 minutes, vortexing continuously. The resin was washed 5 times in DCM and further modifications and/or cleavage and purification were performed using standard procedures.

As described in the present disclosure, in some embodiments, provided peptides may be further modified, e.g., conjugated with a second entity. In some embodiments, a modification, e.g., conjugate, is at or through a N-terminus. An exemplary procedure for preparing N-terminal for further modification (e.g., conjugation) is described below.

Prior to final Fmoc deprotection and capping with acetic anhydride, the Fmoc protected peptides were stapled via standard protocol, e.g., a protocol described above. Following metathesis, the resin was washed with NMP several times. The resin was swelled in NMP for 20 minutes, and treated four times with 20% piperidine and 0.1 M HOBT in NMP for five minutes each at room temperature. The resin was then washed five times with NMP.

In some embodiments, a peptide is conjugated with biotin. An exemplary procedure for preparing biotinylated peptides, e.g., those in Table 1, is described below.

To prepare biotinylated peptides, a free N-terminus was coupled to biotin with 3 equivalents of biotin (0.5 M in NMP), 3 equivalents of COMU (0.5 M in NMP), and 6 equivalents of DIEA (2 M in NMP) for 1 hour at room temperature (standard coupling conditions on the synthesizer produced similar results). Cleavage and purification was then performed using the standard procedures.

In some embodiments, a peptide is conjugated to a label, e.g., a fluorescent label. An exemplary procedure for preparing such peptides, e.g., those in Table 1, is described below.

To prepare fluorescein-conjugated peptides, a free N-terminus was coupled to FITC using five equivalents of FITC (75 mM final concentration) and 10 equivalents of DIEA (neat) dissolved in NMP for 10 hours, vortexing continuously. Cleavage and purification was then performed using the standard procedures.

In some embodiments, a peptide is conjugated to an entity comprising PEG. An exemplary procedure for preparing such peptides, e.g., those in Table 1, is described below.

To prepare peptides comprising a PEG moiety, e.g., PEG containing a free amine handle, N-terminal Fmoc protected PEG was coupled to the stapled peptide on resin using standard coupling conditions and then the N-terminal Fmoc was removed using standard conditions. Cleavage and purification was then performed using standard procedures.

In some embodiments, provided compounds are purified so that a higher purity is achieved. Various purification technologies can be utilized in accordance with the present disclosure. In some embodiments, purification comprises one or more steps using HPLC or UPLC. In some embodiments, provided compounds, e.g., stapled peptides, where dissolved in a small volume of a solvent, e.g., DMSO, and were purified by reverse phase HPLC using a suitable column (e.g., a Rx-C8 column (Agilent)) with suitable mobile phase conditions. Provided compounds and compositions can be characterized using a number of technologies in accordance with the present disclosure. In some embodiments, provided compounds were characterized by mass spectrometry under suitable conditions (e.g., electrospray in positive ion mode). For example, in some embodiments, provided stapled peptides were dissolved in small volume of DMSO and were purified by reverse phase HPLC using a Rx-C8 column (Agilent) and a gradient of Acetonitrile with 0.1% TFA and Water with 0.1% TFA. HPLC fractions were characterized by LC-MS using electrospray (e.g., in positive ion mode), pooled, and lyophilized to provide products having the correct characterization data (e.g., MS). Exemplary provided stapled peptides were presented below, e.g., Table 3.

Example 2. Provided Agents Bind to Beta-Catenin

Among other things, provided agents, e.g., stapled peptides, interact with beta-catenin and modulate its functions as demonstrated in the present disclosure. Various technologies are known in the art and can be utilized to assess interactions in accordance with the present disclosure.

In some embodiments, a direct fluorescence polarization assay is used to assess binding of provided compounds to beta-catenin. In an exemplary procedure, beta-catenin solutions are prepared in a buffer using serial dilution, for example, in some cases, beta-catenin solutions were prepared in a buffer (50 mM Tris pH 8.0, 250 mM NaCl, 2% glycerol, 0.5 mM EDTA, 0.02% w/v sodium azide) using a 3-fold serial dilution from 5 μM. Probe solution (20 nM 5FAM or FITC labeled peptide in buffer) was prepared and 40 μL per well plated in a black polystyrene 384-well plate (Corning). Equal volume of the serial diluted beta-catenin was added to the plate and incubated protected from light for 15 minutes prior to read. Reads were performed on a Spectramax M5 (Molecular Devices) in duplicate.

In some embodiments, a competition fluorescence polarization assay is used to assess binding of provided compounds to beta-catenin. In an exemplary procedure, solutions of provided compounds, e.g., provided stapled peptides, were prepared in a buffer (e.g., 50 mM Tris pH 8.0, 250 mM NaCl, 2% glycerol, 0.5 mM EDTA, 0.02% w/v sodium azide) using a 3-fold serial dilution from 5 μM. Probe solution (15 nM full-length ß-Catenin, 20 nM FITC labeled peptide in buffer) was prepared and incubated for a period of time, e.g., 5 minutes, and the a volume, e.g., 40 μL per well plated in suitable plate, e.g., a black polystyrene 384-well plate (Corning). Equal volume of the serial diluted peptide was added to the plate and incubated protected from light for 15 minutes prior to read. Reads were performed on a Spectramax M5 (Molecular Devices) in duplicate. Suitable probe was FITC-PEG1-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 1) (hydrocarbon staple formed by two S5 via olefin metathesis) and/or FITC-bA-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 3) (hydrocarbon staple formed by two S5 via olefin metathesis). In a competition fluorescence polarization assay, FP0025c displaced a labeled probe from the axin site of β-catenin with an EC₅₀<100 nM. Another peptide, FPO217c (Ac-AR₈ILDAHIM_BRVW (SEQ ID NO: 280), with N-terminal proline removed and valine replaced with isoleucine compared to FP0025c) was prepared. FPO217c Isomer 2 displayed >10-fold better potency than FPO217c Isomer 1 in the competition FP assay; the reduced peptide (FPO217rc) was equivalent to Isomer 2.

Additionally or alternatively, binding to beta-catenin may be measured by Surface Plasmon Resonance. In an exemplary assay, approximately 6 nmol dried peptide diluted in buffer (50 mM Tris pH 8.0, 300 mM NaCl, 2% glycerol, 0.5 mM TCEP, 0.5 mM EDTA, 0.005% Tween-20, 1 mg/mL CM Dextran, 0.02% w/v sodium azide) was assayed on a Biacore X100 using the Biacore Biotin CAPture Kit (GE Healthcare) and biotinylated beta-catenin. Results were analyzed using the Biacore X100 Evaluation Software. As measured, FP0025c displayed a Kd of 15 nM. FPO217c (Isomer 2) bound to the armadillo domain of β-catenin with a K_dof 2 nM. FP0597c showed a Kd of 7 nm. Additional exemplary data were presented in FIG. 1 and Table 2.

Example 3. Provided Agents are Active in Cells

As appreciated by a person having ordinary skill in the art, various technologies can be utilized to assess activities of provided agents, e.g., stapled peptides, in accordance with the present disclosure, e.g., those described in the present disclosure, in WO 2017/062518, etc.

In some embodiments, a provided assay is a TCF/LEF reporter assay. In some embodiments, in an exemplary such assay, TCF/LEF Luciferase reporter HEK293 cell lines (BPS Bioscience) were treated with dilution series of provided peptides for 18 hours. 300 ng/mL of Wnt3a (Peprotech) was added to the cells for the final 6 hours of incubation. Luciferase activity was measured using Bright-Glo Luciferase Assay (Promega) according to manufacturer's protocol. Exemplary data were presented in FIG. 2 and Table 2. FPO217c exhibited an IC₅₀of 0.743 uM. As demonstrated, provided stapled peptides comprising various e.g., sequences, lengths, modifications, amino acid residues, staples, etc., were active. Applicant notes that for the TCF/LEF reporter assay, subsequent efforts to reproduce results observed for certain peptides described herein did not yield the same results, and in some tests, did not show activities under the specific conditions of those tests (e.g., amounts and/or batches of reagents). Additional assays are being performed to assess the reproducibility of observed properties and/or activities of such peptides. Applicant also notes that teachings of the present disclosure are not restricted to a particular mechanism of action of described agents. For example, in some embodiments, one or more agents may have relevant biological effects that are not specific to any interaction with (or lack of interaction with) beta-catenin or any particular site thereon.

Example 4. Provided Agents Modulate Gene Expression

As appreciated by those skilled in the art, beta-catenin regulates expression of many genes. Many conditions, disorders, and/or diseases are associated with aberrant gene expression, including those connected to one or more beta-catenin functions (e.g., regulated by beta-catenin). In some embodiments, as demonstrated by exemplary data herein, provided technologies can modulate expression of a variety of genes, including inhibition of beta-catenin target genes in various cell lines including a number of types of cancer cells.

Many technologies are known in the art, for example, qPCR, can be used to assess levels and/or variations of gene expression and can be utilized in accordance with the present disclosure. In an exemplary qPCR assay, cells, e.g., HCT-116, DLD-1, were treated with a dilution series of provided peptides for a period of time, e.g., 18 hours. Total RNA was extracted using, e.g., commercially available kit such as RNeasy Plus kit (Qiagen) according to manufacturer's protocols, and reverse transcribed to cDNA using, e.g., SuperScript Vilo IV master mix (ThermoFisher Scientific). Gene expression levels were determined by qPCR using, e.g., Taqman probes (Applied Biosciences) and Taqman Advanced Fast Master Mix (Applied Biosciences) on a QuantStudio 3 (Applied Biosciences). Relative expression was quantified using delta Ct method. Exemplary data were presented in FIGS. 3, 4 and 5. In some embodiments, the following reagents were used for qPCR in the examples. In some embodiments, a control for normalization is beta-actin. Methods for qPCR, including design of primers and probes, are widely known and can be utilized in accordance with the present disclosure.

Gene
Assay ID
Dye Label
Scale
Cat #*

ACTB
Hs01060665_g1
FAM-MGB
250rxn
4331182

CTNNB1
Hs00355045_m1
FAM-MGB
250rxn
4331182

BIRC5
Hs04194392_s1
FAM-MGB
250rxn
4331182

CCND1
Hs00765553_m1
FAM-MGB
250rxn
4331182

CD44
Hs00153304_m1
FAM-MGB
250rxn
4331182

AXIN2
Hs00610344_m1
FAM-MGB
250rxn
4331182

MYC
Hs00153408_m1
FAM-MGB
250rxn
4331182

LEF1
Hs01547250_m1
FAM-MGB
250rxn
4331182

LRP6
Hs00233945_m1
FAM-MGB
250rxn
4331182

VEGFA
Hs00900055_m1
FAM-MGB
250rxn
4331182

GAPDH
Hs02786624_g1
TAM-MGB
250rxn
4331182

Human GUSB Endogenous
VIC/TAMRA
2500rxn
4310888E

Control

Human B2M Endogenous Control
VIC/TAMRA
2500rxn
4310886E

*ThermoFisher Scientific.

Example 5. Provided Agents have Improved Properties

Among other things, provided agents, e.g., stapled peptides, have improved properties, including solubility, pharmacokinetic properties, etc.

Among other things, the present disclosure recognizes that one of the challenges associated with stapled peptides for use as therapeutics is solubility. In some embodiments, certain stapled peptides, e.g., those comprising hydrocarbon staples, have relatively low solubility. As appreciated by those skilled in the art, low solubility can negatively impact, e.g., formulation, delivery, efficacy, etc. In some embodiments, the present disclosure provides technologies to improve solubility of improved stapled peptides. In some embodiments, the present disclosure provides stapled peptides with solubility of at least 50, 60, 70, 80, 90, 100, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 350, 400, 450, 500 uM in DPBS buffer (per liter, 8 g Sodium Chloride, 0.2 g Potassium Phosphate, monobasic, 1.15 g Sodium Phosphate, dibasic, and 0.2 g Potassium Chloride).

Suitable assays for assessing solubility are widely known in the art and can be utilized in accordance with the present disclosure. In some embodiments, in an exemplary protocol, dried peptide was reconstituted in DPBS (DPBS, 1×, cell culture grade, Sigma D8537) in triplicate, vortexed, sonicated and then centrifuged. Absorbance of the supernatant was measured at A280 (Nanodrop 2000) and the concentration was determined using the extinction coefficient for tryptophan. Exemplary solubility data are presented in, e.g., Table 2.

Example 6. Provided Agents have Improved Pharmacological Properties

Among other things, provided agents, e.g., stapled peptides, have improved properties, including solubility, pharmacokinetic properties, etc. In some embodiments, provided compounds demonstrate, among other things, improved half-life in animals.

Various technologies can be utilized to assess properties of provided agents, e.g., stapled peptides, in accordance with the present disclosure. In some embodiments, plasma PK methods are used to assess pharmacokinetic properties. In an exemplary assay, peptides were formulated in 10% DMSO:90% saline and dosed by IV at 0.5 mg/kg per compound in three male Sprague-Dawley rats. Serial bleed time-points were taken at 2 min, 6 min, 10 min, 15 min, 30 min, 1, 2, 4, 6, 8, 12 and 24 h and analyzed by quantitative LC/MS using a Thermo Q-Exactive Focus LC/MS/MS. Samples were prepared by protein precipitation with MeOH. Data were fit to a two-compartment model. In one assay, FP0217c (Isomer 2) showed a plasma half-life of >1 hour, and FP0597c displayed a shorter plasma half-life. Exemplary data are presented, e.g., in FIG. 6.

Example 7. Provided Agents can Selectively Modulate Beta-Catenin Interactions with Axin Over Other Entities

In some embodiments, the present disclosure provides agents, e.g. stapled peptides, that selectively bind to one or more beta-catenin sites that interact with Axin. In some embodiments, provided agents, e.g., stapled peptides, selectively compete with interactions with one or more beta-catenin sites that interact with Axin. Particularly, in some embodiments, provided agents selectively modulate interactions with Axin at one or more beta-catenin sites that interact with Axin compared to those at one or more beta-catenin sites that interact with BCL9. In some embodiments, provided agents selectively disrupt beta-catenin interactions with proteins whose beta-catenin interacting sites are identical or overlap with one or more sites that interact with Axin over those whose beta-catenin interacting sites are identical or overlap with one or more sites that interact with BCL9. In some embodiments, provided agents selectively modulate beta-catenin interaction with Axin over beta-catenin interaction with BCL9. In some embodiments, provided agents selectively disrupts beta-catenin interaction with Axin over beta-catenin interaction with BCL9. In some embodiments, a provided agent, e.g., a stapled peptide, has EC50 for disrupting interactions between beta-catenin and BCL9 (or a probe, e.g., Ac-Leu-Ser-Gln-Glu-Gln-Leu-Glu-His-Arg-Glu-Arg-Ser-Leu-Gln-Thr-Leu-Arg-Asp-Ile-Gln-Arg-nLeu-Leu-2NapA-bala-bala-Lys5FAM-NH2 (SEQ ID NO: 2) (from Biochemistry, 2009, 48 (40), pp 9534-9541)) that is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 1000 or more fold of its EC50 for disrupting interactions between beta-catenin and Axin (or a probe, e.g., FITC-PEG1-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 1) (hydrocarbon staple formed by two S5 via olefin metathesis) and/or FITC-bA-PQ-S5-ILD-S5-HVRRVWR (SEQ ID NO: 3) (hydrocarbon staple formed by two S5 via olefin metathesis)) as measured by, e.g., a competition fluorescence polarization assay. In some embodiments, provided agents, e.g., stapled peptides, do not observably disrupt interactions between beta-catenin and BCL9. In such cases, EC50 may not be determinable, but as appreciated by those skilled in the art, can be treated as at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 1000 or more fold of a determinable EC50 from a detectable disruption.

Various technologies can be utilized to assess interactions with beta-catenin at sites, e.g., that interact with BCL9 or Axin. In some embodiments, competition fluorescence polarization is utilized to assess interaction/modulation selectivity. In some embodiments, a competition fluorescence polarization assay for Axin sites (e.g., beta-catenin sites that interacts with Axin) was as described above. In some embodiments, e.g., for assess selectivity between BCL9 sites and Axin sites, a competition fluorescence polarization assay for Axin and/or BCL9 sites may be employed. In some embodiments, in an exemplary BCL9 competition FP assay, peptide solutions were prepared in a buffer (e.g., 50 mM Tris pH 8.0, 250 mM NaCl, 2% glycerol, 0.5 mM EDTA, 0.02% w/v sodium azide) using a, e.g., 3-fold, serial dilution from, e.g., 10 μM. Probe solution (e.g., 250 nM full-length 8-Catenin, 20 nM 5FAM labeled peptide in buffer) was prepared and a volume of, e.g., 40 μL, per well plated in a suitable multi-well plate, e.g., a black polystyrene 384-well plate (Corning). A suitable volume, e.g., an equal volume of the serial diluted peptide was added to the plate and incubated protected from light for a period of time, e.g., 15 minutes prior to read. Reads were performed, e.g., on a Spectramax M5 (Molecular Devices) in duplicate. In some embodiments, a probe is Ac-Leu-Ser-Gln-Glu-Gln-Leu-Glu-His-Arg-Glu-Arg-Ser-Leu-Gln-Thr-Leu-Arg-Asp-Ile-Gln-Arg-nLeu-Leu-2NapA-bala-bala-Lys5FAM-NH2 (SEQ ID NO: 2) (from Biochemistry, 2009, 48 (40), pp 9534-9541). As demonstrated, e.g., by exemplary data in FIG. 7, in some embodiments, provided stapled peptides selectively disrupts interactions at one or more Axin sites over those at one or more BCL9 sites.

Example 8. Preparation of Stapled Peptides with Diverse Structural Elements and Assessment of their Properties

Among other things, the present disclosure provides various structural elements, including of those of the staples, such as chemistry (hydrocarbon linker v. non-hydrocarbon linker), positioning (positions of staple connection, (i, i+4), (i, i+7), etc.), lengths, stereochemistry, etc., and combinations thereof, that can be utilized to design and prepare stapled peptides with significantly improved properties and/or activities. Various structural elements can also impact preparation of stapled peptides in terms of yield, purity, selectivity, etc. The present example illustrates preparation of stapled peptides with diverse structures using different reaction conditions. Among other things, certain structural features, e.g., those of staples (types, lengths, etc.), that can provide various advantages (preparation yield, purity, selectivity, binding affinity, etc.) are identified. In some embodiments, exemplary stapled peptides has better properties, e.g., solubility, binding affinity, cell permeability, etc. than StAx stapled peptides reported in reported in Grossmann et al. PNAS 109 17942-17947. In some embodiments, exemplified stapled peptides contain amino acid sequences that are highly homologous to StAx33 of Grossman.

A number of stapled peptides were prepared, with staple length of about 10-14 for carbamate staples and 8-12 for amino staples (which in this case comprising —N(R)— not bonded to —C(O)—). In some embodiments, some stapled peptides are double stapled (in some cases, stiched peptided). Table 4A illustrates certain results using 2× 30 mol % Grubbs I, at 40° C., 2 hrs. Table 4B illustrates certain results using 2× 5 mol % Hoveyda-Grubbs II, at 60° C., 2 hrs. Az is monomer A. PyrS is Monomer B. PyrR is Monomer C. SgN is Monomer D. RgN is Monomer E. SdN is Monomer F. RdN is Monomer G. SeN is Monomer H. ReN is Monomer I.

In some embodiments, staple length of 11 or more may deliver higher yields compared to a shorter staple length (e.g., for azetidine-containing stapled peptides as illustrated). In some embodiments, a preferred staple length is 11 or more. In some embodiments, staple length of 10-14 or more may deliver higher yields compared to a staple of another length (e.g., for pyrrolidine-containing stapled peptides as illustrated). In some embodiments, a preferred staple length is 11 or more. In some embodiments, a preferred staple length is 10-14. In some embodiments, pyrrolidine-containing staples generally are slower to form compared to azetidine-containing staples under comparable conditions. In some embodiments, for acyclic amines, amino acid residues comprising olefin in a hydrocarbon side chain at the N-terminus position typically resulted in lower olefin metathesis product formation.

FP EC50 data of certain stapled peptides were presented in Table 5.

For amino staple formation reaction, most reactions yielded clean amino stapled peptides under the condition used, with a few exceptions where multiple products and/or double isomers were observed. Exemplary results were presented in Table 6. In some embodiments, acyclic amino staples were more difficult to form compared to cyclic amino staples under certain conditions.

embedded image

Exemplary FP EC₅₀data were presented in Table 5. In some embodiments, stapled peptides with amino staples have lower binding affinity than stapled peptides with other types of staples, e.g., carbamate staples (in one case, FP-0738c (1800 nM) vs. FP-0738a (200 nM)).

In some embodiments, the following staples provided better results and may be preferred (exemplary stapled peptides in parentheses):

Carbamate Staples:

Az/R6 (FP-0725c)

PR/R6 (FP-0745c)

S7/PS (FP-0763c)

R4/PR (FP-0765c)

R5/PR (FP-0766c)

R6/PR (FP-0767c)

R7/PR (FP-0768c)

Staple Length=11 to 14 atoms

Amino Staples:

S7/Az (FP-0738a)

PR/R6 (FP-0745a)

Staple Length=11 to 12 atoms

By a Surface Plasmon Resonance—Biacore assay, R4/PR (FP-0765c) displayed a Kd about 13 nM, S5/S5 (FP-0787c) Kd about 14 nM, R5/PR (FP-0766c) Kd about 7 nM, Az/R6 (FP-0725c) Kd about 22 nM, S7/Az (FP-0738a) Kd about 43 nM, and PR/R₆(FP-0745a) Kd about 34 nM.

Example 9. Additional Methods for Olefin Metathesis

In some embodiments, the present disclosure provides methods for preparing stapled peptides. In some embodiments, the present disclosure provides methods for preparing stapled peptides, comprising forming a staple through olefin metathesis. In some embodiments, the present disclosure provides methods for ring closing metathesis to form a staple.

Various metathesis catalysts may be utilized in accordance with the present disclosure. In some embodiments, a catalyst is a Ru-catalyst. In some embodiments, a Ru-catalyst is Grubbs I, Grubbs II, Hoveyda-Grubbs I and Hoveyda-Grubbs II. In some embodiments, catalyst loading is 5 mol %. In some embodiments, catalyst loading is 20 mol %. In some embodiments, Hoveyda-Grubbs II provides better results than one or more other catalysts.

In some embodiments, 11 substrate peptides for olefin metathesis were used to evaluate various conditions, each of which can be fully stapled with a single 30 mol % Grubbs I treatment. Exemplary results were presented in FIG. 8.

embedded image

For Grubbs I, one treatment in DCE, at 40° C., 2 hrs, all reactions using 20 mol % were complete with 7 yielding no or traces of byproduct while 4 produced 17% to 50% byproduct. Single treatment with 5 mol % was not sufficient to completely staple peptides, with 3 peptides also showing byproduct formation. For Grubbs II, one treatment in DCE, at 40° C., 2 hrs, lower efficiency was observed compared to Grubbs I, no complete reaction was observed, by-product formation was observed, and starting material was the major species throughout. For Hoveyda-Grubbs I, one treatment in DCE, at 40° C., 2 hrs, no complete reactions were observed, and either trace or no stapled product observed with 5 mol %. For Hoveyda-Grubbs II, one treatment in DCE, at 60° C., 2 hrs, all peptides were fully stapled with 5 mol % of Hoveyda-Grubbs II, and lower byproduct to product ratio than with other catalysts.

In some embodiments, an optimized process is

embedded image

In some embodiments, a pre-optimized process is

embedded image

Exemplary results were presented below.

SEQ

1st Treatment

ID

(5 mol % HGII

ID
NO:
Peptide Sequence
at 60 C)
Isomers

FP-0996
281
Ac-HRERSLQTLR-Az-IQR-R6-LF-NH2
Rxn complete; trace of
Single

unstapled

FP-0997
282
Ac-HRERSLQTLR-S5-IQR-Az-LF-NH2
50% stapled
Single

FP-0998
283
Ac-HRERSLQTLR-P_R-IQR-R5-LF-NH2
15% unstapled
Single

remaining

FP-0999
284
Ac-HRERSLQTLR-R6-IQR-P_R-LF-NH2
30% unstapled
Single

remaining

FP-1000
285
Ac-HRE-Az-SLQ-R6-LRDIQR-Nle-LF-
Rxn complete; 13%
Single

NH2
byproduct

FP-1001
286
Ac-HRE-S5-SLQ-Az-LRDIQR-Nle-LF-
40% stapled
Single

NH2

FP-1002
287
Ac-HRE-P_R-SLQ-R5-LRDIQR-Nle-LF-
10% unstapled
Single

NH2
remaining

FP-1003
288
Ac-HRE-R6-SLQ-P_R-LRDIQR-Nle-LF-
13% unstapled
Single

NH2
remaining

FP-1004
289
Ac-Az-HRE-R6-SLQ-R8-LRDIQR-P_S-
Rxn complete; trace of
Double

LF-NH2
unstapled
(2:1)

FP-1005
290
Ac-S5-HRE-Az-SLQ-R8-LRDIQR-P_S-
50% stapled
Double

LF-NH2

(2:1)

FP-1006
291
Ac-P_R-HRE-R5-SLQ-R8-LRDIQR-P_S-
10% unstapled
Double

LF-NH2
remaining
(2:1)

FP-1007
292
Ac-R6-HRE-P_R-SLQ-R8-LRDIQR-P_S-
15% unstapled
Double

LF-NH2
remaining
(2:1)

SEQ

1st Treatment
2nd Treatment

ID

(5 mol % HGII at
(5 mol % HGII

ID
NO:
Peptide Sequence
60 C)
at 60 C)

FP-0719
293
Ac-Pro-Gln-M_A-Ile-Leu-Asp-R3-His-
traces of stapled
NA

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0720
294
Ac-Pro-Gln-M_A-Ile-Leu-Asp-S3-His-
no reaction
NA

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0726
295
Ac-Pro-Gln-M_A-Ile-Leu-Asp-S6-His-
10% stapled
NA

Val-Arg-Arg-Val-Trp-Arg-NH2
product; double

isomers

FP-0741
296
Ac-Pro-Gln-M_C-Ile-Leu-Asp-R4-His-
traces of stapled
NA

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0748
297
Ac-Pro-Gln-M_C-Ile-Leu-Asp-S7-His-
traces of stapled
NA

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0761
298
Ac-Pro-Gln-S6-Ile-Leu-Asp-M_B-His-
60% stapled
rxn complete;

Val-Arg-Arg-Val-Trp-Arg-NH2

traces of

unstapled

FP-0763
299
Ac-Pro-Gln-S7-Ile-Leu-Asp-M_B-His-
42% stapled
rxn complete;

Val-Arg-Arg-Val-Trp-Arg-NH2

traces of

unstapled

FP-0769
300
Ac-Pro-Gln-S5-Ile-Leu-Asp-M_D-His-
20% stapled
46% stapled;

Val-Arg-Arg-Val-Trp-Arg-NH2

double isomers

FP-0770
301
Ac-Pro-Gln-S5-Ile-Leu-Asp-M_F-His-
50% stapled; double
NA

Val-Arg-Arg-Val-Trp-Arg-NH2
isomers

FP-0771
302
Ac-Pro-Gln-S5-Ile-Leu-Asp-M_H-His-
25% stapled; double
NA

Val-Arg-Arg-Val-Trp-Arg-NH2
isomers

FP-0772
303
Ac-Pro-Gln-R5-Ile-Leu-Asp-M_D-His-
20% stapled
50% stapled

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0773
304
Ac-Pro-Gln-R5-Ile-Leu-Asp-M_F-His-
no reaction
NA

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0774
305
Ac-Pro-Gln-R5-Ile-Leu-Asp-M_H-His-
no reaction
NA

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0775
306
Ac-Pro-Gln-R5-Ile-Leu-Asp-M_E-His-

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0776
307
Ac-Pro-Gln-R5-Ile-Leu-Asp-M_G-His-
60% stapled
rxn complete;

Val-Arg-Arg-Val-Trp-Arg-NH2

traces of

unstapled

FP-0777
308
Ac-Pro-Gln-R5-Ile-Leu-Asp-M_I-His-
60% stapled
rxn complete;

Val-Arg-Arg-Val-Trp-Arg-NH2

traces of

unstapled

FP-0778
309
Ac-Pro-Gln-M_D-Ile-Leu-Asp-S5-His-
58% stapled
rxn complete;

Val-Arg-Arg-Val-Trp-Arg-NH2

traces of

unstapled

FP-0779
310
Ac-Pro-Gln-M_F-Ile-Leu-Asp-S5-His-
42% stapled
rxn complete;

Val-Arg-Arg-Val-Trp-Arg-NH2

traces of

unstapled

FP-0780
311
Ac-Pro-Gln-M_H-Ile-Leu-Asp-S5-His-
~33% stapled,
rxn complete;

Val-Arg-Arg-Val-Trp-Arg-NH2
coelutes with −M_H
traces of

truncation
unstapled

FP-0781
312
Ac-Pro-Gln-M_E-Ile-Leu-Asp-R5-His-

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0782
313
Ac-Pro-Gln-M_G-Ile-Leu-Asp-R5-His-
33% stapled
rxn complete;

Val-Arg-Arg-Val-Trp-Arg-NH2

traces of

unstapled

FP-0783
314
Ac-Pro-Gln-M_I-Ile-Leu-Asp-R5-His-
56% stapled
rxn complete;

Val-Arg-Arg-Val-Trp-Arg-NH2

traces of

unstapled

FP-0784
315
Ac-Pro-Gln-M_E-Ile-Leu-Asp-S5-His-

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0785
316
Ac-Pro-Gln-M_G-Ile-Leu-Asp-S5-His-
traces of stapled
NA

Val-Arg-Arg-Val-Trp-Arg-NH2

FP-0786
317
Ac-Pro-Gln-M_I-Ile-Leu-Asp-S5-His-
traces of stapled
NA

Val-Arg-Arg-Val-Trp-Arg-NH2

NA: data not available/not performed.

In some embodiments, a “stiched” stapled peptides is selected from below:

Ac-PyrS-HRE-B5-SLQ-PyrR-LRDIQR-
Ac-HRERSL-PyrS-TLR-B5-IQR-PyrR-LF-

Nle-LF-NH2 (SEQ ID NO: 318)
NH2 (SEQ ID NO: 325)

Ac-SgN-HRE-B5-SLQ-RdN-LRDIQR-Nle-
Ac-HRERSL-SgN-TLR-B5-IQR-RdN-LF-

LF-NH2 (SEQ ID NO: 319)
NH2 (SEQ ID NO: 326)

Ac-SdN-HRE-B5-SLQ-RdN-LRDIQR-Nle-
Ac-HRERSL-SdN-TLR-B5-IQR-RdN-LF-

LF-NH2 (SEQ ID NO: 320)
NH2 (SEQ ID NO: 327)

Ac-SeN-HRE-B5-SLQ-RdN-LRDIQR-Nle-
Ac-HRERSL-SeN-TLR-B5-IQR-RdN-LF-

LF-NH2 (SEQ ID NO: 321)
NH2 (SEQ ID NO: 328)

Ac-SgN-HRE-B5-SLQ-ReN-LRDIQR-Nle-
Ac-HRERSL-SgN-TLR-B5-IQR-ReN-LF-

LF-NH2 (SEQ ID NO: 322)
NH2 (SEQ ID NO: 329)

Ac-SdN-HRE-B5-SLQ-ReN-LRDIQR-Nle-
Ac-HRERSL-SdN-TLR-B5-IQR-ReN-LF-

LF-NH2 (SEQ ID NO: 323)
NH2 (SEQ ID NO: 330)

Ac-SeN-HRE-B5-SLQ-ReN-LRDIQR-Nle-
Ac-HRERSL-SeN-TLR-B5-IQR-ReN-LF-

LF-NH2 (SEQ ID NO: 324)
NH2 (SEQ ID NO: 331)

As described in the present disclosure, provided agents, e.g., stapled peptides, have a number of significantly improved properties and activities, in some embodiments particularly when compared to one or more appropriate reference agents. Among other things, improved stability, increased solubility, increased cell permeability, increase activities, increased selectivity, and/or lowered toxicities, were observed when compared to a number of reference agents, e.g., unstapled peptides, small molecule Wnt pathway inhibitors, stapled peptides comprising hydrocarbon staples, stapled peptides not interacting with one or more beta-catenin sites that interact with Axin (e.g., stapled peptides interacting with one or more beta-catenin sites that interact with BCL9 but not Axin). A number of assays, including those described in the present disclosure and variations thereof, can be utilized to assess one or more properties and activities of provided agents, e.g., stapled peptides.

TABLE 2

Exemplary data.

in vitro
TCF/LEF Reporter

FP EC₅₀
Solubility
K_dby SPR
IC₅₀
Inhibition at

Peptide
(nM)*
(mM)
(nM)
(mM)
10 μM

FP0001c

FP0003c

FP0005c
+++

45%

FP0006a
+++

10%

FP0007c

54%

FP0009c

54%

FP0011c

34%

FP0025c
+++

15

65%

FP0098

18%

FP0099

38%

FP0110

19%

FP0212s Isomer 2
++

35%

FP0216c

37%

FP0217a
NB
111

0%

FP0217c Isomer 1
+

FP0217c Isomer 2
+++
7
2
0.743
72%

c14-FP0217a

c14-FP0217c

54%

c16-FP0217a

FP0217c_bAfree
+++
155
9

FP0217c_btn
+++

FP0217c_cl8a

FP0217rc
+++
26

FP0217s Isomer 1
+++
5

FP0217s Isomer 2
+++
2

FP0217u
+++

FP0218c
++

41%

FP0219c
++

20%

FP0220c
+++
14

39%

FP0221c

38%

FP0222c

22%

FP0223a

18%

FP0224a

15%

FP0243c

35%

FP0244c

68%

FP0247c

0%

FP0249c

0%

FP0250c

0%

FP0253c

63%

FP0264c

59%

FP0265c

64%

FP0268c

0%

FP0269c

0%

FP0270c

0%

FP0271c

0%

FP0272c

FP0273c

4%

FP0274c

42%

FP0278c

0%

FP0279c

34%

FP0280c

78%

FP0281c

38%

FP0282c

42%

FP0284c

0%

FP0285c

19%

FP0286c

0%

FP0290c

60%

FP0292c

23%

FP0293c

32%

FP0295c

36%

FP0296c

64%

FP0298c

38%

FP0299c

2%

FP0300c

39%

FP0302c

51%

FP0306c

48%

FP0317a

34%

FP0318a

FP0318c

48%

FP0321c

59%

FP0324c

51%

FP0325a

FP0325c

73%

FP0327c

0%

FP0335a
++

0%

FP0335c Isomer 1
++

22%

FP0335c Isomer 2
+++

37%

FP0336c

43%

FP0338c
++

3

36%

FP0344c

0%

FP0345c

43%

FP0346c

36%

FP0349c

50%

FP0350c

1%

FP0352c

38%

FP0353c

0%

FP0354c

28%

FP0355c

0%

FP0357c

37%

FP0365c
++

FP0365c Isomer 1
+

FP0365c Isomer 2
+

FP0368c

0%

FP0369c

38%

FP0371c

46%

FP0380c

25%

FP0383c

22%

FP0391c

FP0395c

32%

FP0405c
+

FP0406c
++

FP0407c
+

FP0408c
NB

FP0409a

FP0409c
NB

FP0409c_free

c16-FP0409a

c16-FP0409c

FP0410c
++

FP0411c

FP0412c

FP0495a
+

18%

FP0495c
++

20%

FP0501c
++

33%

FP0502a
+

49%

FP0502c Isomer 1
+++

20%

FP0502c Isomer 2
++

27%

FP0503a
++
236

32%

FP0503c
++
35

10%

FP0506a
+

FP0506c Isomer 1
++

FP0506c Isomer 2
+++

FP0507a
+++

FP0507c
+

FP0509a
+
192

FP0509c
+++
32
3

FP0510a
+
165

FP0510c Isomer 1
+++
65

FP0510c Isomer 2
+++
31

FP0511a
+++
170

FP0511c Isomer 1
+++
49

FP0511c Isomer 2
+++
24

FP0516a Isomer 1
++

FP0516a Isomer 2
+

FP0516c
++

FP0536c
NB

FP0537c
NB

FP0538c
+

FP0539c

FP0539c Isomer 1

52%

FP0539c Isomer 2

36%

FP0540c
NB

FP0541c
NB

FP0542c
+

18%

FP0554c Isomer 1
NB

29%

FP0554c Isomer 2
NB

35%

FP0555c Isomer 1
NB

43%

FP0555c Isomer 2
NB

32%

FP0556c Isomer 1
NB

33%

FP0556c Isomer 2
NB

38%

FP0557c Isomer 1
NB

43%

FP0557c Isomer 2
NB

30%

FP0558c Isomer 1
NB

38%

FP0558c Isomer 2
NB

40%

FP0559c Isomer 1
NB

44%

FP0559c Isomer 2
NB

31%

FP0560c Isomer 1
NB

40%

FP0560c Isomer 2
NB

22%

FP0561c Isomer 1
NB

38%

FP0561c Isomer 2
NB

35%

FP0562c Isomer 1
NB

22%

FP0562c Isomer 2
NB

32%

FP0563c Isomer 1
NB

34%

FP0563c Isomer 2
NB

30%

FP0564c Isomer 1
NB

46%

FP0564c Isomer 2
NB

FP0565c Isomer 1
NB

FP0565c Isomer 2
NB

FP0566c Isomer 1
NB

FP0567c Isomer 1
NB

FP0567c Isomer 2
NB

FP0568c Isomer 1
NB

FP0568c Isomer 2
NB

FP0569c Isomer 1
NB

FP0569c Isomer 2
NB

FP0570c Isomer 1
NB

FP0570c Isomer 2
NB

FP0571c Isomer 1
NB

FP0571c Isomer 2
NB

FP0572c Isomer 1
NB

FP0573c Isomer 1
NB

FP0573c Isomer 2
NB

FP0574c Isomer 1
NB

FP0574c Isomer 2
NB

FP0575c Isomer 1
NB

FP0575c Isomer 2
NB

FP0576c Isomer 1
NB

FP0576c Isomer 2
NB

FP0577c Isomer 1
NB

FP0578c Isomer 1
NB

FP0578c Isomer 2
NB

FP0587c
+++

33%

FP0588c
+++
133

61%

FP0594c
++
166

23%

FP0596c
+

21%

FP0597c
+++
98
4
1.021
81%

FP0597c_c12

4

FP0597c_c8

2

FP0598c
+++

23%

FP0601c
+++

30%

FP0604c
+++

32%

FP0605c
+++

30%

FP0611c
+++

56%

FP0616c
+++
56

51%

FP0617c
+++
63

62%

FP0625c
++

20%

FP0626c
+++
40

53%

FP0628_aib
++
88

FP0629c
+

49%

FP0630c
++

53%

FP0631c
+

0%

FP0632c
++
13

57%

FP0633c
+

16%

FP0634c
+++

45%

FP0635c
++

19%

FP0636c
++

41%

FP0639c
+++

40%

FP0640c
+++

25%

FP0644c
++

34%

FP0645c
+++

26%

FP0721a

FP0721c
+

FP0723a

FP0723c
+

FP0724c
+

FP0725a
+

FP0725c
+++

22

FP0727c
+

FP0728c
+

FP0731c
+

FP0733c
+

FP0734a
NB

FP0734c
NB

FP0735a
+

FP0735c
+

FP0736a
++

FP0736c
+

FP0738a
++

43

FP0738c
+

FP0743a
NB

FP0743c
+

FP0745a
++

34

FP0745c
++

FP0751a
NB

FP0751c
+

FP0752c
+

FP0753a
NB

FP0758a
NB

FP0758c
+

FP0761c
++

FP0763a
+

FP0763c
++

FP0765c
+++

13
N/A
N/A

FP0766c
+++

7
N/A
N/A

FP0767a
+

FP0767c
++

FP0768a
NB

FP0768c
++

FP0776c
+

FP0776a
+

FP0777c
+

FP0777a
+

FP0778c
+

FP0779c
+

FP0780c
+

FP0782c
++

FP0783c
+

FP0783a
+

FP0787s
++

14

*+++: < =100 nM EC50;

++: 100-500 nM EC50;

+: 500-5000 nM EC50;

N/A, N.D.: relevant values not determined from currently available data collected from utilized assay conditions, e.g., dose ranges, concentrations, etc.;

NB: no binding detected under utilized assay conditions.

TABLE 3

Exemplary results.

Part A

Metathesis
Target
Binding Kd
Solubility
Beta-Catenin Luciferase Reporter

ID
Efficiency
Binding
(nM)
in DPBS (μM)
% Inhibition at 10 μM

FP0512c
fair
N.D.
N.D.
N.D.
N.D.

FP0513c
good
N.D.
N.D.
N.D.
N.D.

FP0514c
poor
N.D.
N.D.
N.D.
N.D.

FP0515c
fair
N.D.
N.D.
N.D.
N.D.

FP0516c
fair
151
N.D.
N.D.
27%

FP0517c
poor
N.D.
N.D.
N.D.
N.D.

FP0335c
fair
Yes (Isomer 2
N.D.
N.D.
22% (Isomer 1)

more tightly than

37% (Isomer 2)

Isomer 1)

FP0492c
fair
N.D.
N.D.
N.D.
N.D.

FP0491c
poor
N.D.
N.D.
N.D.
N.D.

FP0490c
poor
N.D.
N.D.
N.D.
N.D.

FP0338c
good
Yes
10
N.D.
30%

FP0495c
good
Yes
N.D.
N.D.
20%

FP0494c
poor
N.D.
N.D.
N.D.
N.D.

FP0493c
poor
N.D.
N.D.
N.D.
N.D.

FP0499c
fair
N.D.
N.D.
N.D.
N.D.

FP0498c
poor
N.D.
N.D.
N.D.
N.D.

FP0497c
poor
N.D.
N.D.
N.D.
N.D.

FP0496c
fair
N.D.
N.D.
N.D.
N.D.

FP0503c
fair
Yes
N.D.
35
10%

FP0502c
fair
Yes
N.D.
N.D.
20% (Peak 1)

27% (Peak 2)

FP0501c
fair
Yes
N.D.
N.D.
33%

FP0500c
poor
N.D.
N.D.
N.D.
N.D.

FP0507c
good but two
Yes
N.D.
N.D.
32% (Only one isomer isolated)

isomers

FP0506c
fair
Yes
N.D.
N.D.
36%

FP0505c
poor
N.D.
N.D.
N.D.
N.D.

FP0504c
poor
N.D.
N.D.
N.D.
N.D.

FP0486c
poor
N.D.
N.D.
N.D.
N.D.

FP0485c
poor
N.D.
N.D.
N.D.
N.D.

FP0484c
poor
N.D.
N.D.
N.D.
N.D.

FP0483c
poor
N.D.
N.D.
N.D.
N.D.

FP0217c
fair
Yes (Isomer 2
4 (Isomer 2)
12 (Isomer 2)
62% (Isomer 2)

more tightly than

Isomer 1)

FP0489c
fair
N.D.
N.D.
N.D.
N.D.

FP0488c
No data
N.D.
N.D.
N.D.
N.D.

FP0487c
poor
N.D.
N.D.
N.D.
N.D.

FP0508c
poor
N.D.
N.D.
N.D.
N.D.

FP0509c
fair
Yes
3
42
39%

FP0510c
good but two
Yes (Isomer 2
N.D.
65 (Isomer 1)
22% (Isomer 1)

isomers
more tightly than

31 (Isomer 2)
33% (Isomer 2)

Isomer 1)

FP0511c
good but two
Yes (Isomer 2
N.D.
49 (Isomer 1)
17% (Isomer 1)

isomers
more tightly than

24 (Isomer 2)
18% (Isomer 2)

Isomer 1)

FP0520c
good
N.D.
N.D.
N.D.
N.D.

FP0521c
fair
N.D.
N.D.
N.D.
N.D.

FP0522c
good but two
N.D.
N.D.
N.D.
N.D.

isomers

FP0523c
good
N.D.
N.D.
N.D.
N.D.

FP0617c
good
Yes
N.D.
63
62%

FP0616c
good
Yes
N.D.
56
51%

FP0615c
poor
N.D.
N.D.
N.D.
N.D.

FP0611c
good
Yes
N.D.
N.D.
58%

FP0623c
poor
N.D.
N.D.
N.D.
N.D.

FP0624c
poor
N.D.
N.D.
N.D.
N.D.

FP0625c
fair
Yes
N.D.
N.D.
0%

FP0592c
good but 2
N.D.
N.D.
N.D.
N.D.

isomers

FP0599c
good
N.D.
N.D.
N.D.
N.D.

FP0606c
poor
N.D.
N.D.
N.D.
N.D.

FP0627c
fair
N.D.
N.D.
N.D.
N.D.

FP0618c
poor
N.D.
N.D.
N.D.
N.D.

FP0619c
poor
N.D.
N.D.
N.D.
N.D.

FP0613c
poor
N.D.
N.D.
N.D.
N.D.

FP0609c
poor
N.D.
N.D.
N.D.
N.D.

FP0610c
poor
N.D.
N.D.
N.D.
N.D.

FP0612c
poor
N.D.
N.D.
N.D.
N.D.

FP0614c
poor
N.D.
N.D.
N.D.
N.D.

FP0620c
poor
N.D.
N.D.
N.D.
N.D.

FP0621c
poor
N.D.
N.D.
N.D.
N.D.

FP0622c
fair
N.D.
N.D.
N.D.
N.D.

FP0587c
good
Yes
N.D.
N.D.
43%

FP0588c
good but 2
Yes
N.D.
133
61%

isomers

FP0589c
good but 2
N.D.
N.D.
N.D.
N.D.

isomers

FP0590c
good but 2
N.D.
N.D.
N.D.
N.D.

isomers

FP0591c
good but 2
N.D.
N.D.
N.D.
N.D.

isomers

FP0593c
good but 2
N.D.
N.D.
N.D.
N.D.

isomers

FP0594c
good
Yes
N.D.
166
23%

FP0595c
fair
N.D.
N.D.
N.D.
N.D.

FP0596c
good
Yes
N.D.
N.D.
11%

FP0597c
good
Yes
4
98
81%

FP0598c
good
Yes
N.D.
91
23%

FP0600c
good but 2
N.D.
N.D.
N.D.
N.D.

isomers

FP0601c
good
Yes
N.D.
N.D.
40%

FP0602c
fair
N.D.
N.D.
N.D.
N.D.

FP0603c
poor
N.D.
N.D.
N.D.
N.D.

FP0604c
good
Yes
N.D.
N.D.
46%

FP0605c
good
Yes
N.D.
N.D.
50%

FP0607c
poor
N.D.
N.D.
N.D.
N.D.

FP0608c
fair
N.D.
N.D.
N.D.
N.D.

FP0626c
good
Yes
N.D.
40
60%

Part B

Carbamate-
Amino-

Beta-Catenin Luciferase

Stapled Starting
Stapled

Solubility in DPBS
Reporter % Inhibition at

Material
Product
CO₂Extrusion
Target Binding
(μM)
10 μM

FP0516c
FP0516a
Yes (Two isomers
Yes (Isomer 1 binds
N.D.
N.D.

isolated)
more tightly than

Isomer 2)

FP0335c
FP0335a
Yes
Yes
N.D.
0%

FP0338c
FP0338a
Yes
N.D.
N.D.
N.D.

FP0495c
FP0495a
Yes
Yes
N.D.
18%

FP0503c
FP0503a
Yes
Yes
236
32%

FP0502c
FP0502a
Yes
No
N.D.
49%

FP0507c
FP0507a
Yes
Yes
N.D.
32%

FP0506c
FP0506a
Yes
No
N.D.
0%

FP0217c
FP0217a
Yes
No
111
0%

FP0509c
FP0509a
Yes
Yes
192
0%

FP0510c
FP0510a
Yes
Yes
165
49%

FP0511c
FP0511a
Yes
Yes
170
0%

Poor: <1:2 stapled:unstapled or <1:1 stapled:unstapled with two isomers

Fair: between approx. 1:2 stapled:unstapled and 2:1 stapled:unstapled, potentially with two isomers (also in this category is combinations that gave up to 3:1 or so stapled:unstapled but gave either two major isomers or significant amount of neither stapled nor unstapled byproduct)

Good: better than 2:1 stapled:unstapled with one major isomer

Good but two isomers: Better than approx. 4:1 stapled but with two major isomers

N.D.—Not determined or not presented in this Table.

TABLE 4

Exemplary results

(Table 4 discloses SEQ ID NOS 293, 294, 229, 231, 232, 234, 295, 235, 236, 332, 333, 237, 238, 240, 242, 244, 334, 246, 335, 296, 248, 336, 250, 337, 297,

338, 252, 253, 339, 340, 256, 341, 342, 257, 259, 343, 260, 261, 263, 265, 300-305, 266, 268, 270-274, 316 and 317, respectively, in order of appearance).

Com-

In-

plete
Com-
com-

with
plete
plete
By-

single
after 2
or No
product

Peptide

treat-
treat-
Re-
forma-
Double

ID
Sequence
ment
ments
action
tion
Isomer

A-2x 30 mol % Grubbs I, at 40° C., 2 hrs

Azetidine Carbamate Staples

FP-0719 FP-0720 FP-0721 FP-0723 FP-0724 FP-0725 FP-0726 FP-0727
Ac-P-Q-Az-I-L-D-R3-H-V-R-R-V-W-R-NH2 Ac-P-Q-Az-I-L-D-S3-H-V-R-R-V-W-R-NH2 Ac-P-Q-Az-I-L-D-R4-H-V-R-R-V-W-R-NH2 Ac-P-Q-Az-I-L-D-R5-H-V-R-R-V-W-R-NH2 Ac-P-Q-Az-I-L-D-S5-H-V-R-R-V-W-R-NH2 Ac-P-Q-Az-I-L-D-R6-H-V-R-R-V-W-R-NH2 Ac-P-Q-Az-I-L-D-S6-H-V-R-R-V-W-R-NH2 Ac-P-Q-Az-I-L-D-R7-H-V-R-R-V-W-R-NH2
x x x
x x
x x x
25% 50%
x

embedded image

FP-0728 FP-0729 FP-0730 FP-0731 FP-0733 FP-0734 FP-0735 FP-0736 FP-0737 FP-0738
Ac-P-Q-Az-I-L-D-S7-H-V-R-R-V-W-R-NH2 Ac-P-Q-R3-I-L-D-Az-H-V-R-R-V-W-R-NH2 Ac-P-Q-S3-I-L-D-Az-H-V-R-R-V-W-R-NH2 Ac-P-Q-R4-I-L-D-Az-H-V-R-R-V-W-R-NH2 Ac-P-Q-R5-I-L-D-Az-H-V-R-R-V-W-R-NH2 Ac-P-Q-S5-I-L-D-Az-H-V-R-R-V-W-R-NH2 Ac-P-Q-R6-I-L-D-Az-H-V-R-R-V-W-R-NH2 Ac-P-Q-S6-I-L-D-Az-H-V-R-R-V-W-R-NH2 Ac-P-Q-R7-I L-D-Az-H-V-R-R-V-W-R-NH2 Ac-P-Q-S7-I-L-D-Az-H-V-R-R-V-W-R-NH2
x x x x
x x x
x x x (80%)
28% 22%

embedded image

Pyrrolidine Carbamate Staples

FP-0739 FP-0741 FP-0743 PP-0744 FP-0745 FP-0746 FP-0748 FP-0749 FP-0751 FP-0752
Ac-P-Q-P_R-I-L-D-R3-H-V-R-R-V-W-R-NH2 Ac-P-Q-P_R-I-L-D-R4-H-V-R-R-V-W-R-NH2 Ac-P-Q-P_R-I-L-D-R5-H-V-R-R-V-W-R-NH2 Ac-P-Q-P_R-I-L-D-S5-H-V-R-R-V-W-R-NH2 Ac-P-Q-P_R-I-L-D-R6-H-V-R-R-V-W-R-NH2 Ac-P-Q-P_R-I-L-D-S6-H-V-R-R-V-W-R-NH2 Ac-P-Q-P_R-I-L-D-S7-H-V-R-R-V-W-R-NH2 Ac-P-Q-P_S-I-L-D-S3-H-V-R-R-V-W-R-NH2 Ac-P-Q-P_S-I-L-D-S5-H-V-R-R-V-W-R-NH2 Ac-P-Q-P_S-I-L-D-S6-H-V-R-R-V-W-R-NH2
x x
x x
x x x x x x

embedded image

FP-0753
Ac-P-Q-P_S-I-L-D-S7-H-V-R-R-V-W-R-NH2

x

28%

FP-0756 FP-0758 FP-0759 FP-0760 FP-0761 FP-0763 FP-0764 FP-0765 FP-0766
Ac-P-Q-R4-I-L-D-P_S-H-V-R-R-V-W-R-NH2 Ac-P-Q-R5-I-L-D-P_R-H-V-R-R-V-W-R-NH2 Ac-P-Q-S5-I-L-D-P_R-H-V-R-R-V-W-R-NH2 Ac-P-Q-R6-I-L-D-P_S-H-V-R-R-V-W-R-NH2 Ac-P-Q-S6-I-L-D-P_S-H-V-R-R-V-W-R-NH2 Ac-P-Q-S7-I-L-D-P_R-H-V-R-R-V-W-R-NH2 Ac-P-Q-R3-I-L-D-P_R-H-V-R-R-V-W-R-NH2 Ac-P-Q-R4-I-L-D-P_R-H-V-R-R-V-W-R-NH2 Ac-P-Q-R5-I-L-D-P_R-H-V-R-R-V-W-R-NH2
x x
x x x
x x (80%) x x

x

embedded image

FP-0767
Ac-P-Q-R6-I-L-D-P_R-H-V-R-R-V-W-R-NH2
x

FP-0768
Ac-P-Q-R7-I-L-D-P_R-H-V-R-R-V-W-R-NH2
x

B-2x 5 mol % Hoveyda-Grubbs II, at 60° C., 2 hrs

Alkyl Carbamate Staples

FP-0769 FP-0770 FP-0771 FP-0772 FP-0773 FP-0774 FP-0776 FP-0777
Ac-P-Q-S5-I-L-D-SgN-H-V-R-R-V-W-R-NH2 Ac-P-Q-S5-I-L-D-SdN-H-V-R-R-V-W-R-NH2 Ac-P-Q-S5-I-L-D-SeN-H-V-R-R-V-W-R-NH2 Ac-P-Q-R5-I-L-D-SgN-H-V-R-R-V-W-R-NH2 Ac-P-Q-R5-I-L-D-SdN-H-V-R-R-V-W-R NH2 Ac-P-Q-R5-I-L-D-SeN-H-V-R-R-V-W-R-NH2 Ac-P-Q-R5-I-L-D-RdN-H-V-R-R-V-W-R-NH2 Ac-P-Q-R5-I-L-D-ReN-H-V-R-R-V-W-R-NH2

x x
x x x x x x

x x x

embedded image

FP-0778 FP-0779 FP-0780 FP-0782 FP-0783 FP-0785 FP-0786
Ac-P-Q-SgN-I-L-D-S5-H-V-R-R-V-W-R-NH2 Ac-P-Q-SdN-I-L-D-S5-H-V-R-R-V-W-R-NH2 Ac-P-Q-SeN-I-L-D-S5-H-V-R-R-V-W-R-NH2 Ac-P-Q-RdN-I-L-D-R5-H-V-R-R-V-W-R-NH2 Ac-P-Q-ReN-I-L-D-R5-H-V-R-R-V-W-R-NH2 Ac-P-Q-RdN-I-L-D-S5-H-V-R-R-V-W-R-NH2 Ac-P-Q-ReN-I-L-D-S5-H-V-R-R-V-W-R-NH2

x x x x x
x x

embedded image

TABLE 5

Exemplary FP EC₅₀ data (nM)

(Table 5 disclolses SEQ ID NOS 229, 231, 232, 234-238, 240, 242,

244, 334, 246, 248, 250, 252, 253, 339, 256, 257, 259, 260, 261,

263, 265, 266, 268, 270-274, 228, 230, 233, 239, 241, 243, 245,

247, 249, 251, 254, 255, 258, 262, 264, 267, 269 and 275).

Peptide ID
Sequence
FP EC₅₀ (nM)

Azetidine Carbamate Staples

FP-0721c
Ac-P-Q-Az-I-L-D-R4-H-V-R-R-V-W-R-NH2
1300

FP-0723c
Ac-P-Q-Az-I-L-D-R5-H-V-R-R-V-W-R-NH2
1400

FP-0724c
Ac-P-Q-Az-I-L-D-S5-H-V-R-R-V-W-R-NH2
540

FP-0725c
Ac-P-Q-Az-I-L-D-R6-H-V-R-R-V-W-R-NH2
80

FP-0727c
Ac-P-Q-Az-I-L-D-R7-H-V-R-R-V-W-R-NH2
520

FP-0728c
Ac-P-Q-Az-I-L-D-S7-H-V-R-R-V-W-R-NH2
2100

FP-0731c
Ac-P-Q-R4-I-L-D-Az-H-V-R-R-V-W-R-NH2
4700

FP-0733c
Ac-P-Q-R5-I-L-D-Az-H-V-R-R-V-W-R-NH2
920

FP-0734c
Ac-P-Q-S5-I-L-D-Az-H-V-R-R-V-W-R-NH2
>5000

FP-0735c
Ac-P-Q-R6-I-L-D-Az-H-V-R-R-V-W-R-NH2
1600

FP-0736c
Ac-P-Q-S6-I-L-D-Az-H-V-R-R-V-W-R-NH2
890

FP-0737c
Ac-P-Q-R7-I-L-D-Az-H-V-R-R-V-W-R-NH2
TBD

FP-0738c
Ac-P-Q-S7-I-L-D-Az-H-V-R-R-V-W-R-NH2
1800

Pyrrolidine Carbamate Staples

FP-0743c
Ac-P-Q-P_R-I-L-D-R5-H-V-R-R-V-W-R-NH2
740

FP-0745c
Ac-P-Q-P_R-I-L-D-R6-H-V-R-R-V-W-R-NN2
110

FP-0751c
Ac-P-Q-P_S-I-L-D-S5-H-V-R-R-V-W-R-NH2
2000

FP-0752c
Ac-P-Q-P_S-I-L-D-S6-H-V-R-R-V-W-R-NH2
2600

FP-0753c
Ac-P-Q-P_S-I-L-D-S7-H-V-R-R-V-W-R-NH2
low yield

FP-0758c
Ac-P-Q-R5-I-L-D-P_S-H-V-R-R-V-W-R-NH2
2700

FP-0761c
Ac-P-Q-S6-I-L-D-P_S-H-V-R-R-V-W-R-NH2
460

FP-0763c
Ac-P-Q-S7-I-L-D-P_S-H-V-R-R-V-W-R-NH2
115

FP-0765c
Ac-P-Q-R4-I-L-D-P_R-H-V-R-R-V-W-R-NH2
30

FP-0766c
Ac-P-Q-R5-I-L-D-P_R-H-V-R-R-V-W-R-NH2
20

FP-0767c
Ac-P-Q-R6-I-L-D-P_R-H-V-R-R-V-W-R-NH2
110

FP-0768c
Ac-P-Q-R7-I-L-D-P_R-H-V-R-R-V-W-R-NH2
150

Alkyl Carbamate Staples

FP-0776c
Ac-P-Q-R5-I-L-D-RdN-H-V-R-R-V-W-R-NH2
570

FP-0777c
Ac-P-Q-R5-I-L-D-ReN-H-V-R-R-V-W-R-NH2
560

FP-0778c
Ac-P-Q-SgN-I-L-D-S5-H-V-R-R-V-W-R-NH2
1000

FP-0779c
Ac-P-Q-SdN-I-L-D-S5-H-V-R-R-V-W-R-NH2
1300

FP-0780c
Ac-P-Q-SeN-I-L-D-S5-H-V-R-R-V-W-R-NH2
1700

FP-0782c
Ac-P-Q-RdN-I-L-D-R5-H-V-R-R-V-W-R-NH2
380

FP-0783c
Ac-P-Q-ReN-I-L-D-R5-H-V-R-R-V-W-R-NH2
990

Amino Staples (Cyclic)

FP-0721
Ac-P-Q-Az-I-L-D-R4-H-V-R-R-V-W-R-NH2
TBD

FP-0723
Ac-P-Q-Az-I-L-D-R5-H-V-R-R-V-W-R-NH2
TBD

FP-0725
Ac-P-Q-Az-I-L-D-R6-H-V-R-R-V-W-R-NH2
580

FP-0734
Ac-P-Q-S5-I-L-D-Az-H-V-R-R-V-W-R-NH2
>5000

FP-0735
Ac-P-Q-R6-I-L-D-Az-H-V-R-R-V-W-R-NH2
2360

FP-0736
Ac-P-Q-S6-I-L-D-Az-H-V-R-R-V-W-R-NH2
470

FP-0738
Ac-P-Q-S7-I-L-D-Az-H-V-R-R-V-W-R-NH2
200

FP-0743
Ac-P-Q-P_R-I-L-D-R5-H-V-R-R-V-W-R-NH2
>5000

FP-0745
Ac-P-Q-P_R-I-L-D-R6-H-V-R-R-V-W-R-NH2
210

FP-0751
Ac-P-Q-P_S-I-L-D-S5-H-V-R-R-V-W-R-NH2
>5000

FP-0753
Ac-P-Q-P_S-I-L-D-S7-H-V-R-R-V-W-R-NH2
>5000

FP-0758
Ac-P-Q-R5-I-L-D-P_S-H-V-R-R-V-W-R-NH2
>5000

FP-0763
Ac-P-Q-S7-I-L-D-P_S-H-V-R-R-V-W-R-NH2
1110

FP-0767
Ac-P-Q-R6-I-L-D-P_R-H-V-R-R-V-W-R-NH2
700

FP-0768
Ac-P-Q-R7-I-L-D-P_R-H-V-R-R-V-W-R-NH2
>5000

Amino Staples (Acyclic)

FP-0776
Ac-P-Q-R5-I-L-D-RdN-H-V-R-R-V-W-R-NH2
580

FP-0777
Ac-P-Q-R5-I-L-D-ReN-H-V-R-R-V-W-R-NH2
4750

FP-0783
Ac-P-Q-ReN-I-L-D-R5-H-V-R-R-V-W-R-NH2
1400

Control: FP-0787 (EC₅₀)~100 nM.

TABLE 6

Exemplary amino staple formation results

(Table 6 discloses SEQ ID NOS 228, 230, 334, 233, 345, 346, 239, 241, 243,

347, 245, 249, 251, 348, 255, 349, 298, 258, 350, 351, 262, 264, 267, 269,

309-311, 313 and 275).

Multiple

Peptide

Reaction

by
Double

ID
Sequence
Complete
Incomplete
products
Isomer

Amino Staple (Cyclic)

FP-0721
Ac-P-Q-Az-I-L-D-R4-H-V-R-R-V-W-R-NH2
no info

no info
no info

FP-0723
Ac-P-Q-Az-I-L-D-R5-H-V-R-R-V-W-R-NH2
x

FP-0724
Ac-P-Q-Az-I-L-D-S5-H-V-R-R-V-W-R-NH2
x

x

FP-0725
Ar-P-Q-Az-I-L-D-R6-H-V-R-R-V-W-R-NH2
x

FP-0731
Ac-P-Q-R4-I-L-D-Az-H-V-R-R-V-W-R-NH2
x

x
x

FP-0733
Ac-P-Q-R5-I-L-D-Az-H-V-R-R-V-W-R-NH2
x

x

FP-0734
Ac-P-Q-S5-I-L-D-Az-H-V-R-R-V-W-R-NH2
x

FP-0735
Ac-P-Q-R6-I-L-D-Az-H-V-R-R-V-W-R-NH2
x

FP-0736
Ac-P-Q-S6-I-L-D-Az-H-V-R-R-V-W-R-NH2
x

FP-0737
Ac-P-Q-R7-I-L-D-Az-H-V-R-R-V-W-R-NH2
x

FP-0738
Ac-P-Q-S7-I-L-D-Az-H-V-R-R-V-W-R-NH2
x

FP-0743
Ac-P-Q-P_R-I-L-D-R5-H-V-R-R-V-W-R-NH2
x

FP-0745
Ac-P-Q-P_R-I-L-D-R6-H-V-R-R-V-W-R-NH2
x

FP-0751
Ac-P-Q-P_S-I-L-D-S5-H-V-R-R-V-W-R-NH2
x

FP-0752
Ac-P-Q-P_S-I-L-D-S6-H-V-R-R-V-W-R-NH2
x

x

FP-0758
Ac-P-Q-R5-I-L-D-P_S-H-V-R-R-V-W-R-NH2
x

fp-0759
Ac-P-Q-S5-I-L-D-P_S-H-V-R-R-V-W-R-NH2
x

x

FP-0761
Ac-P-Q-S6-I-L-D-P_S-H-V-R-R-V-W-R-NH2

x

FP-0763
Ac-P-Q-S7-I-L-D-P_S-H-V-R-R-V-W-R-NH2
x

FP-0765
Ar-P-Q-R4-I-L-D-P_R-H-V-R-R-V-W-R-NH2
x

x

FP-0766
Ac-P-Q-R5-I-L-D-P_R-H-V-R-R-V-W-R-NH2
x

x

FP-0767
Ac-P-Q-R6-I-L-D-P_R-H-V-R-R-V-W-R-NH2
x

FP-0768
Ac-P-Q-R7-I-L-D-P_R-H-V-R-R-V-W-R-NH2
x

Amino Staples (Acyclic)

FP-0776
Ac-P-Q-R5-I-L-D-RdN-H-V-R-R-V-W-R-NH2
x

FP-0771
Ac-P-Q-R5-I-L-D-ReN-H-V-R-R-V-W-R-NH2
x

Fp-0778
Ac-P-Q-SgN-I-L-D-S5-H-V-R-R-V-W-R-NH2

x

x

FP-0779
Ac-P-Q-sdN-I-L-D-S5-H-V-R-R-V-W-R-NH2

x

FP-0780
Ac-P-Q-SeN-I-L-D-S5-H-V-R-R-V-W-R-NH2

x

FP-0782
Ac-P-Q-RdN-I-L-D-R5-H-V-R-R-V-W-R-NH2

x

FP-0183
Ac-P-Q-ReN-I-L-D-R5-I-V-R-R-V-W-R-NH2
x

While various embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the functions and/or obtaining the results and/or one or more of the advantages described in the present disclosure, and each of such variations and/or modifications is deemed to be included. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be example and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings of the present disclosure is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described in the present disclosure. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, provided technologies, including those to be claimed, may be practiced otherwise than as specifically described and claimed. In addition, any combination of two or more features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the scope of the present disclosure.

Number	Name	Date	Kind
7192713	Verdine et al.	Mar 2007	B1
7723469	Walensky et al.	May 2010	B2
7786072	Verdine et al.	Aug 2010	B2
8198405	Walensky et al.	Jun 2012	B2
8324428	Verdine et al.	Dec 2012	B2
8592377	Verdine et al.	Nov 2013	B2
8796418	Walensky et al.	Aug 2014	B2
8815932	Schmalz et al.	Aug 2014	B2
8889632	Bernal et al.	Nov 2014	B2
8895699	Verdine et al.	Nov 2014	B2
8921323	Walensky et al.	Dec 2014	B2
8957026	Verdine et al.	Feb 2015	B2
9056891	Tarasova et al.	Jun 2015	B2
9074009	Bradner et al.	Jul 2015	B2
9079970	Walensky et al.	Jul 2015	B2
9163330	Verdine et al.	Oct 2015	B2
9273099	Walensky et al.	Mar 2016	B2
9290545	Walensky et al.	Mar 2016	B2
9296805	Walensky et al.	Mar 2016	B2
9303024	Walensky et al.	Apr 2016	B2
9458189	Verdine et al.	Oct 2016	B2
9464115	Walensky et al.	Oct 2016	B2
9487562	Moellering et al.	Nov 2016	B2
9505801	Verdine et al.	Nov 2016	B2
9505816	Walensky et al.	Nov 2016	B2
9527896	Bernal et al.	Dec 2016	B2
9556227	Verdine et al.	Jan 2017	B2
9617309	Verdine et al.	Apr 2017	B2
9695224	Walensky et al.	Jul 2017	B2
9822165	Walensky et al.	Nov 2017	B2
9926306	Walensky	Mar 2018	B2
10000478	Walensky et al.	Jun 2018	B2
10000511	Walensky et al.	Jun 2018	B2
10077290	Walensky et al.	Sep 2018	B2
10081654	Verdine et al.	Sep 2018	B2
10087215	Leshchiner et al.	Oct 2018	B2
10106590	Walensky et al.	Oct 2018	B2
10202431	Bernal et al.	Feb 2019	B2
10227390	Verdine et al.	Mar 2019	B2
10259848	Walensky et al.	Apr 2019	B2
10273290	Walensky et al.	Apr 2019	B2
10301351	Verdine et al.	May 2019	B2
10308926	Walensky et al.	Jun 2019	B2
10351554	Walensky et al.	Jul 2019	B2
10464975	Walensky et al.	Nov 2019	B2
10487129	Walensky et al.	Nov 2019	B2
10533039	Verdine et al.	Jan 2020	B2
10703785	Walensky et al.	Jul 2020	B2
10716828	Danial et al.	Jul 2020	B2
10822374	Walensky et al.	Nov 2020	B2
10844053	Walensky et al.	Nov 2020	B2
11046739	Walensky et al.	Jun 2021	B2
20050032800	Bigot et al.	Feb 2005	A1
20060008848	Verdine et al.	Jan 2006	A1
20060281671	Peters et al.	Dec 2006	A1
20080220441	Birnbaum et al.	Sep 2008	A1
20100029552	Watt et al.	Feb 2010	A1
20100152103	Phadke et al.	Jun 2010	A1
20100273704	Korsmeyer et al.	Oct 2010	A1
20110218155	Walensky et al.	Sep 2011	A1
20120172311	Nash et al.	Jul 2012	A1
20130035304	Walensky et al.	Feb 2013	A1
20140005118	Verdine et al.	Jan 2014	A1
20140256912	Moellering et al.	Sep 2014	A1
20150225471	Liang et al.	Aug 2015	A1
20150239937	Verdine et al.	Aug 2015	A1
20150284437	Verdine et al.	Oct 2015	A1
20160024153	Verdine et al.	Jan 2016	A1
20160115215	Dimarchi et al.	Apr 2016	A1
20160122405	Palchaudhuri et al.	May 2016	A1
20160152667	Walensky et al.	Jun 2016	A1
20160171150	Walensky et al.	Jun 2016	A1
20160215036	Verdine et al.	Jul 2016	A1
20160244494	Verdine et al.	Aug 2016	A1
20160257725	Verdine et al.	Sep 2016	A1
20170008930	Walensky et al.	Jan 2017	A1
20170240604	Verdine et al.	Aug 2017	A1
20180009847	Verdine et al.	Jan 2018	A1
20180057565	Liang et al.	Mar 2018	A1
20180100001	Verdine et al.	Apr 2018	A1
20180201658	Rezaei-Araghi et al.	Jul 2018	A1
20180265524	Walensky et al.	Sep 2018	A1
20190002506	Walensky et al.	Jan 2019	A1
20190002514	Walensky et al.	Jan 2019	A1
20190092822	Walensky et al.	Mar 2019	A1
20190202862	Verdine et al.	Jul 2019	A1
20200231638	Walensky et al.	Jul 2020	A1
20200239533	Verdine et al.	Jul 2020	A1
20210002336	Walensky et al.	Jan 2021	A1
20210032234	Walensky et al.	Feb 2021	A1
20210179665	McGee	Jun 2021	A1

Number	Date	Country
1906209	Jan 2007	CN
H02-124887	May 1990	JP
2006-523213	Oct 2006	JP
2008-501623	Jan 2008	JP
2008-510692	Apr 2008	JP
2008-524167	Jul 2008	JP
2010-510236	Apr 2010	JP
2010-522769	Jul 2010	JP
2012-532929	Dec 2012	JP
WO-9717092	May 1997	WO
WO-0129247	Apr 2001	WO
WO-03053996	Jul 2003	WO
WO-2004084809	Oct 2004	WO
WO-2004093798	Nov 2004	WO
WO-2005044839	May 2005	WO
WO-2006018450	Feb 2006	WO
WO-2006067091	Jun 2006	WO
WO-2008061192	May 2008	WO
WO-2008095063	Aug 2008	WO
WO-2008121767	Oct 2008	WO
WO-2008137633	Nov 2008	WO
WO-2009020477	Feb 2009	WO
WO-2009042237	Apr 2009	WO
WO-2009046407	Apr 2009	WO
WO-2009108261	Sep 2009	WO
WO-2010011313	Jan 2010	WO
WO-2010042225	Apr 2010	WO
WO-2010068684	Jun 2010	WO
WO-2010121288	Oct 2010	WO
WO-2010132869	Nov 2010	WO
WO-2010148335	Dec 2010	WO
WO-2011003626	Jan 2011	WO
WO-2011008260	Jan 2011	WO
WO-2011094708	Aug 2011	WO
WO-2011146974	Dec 2011	WO
WO-2012006598	Jan 2012	WO
WO-2012040459	Mar 2012	WO
WO-2012065181	May 2012	WO
WO-2012142604	Oct 2012	WO
WO-2012174409	Dec 2012	WO
WO-2012174423	Dec 2012	WO
WO-2013055949	Apr 2013	WO
WO-2013102211	Jul 2013	WO
WO-2013142281	Sep 2013	WO
WO-2014047673	Apr 2014	WO
WO-2014052647	Apr 2014	WO
WO-2014055564	Apr 2014	WO
WO-2014110420	Jul 2014	WO
WO-2014144148	Sep 2014	WO
WO-2014144768	Sep 2014	WO
WO-2014151369	Sep 2014	WO
WO-2014159969	Oct 2014	WO
WO-2014197821	Dec 2014	WO
WO-2014201370	Dec 2014	WO
WO-2015051030	Apr 2015	WO
WO-2016149613	Sep 2016	WO
WO-2017004591	Jan 2017	WO
WO-2017040323	Mar 2017	WO
WO-2017040329	Mar 2017	WO
WO-2017062518	Apr 2017	WO
WO-2019051327	Mar 2019	WO

Agents modulating beta-catenin functions and methods thereof

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

PCT Information

US Referenced Citations (91)

Foreign Referenced Citations (61)

Non-Patent Literature Citations (71)

Related Publications (1)

Provisional Applications (1)

Entry
Mazzier et al. Enhancement of the Helical Content and Stability Induced in a Linear Oligopeptide by an i,i+4 Intramolecularly Double Stapled, Overlapping, Bicyclic [31,22,5]-(E)ene Motif. Peptide Science. Nov. 6, 2013, vol. 102, No. 1, pp. 115-123. (Year: 2013).
U.S. Appl. No. 16/298,093, filed Mar. 11, 2019, Verdine et al.
U.S. Appl. No. 16/822,722, filed Mar. 18, 2020, Walensky et al.
U.S. Appl. No. 16/876,779, filed May 18, 2020, Walensky et al.
U.S. Appl. No. 17/064,225, filed Oct. 6, 2020, Walensky et al.
U.S. Appl. No. 17/091,541, filed Nov. 6, 2020, Walensky et al.
Anderson, A. The process of structure-based drug design, Chem. Biol., 10: p. 787-797 (2003).
Azzarito, V. et al., Inhibition of α-helix-mediated protein-protein interactions using designed molecules, Nature Chemistry, 5: 161-173 (2013).
Baek, S. et al., Structure of the stapled p53 peptide bound to Mdm2, J. Am. Chem. Soc., 134(1):103-6 (2012).
Becker et al., Three-dimensional structure of the Stat3beta homodimer bound to DNA, Nature, 394: 145-151 (1998).
Bernal, F. et al., Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide, J. Am. Chem. Soc., 129(9)2456-7 (2007).
CAS RN: 933687-66-2; STN entry date: Apr. 30, 2007; 3-(methylamino)-1-(2-propen-1-yl)-3-pyrrolidinecarboxylic acid.
CAS RN: 933687-70-8; STN entry date: Apr. 30, 2007; 3-(dimethylamino)-1-(2-propen-1-yl)-3-pyrrolidinecarboxylic acid.
Chatterjee, N. et al., A stapled POL k peptide targets REV1 to inhibit mutagenic translesion synthesis, Environ. Mol. Mutagen., 61(8):830-836 (2020).
Diderich, P. et al., Phage Selection of Chemically Stabilized α-Helical Peptide Ligands, ACS Chem. Biol., 11: 1422-1427 (2016).
Dinh, T.T.T. et al., Antimicrobial activity of doubly-stapled alanine/lysine-based peptides, Bioorganic & Medicinal Chemistry Letters, 25: 4016-4019 (2015).
Fujimoto, et al., Development of a series of cross-linking agents that effectively stabilize alphahelical structures in various short peptides, Chem. Eur. J., 14(3):857-863 (2008).
Fujimoto, K. et al., Development of a Series of Cross-Linking Agents that Effectively Stabilize α-Helical Structures in Various Short Peptides., Chem. Eur. J., 14: 857-863 (2008).
Genin, M.J. et al., An improved method of oxazolidinone hydrolysis in the asymmetric synthesis of α-alkylprolines, Tetrahedron Letters, 35(28): 4967-4968 (1994).
Ghalit, N. et al., Synthesis of Bicyclic Alkene-/Alkane-Bridged Nisin Mimics by Ring-Closing Metathesis and their Biochemical Evaluation as Lipid II Binders: toward the Design of Potential Novel Antibiotics, Chem Bio Chem., 8(13): 1540-1554 (2007).
Goudreau, N. et al., Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics, Journal of Organic Chemistry, 69(19): 6185-6201 (2004).
Grossmann, T.N. et al., Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin, PNAS, 109(44): 17942-17947 (2012).
Hilinski, G.J. et al., Stitched α-helical peptides via bis ring-closing metathesis, J. Am. Chem. Soc., 136(35):12314-22 (2014).
Holland-Nell et al., Maintaining Biological Activity by Using Triazoles as Disufide Bond Mimetics, Angew. Chem. Int. Ed., 50: 5204-5206 (2011).
International Search Report for PCT/US2018/050101, 5 pages (dated Jan. 28, 2019).
International Search Report for PCT/US2018/050102, 5 pages (dated Mar. 13, 2019).
International Search Report for PCT/US2018/050103, 5 pages (dated Mar. 15, 2019).
Isidro-Llobet et al., Amino Acid-Protecting Groups, Chem Rev. 109(6): 2455-2504 (2009).
Isidro-Llobet et al., Amino Acid-Protecting Groups, Chemical Reviews, 109(6): 2455-2504 (2009).
Kawamoto, S.A. et al., Analysis of the Interaction of BCL9 with β-Catenin and Development of Fluorescence Polarization and Surface Plasmon Resonance Binding Assays for this Interaction, Biochemistry, 48, 9534-9541 (2009).
Khalil et al., An efficient and high yield method for the N-tert-butoxycarbonyl protection of sterically hindered amino acids. Tetrahedron Lett. 1996;37(20):3441-44.
Kim, Y. and Verdine, G.L., Stereochemical effects of all-hydrocarbon tethers in i,i+4 stapled peptides, Bioorg. Med. Chem. Lett., 19(9):2533-6 (2009).
Kim, Y. et al., Introduction of all-hydrocarbon i,i+3 staples into alpha-helices via ring-closing olefin metathesis, Org Lett., 12(13):3046-9 (2010).
Kim, Y. et al., Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis, Nat. Protoc., 6(6):761-71 (2011).
Kutchukian, P.S. et al., An all-atom model for stabilization of alpha-helical structure in peptides by hydrocarbon staples, J. Am. Chem. Soc., 131(13):4622-7 (2009).
Liu, F. et al., Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides, Biopolymers, 96(6): 780-788 (2011).
McGhee, J.H. et al., Exceptionally high-affinity Ras binders that remodel its effector domain, J. Biol. Chem., 293(9):3265-3280 (2018).
Menting et al., How insulin engages its primary binding site on the insulin receptor, Nature. 493(7431):241-5 (2013).
Mitra, S. et al., Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer, Nat. Commun., 8(1):660 (2017).
Moellering, R.E. et al., Direct inhibition of the NOTCH transcription factor complex, Nature, 462(7270):182-8 (2009).